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Abstract  
 
Muscle injuries are one of the most common sports related injuries. An 
audit published by The Football Association (FA) in 2004, suggested that 12% 
of all injuries were hamstring injuries, which are 2.5 times more common than 
quadriceps injuries (Woods et al., 2004). Recent figures published by 
Ekstrand et al suggested that, in a professional male football team of 25 
players, about 5 hamstring injuries occur each season, equivalent to more 
than 80 lost football days (Ekstrand et al., 2011). In terms of professional elite 
athletes, shortened recovery time could mean continuing with training, 
increased game play and benefit to the team and club. Therefore, further 
research is needed to analyse the new techniques in treating muscle injuries.  
 
In 2008, an article in the British Journal of Sports Medicine titled "The 
early management of muscle strains in the elite athlete: Best practice in the 
world with a limited evidence", summarised that currently almost all our so-
called knowledge has a basis of level 4 or level 5 (Orchard et al., 2008a). The 
panel of experts continued to highlight the importance of Dr. Mueller-
Wohlfahrt's injection treatment regimen for treating muscle injuries. In brief, 
the treatment protocol involves multiple local injections and associated back 
injections with a mixture of a homeopathic and pharmacological cocktail 
(Wohlfahrt, 2008). Therefore, the biochemical property, pharmacodynamics 
and pharmacokinetics of each drug are altered and unpredictable. The only 
potential “active” substance in Dr. Mueller-Wohlfahrt’s cocktail could be a drug 
called “Actovegin” which is a licenced clinically used drug with a track record 
of over 60 years. Therefore in this PhD thesis, in order to avoid the 
unpredictable nature of poly-pharmacy as discussed above, only Actovegin 
will be investigated. 
 
In order to investigate the potential therapeutic effect or efficacy of 
Actovegin on muscle injury, basic muscle structures, histology and 
pathophysiology of the healing process were discussed. The biochemical 
 10 
events following skeletal muscle injuries and repair are driven by cytokines, 
monocytes and leukocytes. The speed and quality of muscle healing are 
dependent on the inflammatory process. In order to alter the speed or quality 
of muscle repair, Actovegin must be able to modulate the inflammatory 
process.  
 
The in-vitro study in this PhD thesis was the first study to investigate 
the role of Actovegin in the inflammatory process and demonstrated 
significant results. It confirmed that Actovegin could modulate the 
inflammatory process by influencing the CD68+ and CD163+ macrophages 
and CD163+ THP-1 cells, which could influence the muscle healing process. 
Based on the findings from the in vitro studies and data from previous 
literature, a stand-alone single drug intramuscular Actovegin injection therapy 
regimen was developed to treat acute muscle injuries. The first clinical study 
using this stand-alone Actovegin treatment regimen was conducted in this 
PhD in professional footballer players and translated the in vitro findings to 
clinical practice, which confirmed that Actovegin could influence clinical 
outcome in treating acute muscle injuries. 
 
This thesis summarises the current evidence on Actovegin.  Compared 
with conventional conservative RICE and NSAID therapy, Actovegin proposes 
an exciting and legal alternative for high performance athletes. From the 
studies, Actovegin injection therapy seems safe and well tolerated. Overall, 
this PhD has suggested that Actovegin has an active role in the treatment of 
muscle strain injuries biochemically and clinically. 
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Chapter One 
Introduction 
 
1.1 Introduction  
 
Muscle injuries are one of the most common sports related injuries. 
Their incidence varies from 30-55% in all sports related injuries per year 
(Noonan and Garrett, 1999, Verrall et al., 2001, Jarvinen et al., 2000). 
According to the World Health Organization, musculoskeletal injuries are the 
most common cause of long term pain and physical disability, which affects 
hundreds of millions of people in the world (Woolf and Pfleger, 2003). An audit 
published by The Football Association (FA) in 2004 suggested that 12% of all 
injuries were hamstring injuries, which are 2.5 times more common than 
quadriceps injuries (Woods et al., 2004). In the 2 seasons from 1997 to 1999, 
749 hamstring injuries were reported across the 91 British football clubs 
(Woods et al., 2004). This accounted for 15 matches loss per club per season 
(Woods et al., 2004). Recent figures published by Ekstrand et al suggested 
that in a professional male football team of 25 players, about 5 hamstring 
injuries occur each season, equivalent to more than 80 lost football days 
(Ekstrand et al., 2011). 
 
Muscle injuries are often assessed and diagnosed by clinical 
examination. Ultrasonography and Magnetic Resonance Imaging (MRI) can 
be useful in confirming clinical diagnosis. Muscle strains can be classified into 
three categories according to severity: Grade 1 (mild), a tear of few muscle 
fibres, minor swelling and discomfort with no or minimal loss of strength and 
restriction of movement. Grade 2 (moderate), a greater damage of muscle 
with clear loss of strength. Grade 3 (severe), a tear extending across the 
whole muscle belly, resulting in total loss of function(Jarvinen et al., 2000). 
There has not been any reliable method of predicting return to play or lay-off 
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time following hamstring injuries in high level athletes, as they are often 
multifactorial. Functional assessments such as isokinetic testing have been 
tried and used as a prognostication tool with mixed results (Ayala et al., 2013, 
Clark et al., 2006, Freckleton and Pizzari, 2013, Maffiuletti et al., 2007, 
McCleary and Andersen, 1992, Steiner et al., 1993). 
 
Rest, immobilization (Jarvinen et al., 2000), physical therapy (Cibulka 
et al., 1986) and non-steroidal anti-inflammatory drugs (NSAIDs) (Reynolds et 
al., 1995) have been the mainstay of therapy for grade 1 and 2 muscle injuries 
(Kasemkijwattana et al., 2000). For Grade 3 muscle injuries, surgical repair 
may be possible depending on the location and anatomy (Jarvinen et al., 
2000, Taimela et al., 1997). Immobilization can lead to improved granulation 
of the injured muscle and promote healing, but it will cause significant atrophy 
of healthy myofibres and joint stiffness (Jarvinen et al., 2000). Although some 
studies have shown that the administration of NSAIDs promotes muscle 
healing by reducing degeneration and inflammation (Abramson and 
Weissmann, 1989, Cheung and Tidball, 2003), other research has 
demonstrated that NSAIDs are detrimental to the entire healing process 
(Obremsky et al., 1994, Mishra et al., 1995, Almekinders and Gilbert, 1986). 
Recently, new treatment options such as growth factor injection therapy have 
shown good therapeutic results. However, due to their performance 
enhancing properties, growth factors and anabolic hormones are prohibited by 
the World Anti-Doping Agency (Lee et al., 2011). 
 
In terms of professional elite athletes, shortened recovery time could 
mean continuing with training, increased game play and benefit to the team 
and club. Therefore further research is needed to analyse the new techniques 
in treating muscle injuries. In 2008, an article in the British Journal of Sports 
Medicine titled "The early management of muscle strains in the elite athlete: 
Best practice in the world with a limited evidence", summarised that currently 
almost all our so-called knowledge has a basis of level 4 or level 5 (Orchard et 
al., 2008a). The panel continued to highlight the importance of Dr. Mueller-
Wohlfahrt's Traumeel and Actovegin injection treatment regimen for treating 
muscle injuries. This treatment regimen was considered by the panel of 
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experts to potentially be the current best practice with further research 
required (Orchard et al., 2008a). 
 
Dr. Mueller-Wohlfahrt's is a sports medicine specialist whose treatment 
is based on his conviction and experience over the years. His treatment 
method was popular with athletes, but there has not been any publication in 
regards to his injection therapy regime. I have obtained an unpublished 
injection therapy protocol from Dr. Mueller-Wohlfahrt to further understand his 
method. In brief, his treatment protocol for muscle injuries involves multiple 
local injection and associated back injection with a mixture of homeopathic 
and pharmacological substances(Wohlfahrt, 2008). In this cocktail, Actovegin 
is mixed with Traumeel and local anaesthetics for injection, therefore the 
biochemical property, pharmacodynamics and pharmacokinetics of each drug 
are altered and unpredictable. On the other hand, its desirable therapeutic 
effects could be due to the specific quantity and mixture of these drugs.  
 
As there have been no pharmacological and toxicology studies 
concerning Dr. Mueller-Wohlfahrt's cocktail to predict its lethal dose and half-
life, it is not practical to investigate the therapeutic effect of this mixture in 
muscle injury scientifically without knowing the specific effect of how these 
three substances interact with each other. The only potential “active” 
substance in Dr. Mueller-Wohlfahrt’s cocktail may be a drug called 
“Actovegin” which is a licenced clinically used drug with a track record of over 
60 years in treating ischaemic events and wound healing. Therefore in this 
PhD thesis, in order to avoid the unpredictable nature of poly-pharmacy as 
discussed above, only Actovegin will be investigated.  
 
1.2 Scope of this PhD 
 
In order to investigate the potential therapeutic effect or efficacy of 
Actovegin on muscle injury, basic muscle structures, histology and its healing 
process will be discussed. The biochemical events following skeletal muscle 
injuries and repair are driven by cytokines, monocytes and leukocytes 
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(Gulevskii et al., 2011, Gates and Huard, 2005, Ciciliot and Schiaffino, 2010, 
Chazaud et al., 2009). The speed and quality of muscle healing are 
dependent on the inflammatory process. In order to alter the speed or quality 
of muscle repair, the substance must be able to modulate the inflammatory 
process. Therefore, in vitro experiments will be performed in this PhD to 
investigate any potential role of Actovegin in the inflammatory process, hence 
muscle healing. If the in-vitro study in this PhD establishes significant results, 
ethical approval will be sought and a clinical study will be performed to 
investigate any potential translation effects of the in-vitro findings. Actovegin is 
a licenced drug in Europe, however it does not have marketing authority in the 
UK for human use, therefore specialist approval will be sought for the clinical 
study. Furthermore, the clinical study will be performed in high level athletes 
as this is the patient group that would potentially gain the most potential 
benefit from this method of treatment if it was successful. Due to this specific 
regulation of Actovegin and this patient group, a method will be development 
to batch test and standardise the Actovegin to assure quality control. Although 
the specific rules and regulations on Actovegin do not apply with regards to 
the in-vitro study, to ensure standardisation between the biochemistry and 
clinical studies all Actovegin used in this PhD will be batch tested. With 
regards to the clinical study, the role of isokinetic testing will be explored as a 
functional assessment in this group of patients.  
 
1.3 Aim of this PhD 
 
This PhD thesis is based on the call for future research from the 
current best practice paper from the British Journal of Sports Medicine “The 
early management of muscle strains in the elite athlete: Best practice in a 
world with a limited evidence basis” (Orchard et al., 2008a) on the treatment 
of muscle injuries by a panel of experts. The aim of the experiments and 
studies in this PhD is to provide further information on the role of Actovegin in 
muscle injuries and its clinical efficacy as an injection therapy in the treatment 
of hamstring muscular injuries in professional footballers. The structure of this 
PhD thesis is outlined in the flow diagram below.   
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1.4 Work flow diagram of the experiment in this PhD 
 
 
 
 
 
Literature Review 
Research question 
Acquisition and standardisation of Actovegin 
In-vitro study 
Clinical study 
Discussion 
Conclusion 
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Chapter Two 
Background and Review of literature 
 
2.1 Introduction  
 
In order to investigate any potential therapeutic effect of any substance to 
muscle injury, the basic muscle structures, histology and its healing process 
would need to be explored to identify a possible role of action for such 
substance. Basic Structure of Skeletal Muscle and the pathophysiology of 
muscle injury and healing will be discussed in this chapter. Its aetiology and 
evidence on treatment will be analysed. Background information and the 
evidence of the use of Actovegin in the treatment of muscle injury will be 
discussed. After reviewing all the evidence on muscle injuries and Actovegin, 
research question and hypothesis will be raised. 
 
2.2 Basic Structure of Skeletal Muscle  
 
Skeletal muscle is a mixture of muscle cells, nerves, blood vessels, 
and a complex extracellular connective-tissue matrix. A single unit of skeletal 
muscle cell is known as a myofibre, which is a highly organized, 
multinucleated structure consisting of microfilaments arranged to optimize 
contraction. (Figure 2.2)  
 
(Figure 2.2) Basic Structure of Skeletal Muscle (Gregorio and Antin, 2000) 
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2.2.1 Histology of muscle  
 
Myofibrils are composed of repeating contractile units known as 
sarcomeres, perhaps the most highly ordered macromolecular structures in 
eucaryotic cells (Gregorio and Antin, 2000). Each sarcomere consists of thick 
and thin filaments whose arrangement is largely responsible for the cross-
striated banding pattern observed under light and electron microscopy (Figure 
2.2.1). Sarcomeres are delineated at their ends to Z-lines where thin actin 
filaments of opposite directions are linked together by actinin dimers (Luther, 
2000). Z-lines are located in the middle of the I-band, which appears lighter in 
a light microscope and contains mainly actin filaments. Polymers of myosin 
molecules form the darker A-band. The A band is bisected by a light region 
called the H band, the major component of which is creatinine kinase. 
Running through the midline of H band is the M line in which the thick 
filaments are anchored by several myosin-binding proteins. Thick filaments 
are connected to giant titin molecules expanding to half of a sarcomere, from 
the Z-line to M-line (Figure 2.2). Titin is thought to function as a spring and a 
ruler defining sarcomere length after muscle contraction (Linke et al., 1999), 
which happens when actin filaments interact with the myosin filaments so that 
the thin filaments move past the thick filaments towards the centre of the 
sarcomere thus shortening it. 
 
 
(Figure 2.2.1) Basic histological structure of Skeletal Muscle (Linke et al., 1999) 
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2.2.2 Muscle type and structure 
Although all skeletal myofibres have the same basic sarcomeric 
organization, a number of distinct types have been described according to 
structural, physiological and biochemical criteria. Skeletal muscle fibres can 
be generally classified as fast or slow twitch, based on their contractile and 
metabolic properties and associated patterns of gene expression (Hughes et 
al., 1998). These properties of skeletal muscle fibres are dependent on the 
pattern of motor neuron stimulation, so that tonic motor neuron activity 
promotes the slow fibre phenotype while infrequent motor neuron firing results 
in fast fibres; the muscle phenotype according to neuron activity (Wu et al., 
2000). 
 
There are 2 types of myofibres: 
 
Type I  Myofibres are slow and fatigue-resistant,  
 
Red slow twitch oxidative fibres (type I), are involved in sustained, tonic 
contractile events and maintain intracellular Ca2+ concentrations at 
relatively high levels (100-300nM).  
 
 
Type II  Myofibres are fast and have poor fatigue resistance  
(e.g. hamstring muscle) 
 
White fast twitch glycolytic fibres (type II) are used for sudden bursts of 
contraction and are characterized by brief, high-amplitude Ca2+ 
transients and lower ambient Ca2+ levels (<50nM).  
 
Sub Type A:  Fast twitch and have good fatigue resistance 
 
Used more during sustained power activities such as sprinting 
400 meters or doing repeated lifts with a weight below 
maximum. Type IIA fibres have large amounts of myoglobin, and 
high capacity for generating ATP by oxidative metabolic 
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processes, and break down ATP at a very rapid rate. They have 
a fast contraction velocity and are resistant to fatigue. Such 
fibres are infrequently found in humans. 
 
Sub Type B:  Fast twitch and have poor fatigue resistance 
 
Used for very short-duration high-intensity bursts of power such 
as maximal and near-maximal lifts and 100 metre sprints. Type 
IIB fibres contain a low content of myoglobin, relatively few 
mitochondria, relatively few blood capillaries and large amounts 
glycogen.  
 
Type IIB fibres can generate ATP by anaerobic metabolic 
processes, but are not able to supply skeletal muscle fibres 
continuously with sufficient ATP, and fatigue easily. Such fibres 
are found in large numbers in the muscles of the arms in 
humans. 
 
Structurally, when compared to type II myofibres, type I myofibres tend 
to be narrower, have thicker Z and M bands, have more glycogen, and their 
sarcoplasm is rich in mitochondria. The molecular basis for the functional 
diversity of myofibres is the expression of specific isoforms of most of the 
proteins involved in muscle contraction and relaxation. Myofibre classification 
is based on contraction speed and other physiological properties but 
predominantly according to specific myosin heavy chain (MyHC) isoforms.  
 
Morphological details vary in different muscle fibres. Skeletal muscles 
respond to changes in physiological demands by remodelling the architecture 
of individual fibres. Sarcomeres are added or removed when muscles are held 
at abnormally long or short lengths, and myofilaments are added or removed 
when muscle fibres function against abnormally heavy or light loads (Trotter, 
2002). This leads to changes in overall mass of the tissue. Also the spatial 
relationship among muscle cells and other components of muscle tissue can 
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change and gene expression can be reprogrammed to alter specialized 
metabolic and contractile properties of myofibres (Wu et al., 2000). 
 
The plasma membrane encasing the myofibre is called the 
sarcolemma. External to the sarcolemma is the basal lamina (basement 
membrane), which is a 100- to 200-nm thick external connective tissue layer 
that contains a number of proteins including collagen, fibronectin, laminin, and 
many glycoproteins. Normally, the region between the sarcolemma and the 
basal lamina is occupied by satellite cells that lie quiescent. Acute injury to 
skeletal muscle stimulates satellite cell proliferation and differentiation, 
producing myogenic precursors such as myoblasts (Gates and Huard, 2005). 
This process is discussed in detail in section 2.3.2 
 
2.3 Muscle injuries 
 
Muscle injuries are one of the most common sports related injuries; 
their incidence varies from 30-55% in all sports related injuries per year 
(Noonan and Garrett, 1999, Verrall et al., 2001, Jarvinen et al., 2000).  More 
than 90% are caused either by excessive strain or contusions. Strain injuries 
are common in high power sports that are associated with sprinting or jumping 
(Jarvinen et al., 2000, Garrett, 1996b). These injuries are typically present at 
the myotendinous junction or the mid substance of muscles working across 
two joints, such as hamstrings and calf muscles (Garrett, 1996b). On the other 
hand, contusion injuries are typically associated with contact sports and could 
present at any site. A strain injury frequently occurs in the setting of eccentric 
contraction. Forces generated within eccentrically activated muscle are higher 
than in a concentrically activated muscle, thus increasing susceptibility to 
injury (Jarvinen et al., 2000, Garrett, 1996b). 
 
2.3.1 Classification of muscle injuries 
 
The clinical manifestation of a muscle strain could depend on the 
severity of the injury. Jarvinen et al classified it in three categories according 
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to their severity (Jarvinen et al., 2000). This classification is widely used in 
sports medicine and it is purely a clinical diagnosis, based on patient’s 
symptoms and physical signs from clinical examination. Although radiological 
imaging techniques such as MRI and ultra sound scanning could be a useful 
adjuncts to enforce clinical findings, the diagnosis and classification of muscle 
injuries only depend on the clinical factors. 
 
Clinical Classification of muscle strains by Jarvinen et al (Jarvinen et al., 
2000) : (Figure 2.3.1) 
 
Mild (Grade 1) strain 
Tear of a few muscle fibres; minor swelling, minimal loss of function 
  
Moderate (Grade 2) strain 
Greater damage to muscle, palpable gap, clear loss of strength  
 
Severe (Grade 3) Strain 
Tear across the whole muscle belly, palpable gap, total loss of function 
 
 
 
(Figure 2.3.1) Classification of muscle strain injuries (Jarvinen et al., 2000) 
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2.3.2 Pathophysiology of muscle strain injuries 
 
The damage caused by the strain of the skeletal muscle is defined as a 
shearing injury; this would lead to mechanical and ischaemic damage to the 
muscle cells. The mechanical force tears the entire myofibre, damages its 
plasma membrane and leaves the sarcoplasm open at the end of the stumps 
and initiates necrosis. (Further details on muscle structure please see section 
2.2.1) It will extend along the whole length of the ruptured myofibre causing 
inflammation and further cell damage (Gates and Huard, 2005). At the same 
time the injury has disrupted normal blood supply to the muscle cells and 
leads to ischaemia; this event will further enhance muscle necrosis and 
exacerbate the cellular damage cause by the acute inflammatory responds 
(Blaisdell, 2002). These ischaemic effects would depend on the muscle type 
as they have different cellular characteristics. (Further information on muscle 
type in section 2.2.2) 
 
During the ischaemic event, initially myocyte glycogen and creatine 
phosphate are depleted in preference of ATP, and little muscle necrosis 
occurs(Blaisdell, 2002). However once ATP levels start to diminish, muscle 
necrosis sets in rapidly. Therefore the speed and extent of muscle necrosis 
are dependent on the amount of myocyte glycogen and ATP availability hence 
the muscle type.  The extent of the mechanically induced inflammatory 
response and ischaemic damage to the muscle cells following muscle strain 
injuries are dependent on the severity of injury and muscle type –(type IIB 
muscle are more dependent on ATP, hence are more susceptible  to ischemic 
insult), therefore treatment targeted to modulate the inflammatory response or 
the ischaemic effects can potentially improve overall outcome (Figure 2.3.2). 
 
 
 
 
 
(Figure 2.3.2) illustration to show the cellular pathophysiology of muscle strain injuries. Red 
area = cells in damage zone, Pink area = cells in ischemic zone and Blue area = cells with 
normal tissue perfusion. 
 
 
 
 
Normal cells 
 
 
Cells partially damage from the injury  
 
Damaged cells from injury
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2.3.3 Pathophysiology of the healing process in muscle strain injuries 
 
Muscle injury typically initiates a rapid inflammatory response as 
discussed in 2.3.2. The sequential invasion of inflammatory cells to the injury 
site persists from days to weeks, during muscle repair and regeneration. 
Recent studies have distinguished between inflammatory processes that 
disrupt muscle homeostasis and processes that promote muscle repair after 
muscle injury (Tidball and Wehling-Henricks, 2007). The repair process after 
muscle strain injuries can be divided into three phases, (Figure 2.3.3). 
 
 
 
(Figure 2.3.3) A schematic presentation of the different phases of muscle strain injuries: 
Inflammation destruction phase, Anti-inflammatory repair phase, Remodelling maturation 
phase. (Garrett, 1996a, Grefte et al., 2010, Jarvinen et al., 2000, Gates and Huard, 2005) 
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1) Inflammatory destruction phase 
 
This is characterized by haematoma formation, myofibre 
necrosis and phagocytosis of dead tissue, initiated by 
inflammatory cells and cytokines (Garrett, 1996b, Grefte et al., 
2010, Jarvinen et al., 2000).  
 
Mechanical disruption of the sarcolemma significantly 
increases the permeability of the membrane to calcium, leading 
to an influx of extracellular calcium into the myofibre. This influx 
of calcium triggers a chain of events beginning with the 
stimulation of the complement cascade and culminating with the 
activation of intrinsic proteases that digest the myofibre, leading 
to myofibre necrosis. The necrotic myofibres naturally retract, 
creating a gap (Orchard and Best, 2002, Grefte et al., 2010, 
Gates and Huard, 2005). 
 
Blood vessels are torn and capillaries damaged during 
muscle injuries leading to haematoma formation, which quickly 
fills this gap. It contains multiple growth factors, cytokines, 
macrophage, naive myogenic cells, and infiltrating inflammatory 
cells. Inflammation can be conceptualized as the response of 
the immune system to the injury. The interactions between these 
cells, proteins, and molecules strongly influence the remainder 
of the healing process (Gates and Huard, 2005). 
 
The inflammatory process begins within the first hour 
after injury and peaks at 24 hours. Pro-inflammatory cytokines 
such as interleukin IL-1, IL-8, and tumour necrosis factor α (TNF 
α) are secreted by a variety of cell types, attract and activate 
macrophages, and native myogenic cells (Gates and Huard, 
2005).  
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Macrophages have been traditionally viewed as 
scavengers only involved in the removal of necrotic debris, 
however recent studies have suggested that they may also have 
an active role in promoting muscle regeneration (Garrett, 1996b, 
Grefte et al., 2010, Jarvinen et al., 2000). Recent studies 
suggest that there are two distinct subpopulations of 
macrophages sequentially involved in this process (Garrett, 
1996b, Grefte et al., 2010, Jarvinen et al., 2000). The early 
invading “phagocytic” macrophages CD68+), characterized by 
the expression of the CD68+ cell surface markers and lacking 
the CD163+ marker, reach a highest concentration in damaged 
muscle at about 24 hours after the onset of injury and then 
rapidly decline (Figure 2.5). These CD68+ macrophages are pro-
inflammatory phagocytes that secrete inflammatory cytokines 
such as TNF α and IL-1 and are responsible for the removal of 
necrotic debris. After 48 hours, a second subpopulation of “non-
phagocytic” macrophages (CD163+), characterized by the 
expression of the CD163+ surface marker and lacking the CD68+ 
marker are then found and reach a peak at day 4 after the initial 
injury (Figure 2.3.4).  This CD163+ subgroup displays an anti-
inflammatory property and secretes cytokines, such as IL-10, 
which contributes to the termination of inflammation (Garrett, 
1996b, Grefte et al., 2010, Jarvinen et al., 2000) 
 (Figure 2.3.4) Schematic presentation of current theoretical sequence of events following 
muscle injury: inflammation, anti-inflammation and regenerative (Grefte et al., 2010).  
Regeneration of Mammalian Skeletal Muscle Current Pharmaceutical Design, 2010, Vol. 16, No. 8    907 
1 (IL-1), and are responsible for the phagocytosis of necrotic 
tissue. A second population of CD68-/CD163+ "anti-inflammatory" 
macrophages, apparently derived from inflammatory macrophages 
by phenotype switch, reach their peak at 2 to 4 days after injury: 
they secrete anti-inflammatory cytokines, such as interleukin-10 
(IL-10), that contribute to the termination of inflammation. Earlier 
studies showed that macrophages release factors that enhance 
myogenic precursors proliferation, growth and differentiation [6-8]; 
it is now clear that this is a property of CD163+ "anti-inflam-
matory" macrophages [4]. Thus macrophages have a central regu-
latory role in the muscle response to injury, not only by removing 
necrotic tissue but also by promoting muscle regeneration. 
2.2. Satellite Cell Activation and Differentiation 
 Satellite cells are muscle-specific stem cells located under the 
basal lamina of muscle fibers [9], which are responsible for muscle 
regeneration (see [10, 11]). They also contribute to the increase in 
the number of myonuclei during postnatal muscle growth [12] and 
compensatory muscle hypertrophy [13, 14] by proliferating and 
fusing with the myofibers. Non muscle stem cells, either cells 
associated to blood vessels or circulating stem cells have been 
hypothesized to participate in muscle regeneration, but their role 
appears to be minimal under normal conditions. A crucial experi-
ment supporting the central role of satellite cells was the demons-
tration that grafting a single myofiber with as few as seven asso-
ciated satellite cells into an irradiated host muscle can generate over 
100 new myofibers with thousands of myonuclei and repopulate the 
host muscle with new satellite cells [15]. Thus satellite cells are 
able to self-renew and to give rise to differentiated cells, the two 
distinctive properties of stem cells. 
 Satellite cells can be identified by the presence of specific 
markers, such as Pax7, M-cadherin and CD34 (Fig. (2)). Pax3, the 
paralogue of Pax7, is also expressed in satellite cells of some adult 
muscles. Pax3 and Pax7 (paired box proteins 3 and 7) are trans-
cription factors playing a crucial role in embryonic myogenesis 
[16]. Satellite cells undergo apoptotic cell death early after birth in 
Pax7 knockout mice and are absent in adult Pax7 null muscles [17]. 
However, a recent study using an inducible knockout technique, 
demonstrated that Pax7 is not necessary for the survival of satellite 
cells in adult animals [18]. Even in the absence of Pax7, rege-
neration occurs in a normal way, and muscle can recover from 
severe injuries. Moreover, satellite cells become activated, proli-
ferate, and colonize again the niche between the sarcolemma and 
the basal lamina of the regenerated fibers. Normal muscle rege-
neration takes place also after dual inactivation of Pax3 and Pax7, 
thus excluding the possibility of a rescue of Pax7 due Pax3 
activation [18]. These findings demonstrate that regeneration does 
not recapitulate development in this respect. 
 Following injury, satellite cells undergo rapid proliferation, 
starting during the second day after injury. Multiple signals appear 
to trigger satellite cells activation. Generation of sphingosine-1-
phosphate in the inner side of the plasma membrane of the satellite 
cell is required for satellite cell activation: when its synthesis is 
abrogated, satellite cells do not enter the cell cycle and the 
regeneration process is defective [19]. Nitric oxide (NO) production 
by increased NO synthase (NOS) activity is also important for 
satellite cell activation, possibly through activation of matrix metal-
loproteinases, which induce the release of hepatocyte growth factor 
(HGF) from the extra-cellular matrix [20]. By binding to its recep-
tor, c-Met, which is expressed by satellite cells, HGF is able to 
stimulate satellite cell activation [21] but in the same time inhibits 
muscle differentiation [22]. The switch from satellite cell 
proliferation to differentiation appears to be controlled by Wnt and 
Notch signaling, Notch signaling being prevalent during the proli-
feration phase [23] and Wnt signaling during the differentiation 
phase [24]. In the first days after injury, sustained Notch signaling 
is required for the expansion of satellite cell progeny, then 
canonical Wnt signaling drives muscle differentiation [23-25]. 
Defective Notch signaling leads to inhibition of satellite cell 
proliferation and self-renewal, while enhancement of Notch signal-
ing promotes muscle regeneration in aged muscle (see below, 
section 6, [25, 26]). Increased Wnt signaling, acting through the 
canonical Wnt pathway, induces the differentiation of proliferating 
myoblasts [24]. Correct timing is crucial, since premature Wnt 
signaling activation leads to premature differentiation and fusion of 
myoblasts, when the number of proliferating myoblasts is still not 
sufficient to completely repair the lesion [24]. A recent study point 
to a more complex role of Wnt signaling during muscle 
regeneration. Wnt7a, which is upregulated during regeneration and 
acts through a non-canonical Wnt pathway, is required for the 
expansion of satellite cell population during regeneration [27], but 
has no effect on growth or differentiation of myoblasts. Overex-
pression of Wnt7a enhances regeneration, while silencing of Frz7 
(the candidate receptor for Wnt7a) abrogates Wnt7a stimulation of 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Major events in muscle regeneration. Schematic representation of the temporal sequence of inflammatory and regenerative events following muscle 
injury.  
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2) Anti-inflammatory, repair phase  
 
Several findings suggest that macrophages may play a 
more direct role in muscle repair and re-modelling than merely 
removing tissue debris. After 48 hours, a second subpopulation 
of “non-phagocytic” macrophages (CD163+), characterized by 
the expression of the CD163+ surface marker and lacking the 
CD68+ marker are then found and reach a peak at day 4 after 
the initial injury. This CD163+ subgroup displays an anti-
inflammatory property and secretes cytokines, such as IL-10, 
which contributes to the termination of inflammation (Garrett, 
1996b, Grefte et al., 2010, Jarvinen et al., 2000, Orchard and 
Best, 2002, Gates and Huard, 2005). Thus macrophages have a 
central regulatory role in the muscle response to injury, not only 
by removing necrotic tissue but also by promoting muscle 
regeneration. 
 
3) Remodelling, maturation phase  
 
Satellite cells located under the basal lamina of muscle 
fibres are responsible for muscle regeneration following the 
inflammatory process. There are several postulated 
mechanisms explaining satellite cell activation after trauma. 
Some researchers have posited that disruption of the integrity of 
the sarcolemma and basal lamina activates satellite cells 
(Orchard and Best, 2002, Grefte et al., 2010, Gates and Huard, 
2005). Others maintain that cytokines released by infiltrating 
inflammatory cells result in satellite cell activation. Activated 
satellite cells proliferate and differentiate for as long as 10 days. 
The progeny of satellite cell differentiation are myogenic 
precursors such as myoblasts, which proliferate and begin to 
differentiate and fuse into multinucleated myotubes, immature 
myofibres, and eventually mature myofibres (Orchard and Best, 
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2002, Grefte et al., 2010, Gates and Huard, 2005). Figure 2.3.5 
summarizes these events. 
 
 
 
(Figure 2.3.5) A schematic presentation of the remodelling / regeneration 
phase after muscle injury (Gates and Huard, 2005). 
 
 
Several growth factors released at the injury site play key 
roles in enhancing myoblast proliferation and differentiation. 
These growth factors include insulin-like growth factor 1 (IGF-1), 
basic fibroblast growth factor (bFGF), Epidermal Growth Factor 
(EGF) and hepatocyte growth factor (HGF). This leads to the 
maturation of regenerated myofibres, contraction and re-
organisation of scar tissue. (Orchard and Best, 2002, Grefte et 
al., 2010, Gates and Huard, 2005) 
 
 
  
generation through at least three mechanisms. First, ECM
proliferation confines the regenerative growth of the myofi-
bers32,47; second, dense fibrotic tissue that lacks the elasticity
of native muscle renders the muscle more prone to reinjury;
third, fibrotic tissue inhibits new axons from reaching the
muscle fibers, thus exacerbating denervation atrophy.32,35
Previous reports indicated that overproduction of TGF-!1
is a major cause of fibrosis in both animals and humans.58,59
Though the entire process f fibrosis is only partially under-
stood, current studies suggest that TGF-!1 also plays a key
role in initiating and perpetuating the fibrosis cascade in
injured skeletal muscle.60–63 An excess of TGF-!1 leads to
chronic inflammation, fibrosis, and accumulation of
ECM.64,65 Two mechanisms through which TGF-!1 pro-
motes fibrosis have been postulated. First, TGF-!1 stimu-
lates the production of ECM proteins and simultaneously
blocks their degradation.66,67 Second, TGF-!1 promotes
myogenic precursor differentiation down the myofibroblast
lineage rather than the myoblast lineage.47,63 These observa-
tions suggest that the expression of TGF-!1 in skeletal mus-
cle may play an important role in the fibrotic cascade follow-
ing the onset of muscle disease or trauma.
Current and
Experimental Therapeutics
of Skeletal Muscle Injuries
Skeletal muscle injuries in military personnel are common
and heal only incompletely resulting in a loss of flexibility
and strength, placing the patient at an increased risk for
reinjury. For these reasons, improvements in treatment reg-
imens for skeletal muscle injuries have a great potential to
impact military readiness and lower monetary costs associ-
ated with muscle injuries. Therapies have been devised tar-
geting each phase of healing. Current research trends focus
on enhancing regeneration and minimizing fibrosis so as to
reduce the amount of scar tissue formed within the muscle.
This would potentially restore normal tissue architecture and
maximize functional outcomes. The role of inflammation and
Muscle Injury
Activation of MDSCs
Activation of 
quiescent 
satellite cells
Formation of nerve, 
blood vessels, 
and other tissues
Myoblast proliferation
Regenerating Myotube formation
Mature Myofiber
Self-renewal of MDSCs
Figure 2 Muscle regeneration after injury. (Color version of figure is available online.)
One Two Three Four
Weeks
Zero
Degeneration
Regeneration
Fibrosis
Figure 3 Timeline of phases of healing after injury. (Color version of figure is available online.)
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2.3.4 Areas identified for further investigation in this PhD  
 
The pathophysiology of muscle injuries and its repair process are 
complex as described in 2.3.2 and 2.3.3. The extent of the tissue damage and 
myofibre necrosis depends on the inflammatory response and ischaemic 
damage, which are dictated by the mechanical strain at the time of the injury. 
As discussed in 2.3.2, myofibre necrosis depends on the available ATP, 
hence ischemia time. It would be logical to assume that, at the zone of injury, 
cell necrosis sets in rapidly due to the initial tissue trauma; little can be done 
to mitigate cell death at the zone of injury. However, at the peripheral zone 
around the zone of injury, the blood supply is interrupted and muscle 
homeostasis is imbalanced. Therefore the cells in the perhiperal zone are 
susceptible in developing cellular necrosis if they sustain further insult 
(Blaisdell, 2002). As the secondary inflammatory response from the zone of 
injury progresses, the cytotoxic effects from its metabolites increase the 
hostility of the surrounding cells. It will have a negative effect on the cells in 
the perhieral zone and cause further cell necrosis; hence exacerbate the initial 
damage caused by the injury. As discussed in 2.3.2, this secondary onset of 
myofibre necrosis depends on muscle cell type and its metabolic rate. 
Therefore, the ability of the cells in the peripheral zone to withstand further 
insult can influence the overall effect of the injury. With regards to the healing 
process, the biochemical events involved in the muscle healing process are 
better understood, as discussed in 2.3.3. Macrophages play an important role 
in the inflammatory and anti-inflammatory process (Gulevskii et al., 2011, 
Gates and Huard, 2005, Ciciliot and Schiaffino, 2010, Chazaud et al., 2009); 
therefore modulation of specific macrophages could also potentially influence 
the muscle repair process. 
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2.4 The hamstrings 
 
The Hamstrings is a muscle group consisting of three muscles - 
semitendinosus, semimembranosus and biceps femoris. These posterior leg 
muscles originate at the bottom of the pelvis from the ischial tuberosity. Two 
of the hamstrings insert into the top of the tibia (medial); the other inserts into 
the fibula (lateral). Its main function is hip extension; semitendinosus and 
semimembranosus also flex the knee and medially rotate the lower leg when 
the knee is bent. Whereas the biceps femoris (both short and long heads) 
laterally rotates the lower leg during flexion (Bennell et al., 1998, Slavotinek et 
al., 2002, Woods et al., 2004, Maffiuletti et al., 2007, Ekstrand et al., 2009, 
Goldman and Jones, 2009). The hamstrings play a crucial role in many daily 
activities, such as, walking, running, jumping, and controlling some movement 
in the trunk. In walking and running they are most important as an antagonist 
to the quadriceps in the deceleration of knee extension.  
 
The hamstrings muscles are skeletal muscles; their histological 
structures have been discussed in 2.2.1. This group of muscles contain type II 
fast twitch glycolytic fibres, its ratio of A and B type fibres varies between 
individuals and depends on training(Jarvinen et al., 2000). Further details of 
muscle sub types and structure were discussed in 2.2.2. Type II muscle fibres 
are highly energy dependent and therefore its function is sensitive to the 
availability of ATP. During muscle injuries, the blood supply to the muscle is 
disrupted; hence the oxidative metabolic processes are compromised and 
reduce the amount of available ATP. As the hamstring muscles are highly 
energy dependent, tissue damage alongside with this ischaemic effect could 
cause further damage to the surrounding tissue after the initial injury. For 
further details of the pathophysiology of muscle injury please see 2.3.2 
 
2.4.1 Hamstring injuries 
 
Hamstring injuries are very common in sport with high demands on 
speed and power such as football (soccer), Australian-rules football, rugby, 
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basketball and American football. They are 2.5 times more common than 
quadriceps injuries (Woods et al., 2004, Askling C, 2003).  
 
Hamstring injuries occur during the last part of the swing phase or at 
foot strike(Liemohn, 1978, Paton et al., 1989, Burkett, 1970). At both of these 
phases of running, the hamstrings generate peak torque values and work 
maximally eccentrically to decelerate the leg(Reurink et al., 2012, Paton et al., 
1989, Liemohn, 1978, Herzog, 1988). Therefore most hamstring tears are 
typically partial and commonly take place during the eccentric phase of 
muscle usage when the muscle develops tension while lengthening (Kujala et 
al., 1997, Liemohn, 1978, Paton et al., 1989). The most commonly injured 
hamstring muscle is the biceps femoris (Slavotinek et al., 2002). Muscle 
strength deficiency has been proposed as one of the risk factors for such 
injuries(Kujala et al., 1997, Jarvinen et al., 2000, Clark et al., 2006, Goldman 
and Jones, 2009). Some studies suggest that a greater than 10% bilateral 
deficit in isometric hamstring strength is predictive of hamstring injury (Burkett, 
1970, Orchard et al., 1997). Strength imbalances between the quadriceps and 
hamstring muscle groups have been reported as the mechanism behind the 
hamstring injuries (Askling C, 2003, Orchard et al., 1997, Woods et al., 2004, 
Gabbe Bj, 2006). It was associated with significantly lower concentric 
isokinetic hamstring to quadriceps muscle peak torque ratio (Bennell et al., 
1998, Askling C, 2003, Woods et al., 2004). The injured hamstring muscles 
were weaker than in the opposite leg in absolute values and hamstring-to-
quadriceps muscle ratios(Herzog, 1988, Garrett, 1996a, Orchard et al., 1997, 
Funk D, 2001, Woods et al., 2004). It was significantly associated with a low 
hamstring-to-quadriceps muscle peak torque ratio at 60 deg/sec on the 
injured side and a low hamstring muscle side-to-side peak torque ratio at 60 
deg/sec (Orchard et al., 1997). However, there are also retrospective and 
prospective observational studies suggesting that isometric (Liemohn, 1978) 
and isokinetic (Paton et al., 1989) quadriceps to hamstring ratios cannot 
reliably predict the likelihood of hamstring injuries. Further discussion and 
detail on isokinetic testing will be discussed in section 4.3.4. 
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2.4.2 Literature review of the treatment of hamstring injuries 
 
Although hamstring muscle injuries are one of the most common 
muscle injuries sustained by athletes, the evidence of therapeutic intervention 
is limited (Orchard et al., 2008a). There is currently no consensus on the best 
management options. Rest, ice, compression, elevation (RICE), non-steroidal 
anti-inflammatory drugs (NSAIDs) and injection therapy are used among 
sports physicians to treat varying types of hamstring injuries (Orchard et al., 
2008a, Reurink et al., 2012). 
 
2.4.2.1 RICE 
 
Rest, ice, compression, elevation (RICE) treatment is the most 
traditional and commonly used method to treat muscle sprains and strains. It 
has been described in textbooks and practiced by many professional athletes, 
coaches and members of the healthcare team. These four procedures have 
the same objective, to minimize bleeding from ruptured blood vessels at the 
rupture site. It was assumed that it would prevent the formation of a large 
haematoma, which could impact upon the size of scar tissue at the end of the 
regeneration. A small haematoma and the limitation of interstitial oedema 
accumulation at the rupture site was believed to shorten the ischaemic period 
in the granulation tissue, which may in turn accelerate regeneration (Jarvinen 
et al., 2000).  
 
 
Rest and Elevation  
 
Although it is the most commonly used method of treatment in 
acute hamstring injuries, there is no consensus on the duration and 
technique used in the practical aspect (Reurink et al., 2012). The initial 
resting period could range from 2 -72 hours and some protocols 
describe complete rest of the limb as compared to mobilising the limb 
as pain allows (Reurink et al., 2012, Rask and Lattig, 1972, MacAuley, 
2001). Furthermore, resting methods vary between protocols and 
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patient perception. It ranges from complete splinting(Lipscomb et al., 
1976), passive range of movement to minimal active resistance 
exercise(Reurink et al., 2012, Freckleton and Pizzari, 2013).  
 
In terms of elevation, the general principle is to raise the injured 
site above heart level to facilitate lymphatic drainage and venous 
return. There is no evidence suggesting that elevation alone can 
reduce soft tissue swelling. In facial and shoulder injuries, although 
there is assumed anatomical advantage of the injured site being above 
the heart, the amount of swelling is not slighter compared to lower limb 
injuries. Unless the patient is supervised 24 hourly with a team nursing 
staff support, it is impossible to completely rest and elevate the injured 
limb, therefore compliance to such protocols may be difficult. Due to 
these logistical factors, there are currently no control trials to 
demonstrate the effect of rest and elevation (Thorsson et al., 1997, 
Reurink et al., 2012). As there is such large variation in the 
understanding and practice of rest and elevation, there are no common 
consensus of best practice. 
 
Ice 
 
With regards to ice treatment (cryotherapy), it is perhaps the 
simplest and oldest therapeutic modality in the treatment of acute soft-
tissue injuries. It is assumed that by decreasing tissue temperature, 
cryotherapy can reduce pain, slow down metabolism and minimise the 
inflammatory process (K, 1989, KL, 1976). The majority of research 
studies and reviews to date have used healthy human subjects to 
investigate these proposed physiological effects. Although there is 
evidence that cryotherapy can reduce deep-tissue temperature in both 
animal (Barlas et al., 1996) and human subjects, (Draper et al., 1995, 
Merrick et al., 1993, Zemke et al., 1998) the degree of cooling seems 
to depend on the method and duration of application, the initial 
temperature of the ice, and even the depth of subcutaneous fat 
(MacAuley, 2001). 
 33 
 
Current recommendations in standard textbooks on the clinical 
use of ice also have many shortcomings, and most physicians rely on 
empirical evidence (MacAuley, 2001). The selection of parameters in a 
clinical environment continues to be made pragmatically, and 
recommendations in review articles range from 10 to 20 minutes, 2 to 4 
times per day, up to 20 to 30 minutes, or 30 to 45 minutes every 2 
hours (Bleakley et al., 2004). The most recent surveys of clinical 
practice have identified variations on the optimal mode, duration, and 
frequency of ice application, yet such factors dictate the degree of 
cooling and the potential effectiveness of treatment (MacAuley, 2001).  
 
There is no consensus on the duration of time the ice pack is 
applied and the frequency of use. However, there seems to be a 
common agreement that ice packs should not be used more than 48 
hours post injury. There are no randomized studies assessing the 
efficacy of ice in the treatment of muscle contusions; only five studies 
have assessed the effect of ice on acute ankle sprains. Single 
applications of combined ice and compression seem to be as effective 
as no treatment after an acute sprain.  
 
Given the popularity of cryotherapy treatment with the layman, it 
may be difficult to randomize a subject to a “no ice” group.  Within 
clinical practice, ice is commonly combined with compression and 
elevation, making it difficult to determine the value of cryotherapy alone 
(Meeusen and Lievens, 1986, Thorsson, 2001).  There have been 
some side effects of cryotherapy reported such as skin burns (O'Toole 
and Rayatt, 1999) and nerve damage (Moeller et al., 1997) after as 
little as 20 minutes of cooling.  
 
Cryotherapy is a versatile modality and may be used in the 
immediate and rehabilitative phases of injury management. 
Immediately ice application is advocated post injury, it is assumed that 
cryotherapy can reduce tissue metabolism and may reduce secondary 
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hypoxic injury, cell debris, and oedema. Therefore cryotherapy initiated 
between 24 and 48 hours after injury may not have optimized this 
positive physiological effect.  
 
The majority of studies in current literature have not fully 
considered the pathophysiological basis of cryotherapy and may not 
have used it to its full potential. Recommendations on ice dosage 
remain anecdotal and usually do not change based on the 
circumstances of injury. The depth of muscle injury and the 
surrounding adipose tissue must be considered and collate with the 
clinical effectiveness of cooling (Bleakley et al., 2012). Future research 
into the effectiveness of ice and muscle injury is needed. Treatment 
dosage should potentially be developed based on injury depth and 
should be factored into future clinical trial design.  
 
Compression 
 
The principle of acute compression to treat soft tissue injury is 
widely based on bleeding control and reduction of haematoma; it was 
believed to shorten recovery time and prevent myositis ossificans 
(Rask and Lattig, 1972, Lipscomb et al., 1976, Thorsson et al., 1997). 
Although there is an extensive amount of literature on acute soft tissue 
injuries, there is no stand-alone controlled clinical study comparing 
compression to no treatment. The majority of publications regarding the 
use of compression to treat acute muscle injuries are based on post 
eccentric training rather than traumatic muscle injuries. For the 
remaining studies, ice or crythotheapy are usually combined with 
compression post injury and duration and frequency are also different, 
therefore it is impossible to draw meaningful conclusions from these 
studies. Furthermore, due to different body habitus, the type of 
compression bandage used, and the technique of its application, the 
compressive force across the injured site cannot be standardised.  
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Thorsson et al 1997 demonstrated that immediate treatment 
(within 5 min of the occurrence of an acute muscle injury) with a 
maximum compression bandage did not reduce the formation of a 
haematoma and did not shorten the recovery time of the injured 
players in this investigation compared with treatment of minimal 
compression, rest and elevation only (Thorsson et al., 1997).  
 
 
2.4.2.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
 
NSAIDs are primarily used for their analgesic, anti-inflammatory, and 
antipyretic properties, although their in-vivo effects in treating musculoskeletal 
injuries in humans remain largely unknown (Paoloni et al., 2009). Non-
steroidal anti-inflammatory medications have become popular in the treatment 
of sports injuries. Conventional wisdom has dictated that inflammation is bad 
and needs to be reduced after acute injuries. Although there is little evidence 
to promote the use of NSAIDs in acute muscle injuries and some studies even 
suggests that NSAIDs could be counterproductive to the healing process, 
their use is still remains common (Reurink et al., 2012).  
 
NSAIDs’ analgesic action is not significantly greater than paracetamol 
for musculoskeletal injuries but they have a higher risk profile, with side 
effects including asthma exacerbation, gastrointestinal and renal side effects, 
hypertension and other cardiovascular diseases. A number of studies and 
reviews found that NSAIDs are no more effective than placebo in the 
management of acute soft tissue injuries (Mehallo et al., 2006, Ziltener et al., 
2010). Furthermore, concerns have been raised about the possible harmful 
effect of NSAIDs on muscle healing after acute injury, because of delayed 
muscle regeneration and promotion of fibrosis (Ziltener et al., 2010, Shen et 
al., 2005). Reynolds et al found no statistically significant effect of treatment 
with NSAIDs on pain score and isokinetic hamstring testing compared with 
placebo. Pain scores measured with a visual analogue scale after 1 week 
were 7.9±6.6, 8.8±7.7 and 3.9±3.3 for the meclofenamate, diclofenac and 
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placebo group, respectively (Reynolds et al., 1995). Adverse effects such as 
gastrointestinal upset and headache were reported in 38% of the NSAIDs 
group compared to 14% of the placebo group (Reynolds et al., 1995). 
 
Inflammatory cells play an important role in the healing process of an 
injured muscle. Therefore, the use of drugs that inhibit these cells, such as 
NSAIDs, is contradictory. On the other hand, NSAIDs could also play a 
beneficial role in the acute injury setting. The inflammatory process can be 
excessive and cause oedema, resulting in anoxia and further cell death. This 
can be prevented by the administration of low-dose NSAIDs (Paoloni et al., 
2009). 
 
There have been many review papers on the use of NSAIDs, but none 
have advocated their use as a first line treatment or routine management to 
treat acute muscle injuries (Paoloni et al., 2009, Reurink et al., 2012, Ziltener 
et al., 2010, Orchard et al., 2008b). NSAIDs may be used but no sooner than 
48 hours following exercise-induced muscle injuries to provide analgesia and 
to reduce the early inflammatory response. Earlier use can interfere with the 
cell chemotaxis that is necessary for the repair and remodeling of 
regenerating muscle. Prolonged use of NSAIDs (over 7 days) is not 
recommended; it may delay muscle regeneration by inactivating the 
proliferation and differentiation of satellite cells and inhibiting the production of 
growth factors (Reynolds et al., 1995, Shen et al., 2005, Reurink et al., 2012, 
Paoloni et al., 2009).  
 
There is limited evidence that the use of NSAIDs has no effect on pain 
scores and isokinetic strength testing in acute hamstring injuries. 
Furthermore, concerns have been raised about the possible harmful effects of 
NSAIDs on the cardiovascular system and muscle healing after acute injury. 
Despite the widespread use of NSAIDs in acute muscle injuries, there is no 
evidence for their efficacy for hamstring injuries (Orchard et al., 2008b).  
2.4.2.3 Injection therapy 
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In recent years, injection therapies have gained popularity for the 
treatment of muscle injuries. Many pharmaceutical or homeopathic 
substances have been described in the literature to treat acute muscle 
injuries. In the past, corticosteroids such as dexamethasone sodium 
phosphate, triamcinolone hexacetonide, or triamcinolone acetonide were used 
in conjunction with either lidocaine hydrochloride or bupivacaine hydrochloride 
to treat such injuries (Levine et al., 2000).  Prolotherapy such as hypertonic 
saline, dextrose, phenol, glycerine, and cod liver oil extract have also been 
tried (Reurink et al., 2012). There have been limited and yet contradictory 
results in the literature regarding these substances for intramuscular 
injections. Local anaesthetic drugs are commonly used and mixed with these 
substances for intramuscular injections, in the aim of reducing discomfort and 
providing immediate pain relief (Zink and Graf, 2004). Although it is an 
uncommon side effect, local anaesthetic intramuscular injections can result in 
reversible myonecrosis (Zink and Graf, 2004). (Figure 2.4.2.3) Furthermore, 
when the “therapeutic substance” is mixed with local anaesthetic drugs, the 
pharmacodynamic and pharmacokinetic properties of each substance is 
altered and unpredictable.  
 
 
Figure 2.4.2.3 Skeletal muscle cross-section with characteristic histologic changes after 
continuous exposure to bupivacaine for 6 hours. A whole spectrum of necrobiotic changes 
can be encountered, ranging from slightly damaged vacuolated fibres and fibres with 
condensed myofibrils to entirely disintegrated and necrotic cells. (Zink and Graf, 2004). 
As the understanding of human biochemistry has increased over the 
past decade, human growth hormone and insulin like growth factors have 
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been used to accelerate the recovery of muscle injuries. However, due to the 
anabolic nature of these growth factors, their use may lead to over growth or 
even malignant cell transformation (Falk et al., 1979, Socas et al., 2005, 
Gorayski et al., 2008). It is classified as doping in section S1 of the prohibited 
list by WADA. Recently, platelet rich plasma (PRP) has become popular 
among professional athletes as of 2011 WADA relaxing its rule and it is no 
longer prohibited under certain circumstances. Recently, the International 
Olympic Committee (IOC) released a consensus statement, which further 
promoted the use of PRP (Engebretsen et al., 2010).  The consensus paper 
highlighted and summarised the current facts and published reports on PRP. 
Although this paper did not find any clinical noticeable or significant beneficial 
effect with PRP, it heavily focused on reporting no negative effects of PRP 
and therefore recommended its use. It is rather unusual for an international 
governing body to release such a publication to support the use of PRP based 
on very poor evidence (Kjaer and Bayer, 2011). On the other hand, the IOC, 
in the past, issued a ban on a drug in similar circumstances based on 
speculation and rumours. Therefore, any statement, evidence or publication 
produced by the IOC should be treated with caution, as with PRP.   
 
Besides corticosteroids, prolotherapy, growth factors and PRP, there is 
another alternative regarding muscle injection therapy. In professional elite-
level athletes, Orchard et al (2008) summarised that currently almost all the 
so-called knowledge in the treatment of muscle injuries was based on very 
poor scientific evidence (Orchard et al., 2008b). Dr. Mueller-Wohlfahrt's 
Actovegin / Traumeel injection treatment regime for treating muscle injuries 
was considered by a panel of experts to be the current best practice (Orchard 
et al., 2008b). In 2006, an article from the Times newspaper reported a 
comment from Dr. Hans-Wilhelm Müller-Wohlfahrt, team doctor for the 
German National Football Team and Bayern Munich Football Club regarding 
the use of this regimen.   
 
In this report Dr. Müller-Wohlfahrt discussed his experience with 
Actovegin/Traumeel and the success of its treatment with high profile sports 
people such as Maurice Green, Asafa Powell, Diego Maradona, Darren 
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Gough and Paula Radcliffe (Crompton, 2006) “I am an empirical doctor and, 
over 30 years, I have treated so many that nobody can tell me it doesn’t work. 
Nobody I have seen has had an adverse effect, or an allergic or other 
reaction.” (Crompton, 2006) A best practice statement mentioned Dr. Mueller-
Wohlfahrt’s Actovegin and Traumeel injection therapy, although it is not a 
published clinical study but his thirty years specialist experience with muscle 
injuries in elite athlete should not be overlooked (Orchard et al., 2008a). 
 
2.4.2.4 Areas identified for further investigation in this PhD 
 
In terms of the professional elite athletes, shortened recovery time 
could mean continuing training, increased game play and benefit to the team 
and club. As the review in 2.4.2 suggested, traditional treatment of muscle 
injuries such as RICE, NSAIDs and injection therapies are based on “fashion” 
and poor evidence. Dr. Mueller-Wohlfahrt’s injection treatment regimen seems 
to produce internationally recognised anecdotal results among elite athletes. 
Therefore, this PhD will further explore this regimen.  
 
In terms of Dr. Mueller-Wohlfahrt’s injection regime, Actovegin is mixed 
with Traumeel and local anaesthetics for injection, therefore the biochemical 
property, pharmacodynamics and pharmacokinetics of each drug are altered 
and unpredictable. Local anaesthetics can lead to myonecrosis and Traumeel 
is a homeopathic substance which contains 99% sterile isotonic saline 
(Schneider, 2011); the only potential “active” substance in Dr. Mueller-
Wohlfahrt’s regimen may be a drug called “Actovegin”. For further details, 
please see 2.4.2.3 In order to reduce the complex pharmacodynamics and 
pharmacokinetics of drugs / substance interaction, this PhD thesis will focus 
on Actovegin only. 
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2.5 Background information on Actovegin 
 
Through the background research and literature review summarised in 
2.4.2.4, Actovegin was identified to be a drug that is potentially useful in the 
treatment of acute hamstring injuries. Therefore in this PhD Actoveign will be 
further analysed.  
 
Actovegin ® is a deproteinised haemodialysate of ultra-filtered calf 
serum under 8 months of age, produced by Nycomed GmbH, Austria. Austria 
is officially categorized as a Bovine Spongiform Encephalopathy (BSE), 
Transmissible Spongiform Encephalopathies (TSE) and Scrapie free country 
by the World Organization for Animal Health (WOAH) and the Scientific 
Steering Committee of the European Union. The manufacturing process of 
Actovegin® is BSE validated, thus proven to be capable of removing 
hypothetically present TSE agents (Nycomed). According to the manufacturer, 
it is ultra filtered to 6000 Daltons, therefore it does not contain protein, growth 
factors or hormone-like substances. Physiological components, such as 
amino acids, nucleosides, intermediary products of carbohydrate and fat 
metabolites constitute approximately 30% of the organic components in 
Actovegin (Nycomed). The active ingredients in this mixture have yet to be 
identified. Actovegin can be administered as tablets, topical formulations, 
injections or infusion via intramuscular, intravenous or intra-arterial routes 
(Nycomed). Within the scope of this PhD, only the injectable form of 
Actovegin will be discussed. 
 
Actovegin is a licensed drug in Europe, China and Russia and has 
been used by clinicians for over 60 years (Nycomed, Pforringer et al., 1994, 
Wright-Carpenter et al., 2004, Beetz et al., 1996). Clinically, it has been used 
as an intravenous infusion to treat acute stroke (Derev'yannykh et al., 2008, 
Boyarinov et al., 1998) and as a topical form to treat skin and mouth ulcers 
(Biland et al., 1985). It has also been reported to be used as an intra-arterial 
infusion to treat long bone fractures (Khomutov et al., 1999) and postpartum 
haemorrhage (Appiah, 2002).  
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2.5.1 Manufacturing process 
 
Actovegin® is a deproteinised, pyrogen- and antigen-free haemodialysate 
of calf blood. It is manufactured from calf blood in several steps by 
ultrafiltration (Buchmayer et al., 2011):  
 
1) Ultrafiltration cut off of 6 kD  
2) Vacuum distillation to remove the precipitate by filtration (0.45 µm)  
3) Titration to pH 6.8  
4) Sterile filtration with pre-filters of 0.2 µm and 0.45 µm  
5) Stored at 2 – 6°C for 14 days 
6) Sterile filtration (0.45 µm) and titrated to pH 6.8 
7) Ultrafiltration step with a 10 kD cut off 
8) Sterile filtration a pre-filter of 0.45 µm and 0.2 µm 
9) Storage at 2 – 6°C for 56 days 
10) Final precipitate is removed by filtration (0.45 µm) and diluted to a 
nominal concentration to 200 mg/ml dry weight. 
11) Finally, deproteinization is completed by sterile filtration with prefilters 
of 0.2 µm and 0.45 µm.  
 
The analysis of the final product shows that it contain a mixture of substances 
(Buchmayer et al., 2011): 
 
Inorganic components Organic components 
Chloride Amino acids 
Phosphate Oligopeptides (<20 amino acid) 
Sodium Nucleosides 
Potassium Glycosphingolipids 
Calcium  
Magnesium  
Several sources for nitrogen  
Amino acids  
Peptides  
Glucose  
Acetate  
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 Quality control by the manufacturer  
 
Since Actovegin® is being produced from a biological source it 
undergoes two bio-assay tests to ensure homogenous activity of the 
product (Buchmayer et al., 2011). 
  
1) Determination of the oxygen consumption (µloxygen/mgtissue/hour) in 
the homogenate of guinea pig liver homogenates (measured with 
a Warburg micro spirometer). The target value for Actovegin® is 
oxygen consumption of 1.0 µl per 2 mg per hour. (0.5 µl/mg/hr) 
 
2) The uptake of tritium labelled glucose into the lipid fraction of 
adipocytes, prepared from epididymic rat adipose tissue. 
Actovegin® enhances this uptake in an Insulin-like fashion and 
exhibits at 1 mg/ml incubation medium an Insulin-like activity (ILA) 
of more than 20 µU. 
  
Toxicity  
 
Toxicity tests in mice and other relevant species reveal that 
Actovegin®, after intravenous application, has an acute toxicity of more 
than 50 times the maximum therapeutic dose. Negative subchronic toxicity 
testing over a period of three months also lends support that Actovegin® is 
non-toxic and no chronic pathological organic changes have been 
observed either macro or microscopically (Buchmayer et al., 2011).  
 
2.5.2 potential active ingredients in Actovegin  
 
Actovegin® was believed to have a broad range of activities, it can 
influence cell metabolism and leads to increased oxygen uptake and utility 
as well as glucose uptake by the cells (Boyarinov et al., 1998, Hoyer and 
Betz, 1989, Peronnet and Massicotte, 1991). It promotes oxidative 
metabolism and shifts the redox-balance of the cells into the direction of 
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oxidised substrates(K.W et al., 1992). This may also lead to an increased 
availability of energy-rich phosphates like ATP and creatine phosphate. 
The pre-clinical studies leading to the assumption of these positive effects 
have been reported from a broad repertoire of testing strategies conducted 
in both mainly rat’s and guinea pig’s cell cultures(Haring et al., 1981, 
Hoyer and Betz, 1989, Kuninaka et al., 1991, Villalba et al., 1988).  
 
Many studies have tried to identify the active ingredients from this 
mixture, but have been unsuccessful. Studies in vitro have suggested that 
Actovegin promotes oxidative metabolism and shifts the redox-balance of 
the cells into the direction of oxidised substrates, which may protect 
against hypoxic cell injury (Schoenwald et al., 1991). Hoyer et al 
suggested that Actovegin does not directly influence cells during the 
ischaemic period as the cells’ glucose and lactate levels are similar to the 
untreated animal cells during the ischaemic period (Hoyer and Betz, 
1989). One of the most important goals of any post-ischaemic therapeutic 
strategy should be the early interruption of the process of cell-damaging 
events to avoid cell death. Because of the properties of Actovegin to 
promote oxidation and energy production, the efficacy of Actovegin was 
assumed to benefit post-ischaemic metabolic events although its active 
constituent has not yet been elucidated (Hoyer and Betz, 1989). 
 
Obermaier-Kusser et al (1989) isolated Inositol phosphate 
oligosaccharides (IPO) from Actovegin, its composition were (Obermaier-
Kusser et al., 1989):  
 
• Erythrose 2.54mM (0.305 mg/mI) 
• Ribose 1.49mM (0.166 mg/mI)  
• Arabinose 0.5mM (0.150 mg/mI) 
• Xylose 1.26mM (0.189 mg/mI) 
• Mannose 0.60mM (0.108 mg/mI) 
• Galactose 0.30 mM (O.053 mg/mI) 
• Glucose 1.22 mM (0.220 mg/mI) 
• Inositol 0.56mM (0.100 mg/mI) 
• Saccharides were complexed as phosphates or sulphates 
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In the same study, they also showed partial insulin-like dose dependent 
effects on glucose transport activity of fat cells (Obermaier-Kusser et al., 
1989) (Figure 2.5.2.1). Furthermore, in another experiment preformed by the 
same group with isolated rat adipocytes and 3-O-methylglucose transport 
measurement, after 20 minutes of incubation, the IPO fraction from Actovegin 
achieved approx. 70% of glucose transport compared to Insulin. (Figure 
2.5.2.2) 
 
 
 
 
(Figure 2.5.2.1) Graph to show insulin like activity from IPO extract from Actovegin 
against insulin in isolated rat adipocytes. The curves show mean values ± SEM. IPO 
fraction from Actovegin have similar dose dependent effects to glucose uptake compared 
to insulin. (Obermaier-Kusser et al., 1989) 
myocytes (BC3H-1), insulin induced hydrolysis of 
phosphatidylinositol-glycan that stimulated the gener-
ation of inositol-glycan and diacylglycerol [14]. How-
ever, these authors failed to obtain evidence that 
inositol-glycan facilitated the uptake of glucose in these 
cells; only glucose oxidation and lipogenesis were clear-
ly enhanced. 
To further substantiate the idea of ILA of IP-
oligosaccharides derived from Actovegin h modialy-
sate, Obermaier-Kusser et al. [9] used rat adipocytes to 
measure the influence of IPO on glucose transport in 
direct comparison to insulin: appl cation ofIPO on 3-0-
methylglucose transport exerted a significant and dose-
dependent effect; in comparison to insulin which 
stimulated glucose transport lO-fold, IP oligosacchar-
ides stimulated glucose transport 5-fold (Fig. 2). 
However, in the same publication, Obermaier-
Kusser et al. also measured the binding of cytochalasin 
B to the plasma-membrane bound glucose carriers; to 
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Rg. 2: Freshly Isolated rat adlpocytes [(4.5-5.5) x 10& cellslmI] were Incu-
bated with Insulin or IP-ollgosaccharides derived from hemodia-
lysate for 20 min at the concentrations given on the abscissa. The 
composition of the IP-oligosaccharide fraction was as follows: erythrose 
2.54 mM (0.305 mglmI). ribose 1.49 mM (0.166 mglmI). arabinose 0.5 mM 
(O.150lT1I¥mI). xylose 1.26mM (0.189lT11¥mI). mannose O.60mM (O.108mg1 
mI). galactose 0.30 mM (O.053lT11¥mI). gluc se 1.22 mM (0.220 mglmI). 
inositol O.56mM (O.100mglmQ. The saccharides were complexed as phos-
phates or sulphates. The IP-oIlgosaccharide fraction Is acid- and alkali-labile. 
3-0-Methylglucose uptake was then determined for 4 s as described in the 
Materials and methods section and Is expressed as % of e<JJilibrium. The 
curves show mean values ± SEM of six experiments. Acetylation of the IP-
oligosaccharide fraction decreased the effect of 27 or 270 Il9Iml by approx. 
50% (n = 2) Reprinted with pennlssion from Ref. (9) 
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their surprise, the number of glucose carriers was not 
enhanced in the presence of IP-oligosaccharides in 
contrast to the activity of insulin which enhanced the 
number of active carrier sites by 3-5-fold [9). They 
also excluded the possibility that IP-oligosaccharides 
stimulated the insulin receptor-associated receptor tyr-
osin kinase and therefore suggested that they do not 
interact with steps in signal transmission beyond the 
receptor-kinase level Therefore, the authors insinuate 
that a two-step model may be applicable involving not 
only the activity of the compounds on the trafficking of 
transporters to the plasma membrane but also a direct 
way of transport stimulation. Further characterisation 
of the IP-oligosaccharide subfractions will substantiate 
the active compound in more detail. 
In conclusion, direct as well as indirect evidence 
supports the notion that Actovegin exerts a clear insu-
lin-like effect, which is, nevertheless, distinct from the 
action of insulin: it is more direct activation of the 
transport process rather than an enhancement of the 
trafficking that is stimulated by insulin. Nevertheless, 
the endpoint of the activities of both insulin and IP-
oligosaccharides exerting ILA is the enhancement of 
glucose utilization which may directly impact on the 
cellular metabolism and energy balance in distinct 
cellular systems. 
Oxygen uptake, metabolism 
and hypoxia 
Studies on oxygen uptake, metabolism and hyp-
oxia have been performed in different animal models 
such as rat, guinea pig and dog. Jager et al. [15] 
published a study on the first evidence that Actovegin 
exerts effects on cellular respiration of purified rat liver 
mitochondria: oxygen consumption was Significantly 
enhanced. de Groot et al. [16] examined the effect of 
hypoxia on isolated rat hepatocytes using a trypan blue 
survival test: hypoxic conditions in the presence of 
Actovegin led to a significantly higher survival. The 
authors concluded that Actovegin exerted a marked 
protection/retardation against hypoxic cell injury. 
Brecht and de Groot [17] tested free amino acids on 
hypoxic cell injury in isolated, cultured rat hepato-
cytes. Experiments were performed as described 
above in de Groot et aI. [16]. This report supports the 
notion that amino acids contained in Actovegin might 
be underlying for its protective effect against hypoxic 
damage. In line with these observations, Schafer [18] 
analysed the oxygen uptake in rat liver parenchyma 
cells under the influence of Actovegin in comparison 
Buchmayer et al. - Actovegin - homing for new grounds 
I 
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(Figure 2.5.2.2) Graph to show 3-O-methylglucose transport activity from IPO extract from 
Actovegin and insulin in isolated rat adipocytes over time. The curves show mean values ± 
SEM. IPO fraction from Actovegin can achieve approx. 70% of Insulin -0-Methylglucose 
uptake. (Obermaier-Kusser et al., 1989) 
 
 
Furthermore, IPOs do not induce carrier translocation or stimulate 
insulin-receptor kinase in vitro or in vivo (Obermaier-Kusser et al., 1989). It 
activates glucose transporters (GluTs) in the plasma membrane (Kelly et al., 
1987) and improves glucose uptake by cells (de Groot et al., 1990). IPOs can 
contribute up to 70% of the maximum insulin effect of glucose transport and 
also stimulate the activity of certain enzymes including pyruvate 
dehydrogenase, the key enzymes of the citric acid cycle (Obermaier-Kusser 
et al., 1989), hence improve the efficiency of the respiration process via an 
independent route. 
 
Schoenwald et al (1991) suggested that the active fractions in 
Actovegin were strongly negatively charged and were thought to be 
phosphorylated and/or sulfated oligosaccharides of approximately 3K Dalton 
Evidence for a two-step model of glucose-transport regulation
NaNO2, pH 3.7 (100 %o), methanol/HCl (24 %O), NaBH4
(50 %o), HNO3 (42 %O), acetylated (38 %o). The lipogenicactivity of this fraction could be inhibited by inositol
monophosphate (0.3-2.5 mM) as described also by Saltiel
& Sorbara-Cazan (1987) for their inositol phosphate-
glycan. 1251-insulin binding to fat-cells was not altered by
the active fraction. The results of the chemical analysis
and the inactivation procedure suggest that the active
compound contained in this IP-oligosaccharide fraction
has many homologies with, but also some composition
differences from, those IP-glycans described as putative
second messengers (Saltiel & Cuatrecasas, 1986; Fox
et al., 1987; Mato et al., 1987; Alemany et al., 1987; Low
& Saltiel, 1988).
(3) The substances BM 13907 and BM 130795 are
recently developed anti-diabetic drugs from Boehringer
Mannheim. These at-activated carbonic acids were shown
to lower blood sugar in animal models resembling type II
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diabetes (H.-F. Kiihnle, H.-P. Wolf & F. Schmidt, un-
published work). The site of action of these substances is
so far unknown. BM 13705 is an inactive analogue.
(4) Furthermore, the effect of the alkaloid vinblastine
on glucose-transport activity was investigated: vin-
blastine binds to the microtubular system and alters its
function (Olmsted & Borisy, 1973). The effect of these
substances on glucose-transport activity and CBB is
described in the following paragraphs.
Stimulation of 3-O-methylglucose transport
There is a stimulatory effect of diacylglycerol (0.25 mM),
but no significant effects of inositol I-phosphate,
inositol 1,4,5-trisphosphate and myo-inositol (all
0.25 mM; stimulation factors over basal: diacylglycerol
3.3+0.6, n = 5; inositol trisphosphate 1.7+0.7, n = 5;
inositol monophosphate 1.7 + 0.1, n = 2; myo-inositol
2.4 + 1.1, n = 4). In contrast, the IP-oligosaccharide frac-
tion, the BM substances and the alkaloid vinblastine
showed significant effects. Fig. 1(a) shows the
dose-response effect of the IP-oligosaccharides on
glucose transport. Insulin was used as a reference; it
stimulates glucose transport in a dose-dependent way up
to 10-fold. The IP-oligosaccharide fraction stimulates in
a dose-dependent way up to approx. 5-fold. The effect of
the oligosaccharide fraction occurs as rapidly as the
insulin effect (Fig. lb). The time course of the effect of the
IP-oligosaccharide fraction and, for comparison again,
the effect of insulin, which was measured in parallel, are
shown in Fig. 1(b). Both agents start to act within 1 min
and reach maximal values after 5 min. Acetylation of the
IP-oligosaccharide fraction decreased the effect by
approx. 50 %. Fig. 2 shows the dose-response effect of
the substances BM 13907 and BM 130795, and BM
13705, which was used as inactive analogue. BM 13907
and BM 130795 stimulate in a dose-dependent way the
glucose-transport activity of fat-cells. BM 130795 mimics
the insulin effect by 40-60 %, i.e. it causes a 5-6-fold
stimulation. Again, a similar time course to that with
insulin is found (results not shown). Fig. 3(a) shows the
Fig. 1. Dose-response curve and time course of the effect of
IP-oligosaccharides on 3-O-methylglucose uptake in
isolated fat-cells
(a) Freshly isolated rat adipocytes [(4.5-5.5) x 106 cells/ml]
were incubated with insulin or IP-oligosaccharides (IP) for
20 min at the concentrations given on the abscissa. The
composition of the IP-oligosaccharide fraction was as
follows: erythrose 2.54 mM (0.305 mg/ml), ribose 1.49 mM
(0.166mg/ml), arabinose 0.5mm (0.150mg/ml), xylose
1.26 mm (0.189 mg/ml), mannose 0.60 mm (0.108 mg/ml),
galactose 0.30 mm (0.053 mg/ml), glucose 1.22 mM
(0.220 mg/mI), inositol 0.56 mm (0.100 mg/ml). The
saccharides are complexed as phosphates or sulphates. The
IP-oligosaccharide fraction is acid- and alkali-labile. 3-0-
Methylglucose uptake was then determined for 4 s as
described in the Materials and methods section and is
expressed as % of equilibrium. The curves show mean
values+S.E.M. for six experiments. Acetylation of the IP-
oligosaccharide fraction decreased the effect of 27 or
270 ,sg/ml by approx. 50% (n = 2). (b) Freshly isolated
rat adipocytes [(4.5-5.5) x 106 cells/ml] were stimulated
with insulin (2 nM) or IP-oligosaccharides (27 ,ug/ml) at
zero time (arrow). 3-0-Methylglucose uptake was deter-
mined at the time points indicated in the Figure. Mean
values of two experiments are shown.
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molecular weight and different to the IPO fraction reported by other studies 
(Schoenwald et al., 1991).  
 
Actovegin has a synergistic effect on cell proliferation in vivo with 
Epidermal growth factor (EGF), Basic fibroblast growth factor (bFGF), and 
Endothelial Cell Growth Factor (ECGF), causing an increase in cell numbers, 
increased activity of acid phosphatase and an improved level of thymidine 
incorporation compared to controls, as demonstrated in figure 2.5.2.3 
(Schoenwald et al., 1991). As shown in Figure 2.5.2.3, these effects are 
resistant to proteinase K digestion, therefore the active compounds of 
Actovegin are unlikely to be growth factors or their derived fragments 
(Schoenwald et al., 1991). The trivial nutritive effects of Actovegin were 
excluded as a mixture of the same level of amino acids and substrates did not 
stimulate proliferation or have insulin like activity in vivo (Schoenwald et al., 
1991). 
 
 
(Figure 2.5.2.3) HD – Actovegin group, PK – proteinase K group, HD+PK – proteinase K 
digested IPO group.  0.1 mg/ml; 0.25 mg/ml;  0.5 mg/ml. There was no 
significant difference in the thymidine incorporation between the Actovegin and Actovegin 
with proteinase group in all conditions (Schoenwald et al., 1991).  
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Fig. 7. Proliferative activity of hemo- 
dialysate prior to and post chloroform 
extraction. Placebo (PLAC), hemo- 
dialysate (HD), and the aqueous (AQ- 
P) as well as the organic phase (ORG- 
P) obtained after extraction with 
chloroform/methanol/HC1 were added 
to the culture medium in the concentra- 
tions indicated and tested for the 
stimulation of [3H]-thymidine incorpo- 
ration of CEC in the standard assay. NN, 
0.02 mg/ml; N~, 0.1 mg/ml; B ,  0.5rag/ 
ml; l ,  1.0mg/ml 
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Fig. 8. Proliferative activity of 
hemodialysate prior to and post pro- 
teinase K digestion. Hemodialysate 
(HD) and proteinase K digested 
hemodialysate (HD + PK) were 
added to CEC test cultures in the 
concentrations indicated as well as 
the respective volumes of medium 
subjected to proteinase K (PK) as 
described in 'Materials and Meth- 
ods'. The assay was performed 
under standard conditions. N~, 
0.1 mg/ml; IN], 0.25 mg/ml; U ,  
0.5 mg/ml 
chromatography by FPLC on a calibrated TSK-HW40-Column revealed they 
had an apparent molecular weight of 3000 Dalton. The fraction was free of 
amino acids, monosaccharides, and peptides, but contained predominantly 
oligosaccharides and reasonable amounts of bound phosphate and sulphate, as 
determined by chemical analysis prior to and after hydrolysis. From the proper- 
ties of the active compounds, which are summarized in Table 1, we deduce that 
they are strongly negatively charged oligosaccharides of approximately 3000 
Dalton apparent molecular weight. 
Discussion 
We have devised an in vitro assay and used it to measure the stimulation of CEC 
proliferation by hemodialysate components, EGF, insulin, bFGF, and ECGF. 
Exclusively CEC secondary cultures were assayed to avoid major changes of cel- 
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From the results of the pre-clinical studies, the properties of the active 
compounds in Actovegin are summarized in Table below: 
 
Property Determined by 
Molecular weight approx. 3KD Gel filtration 
Strong negative charge, pKa< 2 Anion exchange 
Bound phosphate and/or sulphate Analysis prior to and post hydrolysis  
Insensitive to protease Proteinase K digestion  
Un-extractable by organic solvents Chloroform/methanol/HCl-extraction  
contains mainly oligosaccharides Analysis prior to and post hydrolysis 
 
2.5.3 Legality 
 
Actovegin® has received a great deal of media attention in recent 
years, especially surrounding its use in sports medicine. In 2009, a sports 
physician was arrested with this "performance-enhancing drug", while an 
editorial in a sports medicine journal strongly questioned the evidence base 
for using this drug in the treatment of acute muscle injuries (Franklyn-Miller et 
al., 2011). There is also a report suggesting that Actovegin might have 
induced anaphylactic shock in a cyclist (Maillo, 2008).  However, as discussed 
in 2.6.3, there are also good safety results from a large multi-centre 
randomized control trial (Ziegler et al., 2009). Nevertheless, Actovegin has 
received much publicity and there are also many anecdotal beliefs 
surrounding this drug (Franklyn-Miller et al., 2011).  Currently, Actovegin is 
not on the World Anti-Doping Agency (WADA) prohibited substance list 
(WADA, Accessed 21st April, 2011). However, many athletes, coaches and 
doctors still have reservations about its use in sports medicine. In this section, 
the evidence of the potential role of Actovegin in sports medicine is discussed. 
 
Besides its clinical properties, there are anecdotal beliefs among 
athletes that Actovegin® possesses an oxygen carrying capacity and has the 
potential to enhance oxygen uptake which leads to better performance. 
Although these claims are not based on any objective scientific evidence or 
published clinical reports, the IOC announced in December 2000 that 
Actovegin was banned under the classification of blood-doping agents. Two 
months later, however, the IOC lifted the ban as there was no evidence that 
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Actovegin actually enhances performance (Tsitsimpikou et al., 2009). So far, 
there have not been any sports related studies or performance testing with 
this drug on healthy individuals. Currently, the intramuscular use of Actovegin 
is not prohibited in or out of competition for any given sport according to the 
latest search (2010) of Global Drug Reference Online (Global DRO), which is 
approved by UK Anti-Doping (UKAD), the Canadian Centre for Ethics in Sport 
(CCES), the United States Anti-Doping Agency (USADA) and WADA.  
According to the latest 2011 WADA prohibited list, Actovegin is not prohibited 
in any sport. Furthermore, WADA has issued a specific guidance on 
Actovegin on their website(WADA, Accessed 21st April, 2011). According to 
Section M2 of the WADA code, the volume of intravenous injection of any 
non-prohibited substance must not exceed 50 ml with a simple syringe and 
further serial injections must be at least 6 hours apart. Therefore, it should be 
stated clearly here that Actovegin® cannot be administered by intravenous 
infusion or single intravenous injection with a volume exceeding 50 ml 
(WADA, Accessed 21st April, 2011). Further more write evidence was 
obtained from the FA in the UK to confirm that the use of Actovegin is not 
prohibited in or out of competition. (see appendix A) 
 
2.5.4 Areas identified for further investigation in this PhD 
 
Wound healing is heavily dependent on oxygen, glucose and ATP. It 
relies on the capacity of single cells to migrate into the area of the wound and 
replication of these cells. Actovegin is likely to have membrane stabilising 
effects in ischaemic cells. This may be due to the presence of negatively 
charged IPO, shifting the cells to the direction of oxidized substrates. In the 
immediate post ischemic period, these factors may help cellular recovery. Its 
insulin and growth factor synergistic properties could also be beneficial and 
make the initial recovery period more efficient. Therefore, Actovegin is 
assumed to be useful in circulatory disturbances and post ischaemic events. 
With regards to muscle injuries, the features of Actovegin listed above could 
be potentially beneficial. In the next section, in vitro and in vivo published 
studies will be explored and discussed. 
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2.6 Literature review of Actovegin  
 
2.6.1 in vitro and in vivo studies 
 
Over the past 60 years, researchers have endeavoured to identify the 
active ingredients in Actovegin, but have been unsuccessful. Studies in vitro 
have suggested that it promotes oxidative metabolism and shifts the redox-
balance of cells into the direction of oxidised substrates. Actovegin was 
therefore initially thought to have protective effects against hypoxic cell injury 
(Schoenwald et al., 1991). Hoyer et al demonstrated that Actovegin does not 
directly influence cells during the ischaemic period as the intracellular levels of 
glucose and lactate are similar to untreated animal cells during this period 
(Hoyer and Betz, 1989). Therefore, its mechanism of action is thought to 
improve the efficacy of cell’s energy balance in the post-ischaemic metabolic 
events and interrupt the process of cell damage to avoid further cell death 
(Hoyer and Betz, 1989). 
 
Studies on oxygen uptake, metabolism and hypoxia have been 
performed in different animal models like rat, guinea pig and dog. Jager et al, 
published a study on the first evidence that Actovegin® exerts effects on 
cellular respiration of purified rat liver mitochondria: oxygen consumption was 
significantly enhanced (Malaker and Sellwood, 1970). De Groot et al, 
examined the effect of hypoxia on isolated rat hepatocytes using a trypan blue 
survival test: hypoxic conditions in the presence of Actovegin® led to a 
significantly higher survival (de Groot et al., 1990). In line with these 
observations, Schäfer analysed the oxygen uptake in rat liver parenchymal 
cells under the influence of Actovegin® in comparison to placebo and 
described an enhancing effect by Actovegin® on cell respiration (Schreier et 
al., 1993). Reichel et al, showed that the augmenting effect of Actovegin® on 
oxygen intake and glucose uptake in cellular systems relies on an 
enhancement of the phosphorylating properties of the cells in that oxygen 
uptake increases by up to 40% in the presence of Actovegin® (Malaker and 
Sellwood, 1970). Kuninaka et al assessed mitochondrial respiration by 
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polarography in a rat liver mitochondria preparation and suggested that 
oxidative phosphorylation is significantly augmented by the addition of 
Actovegin (Kuninaka et al., 1991).  
 
Rammler et al, photometrically determined whether Actovegin® exerts 
an effect on the ATP-concentrations of the brain over 240 min (Charlesworth 
et al., 1975). The results show that Actovegin® possesses the potency to 
increase the ATP in tissue. This result was one of the first observations to 
clearly show that Actovegin® has a direct bearing on metabolism in the brain. 
In later years, Chanh et al, demonstrated that Actovegin can also be a 
beneficial support to oxygen consumption and metabolism of heart tissue 
(Chanh et al., 1980). 
 
Actovegin® has the capability to stimulate cellular metabolism, increase 
oxygen uptake and performance of energy production. Therefore, it is 
assumed to be a stimulant agent to support energy-deprived and starved 
tissues. It should have a positive effect on wound healing. 
 
Inositol phosphate oligosaccharides (IPO) are one of the ingredients in 
Actovegin (Obermaier-Kusser et al., 1989). The IPOs have been shown to 
have a partial insulin-like effect on the glucose transport activity of adipocytes 
but do not induce carrier translocation or stimulate insulin-receptor kinase in 
vitro or in vivo (Obermaier-Kusser et al., 1989).  It has been reported that 
IPOs activate glucose transporters (GluTs) hence promoting glucose uptake 
by cells (de Groot et al., 1990).  IPOs can contribute up to 50% of the 
maximum insulin effect on glucose transport and can also stimulate the 
activity of certain enzymes including pyruvate dehydrogenase, the key 
enzymes of the citric acid cycle (Obermaier-Kusser et al., 1989). It has a 
synergistic effect with insulin and promotes glucose activity when insulin 
levels are suboptimal, but does not alter the peak effect (Obermaier-Kusser et 
al., 1989). A strongly negatively charged sulphated oligosaccharide of 
approximately 3000 Daltons molecular weight has also been isolated from 
Actovegin, which is different to the IPO fraction reported by the other studies 
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(Schoenwald et al., 1991). This fraction has a similar effect to IPO but with 
less effectiveness.  
 
Actovegin has a synergistic effect on cell proliferation in vivo with 
Epidermal growth factor (EGF), Basic fibroblast growth factor (bFGF), and 
Endothelial Cell Growth Factor (ECGF), causing an increase in cell numbers, 
increased activity of acid phosphatase and an improved level of thymidine 
incorporation compared to controls (Schoenwald et al., 1991). These effects 
are resistant to proteinase K digestion, therefore the active compounds of 
Actovegin are unlikely to be growth factors or their derived fragments 
(Schoenwald et al., 1991). The trivial nutritive effects of Actovegin were 
excluded as a mixture of the same level of amino acids and substrates did not 
stimulate proliferation or have insulin like activity in vivo (Schoenwald et al., 
1991). 
 
2.6.2 Actovegin in Wound healing  
 
Neinhardt et al, observed that Actovegin® treatment leads to wound 
closure approximately 2 days earlier as compared to controls. Mochida et al 
tested the influence of Actovegin® on the tensile strength of an incised 
abdominal muscle in animals; it concludes that Actovegin® significantly 
supports wound healing (Mochida et al., 1989).  
 
Wound healing heavily relies on the capacity of single cells to migrate 
into the area of the wound and replication of these cells. Therefore, several 
studies investigated the migration-stimulative effects of Actovegin® in cell 
culture assays. Miltenburger et al, assessed the influence of Actovegin® on 
the functions of fibroblasts and keratinocytes and found that cell migration 
was highly significantly affected by the addition of Actovegin® alone, and even 
more stimulated by the co-administration of Actovegin® and TGF-β 
(Miltenburger et al., 1994). Furthermore, the keratinocyte outgrowth was 
distinctly enhanced in the presence of Actovegin®, hence the trophic 
possibilities of tissue to actively rebuild tissue integrity.  
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Actovegin also affects the functional integrity and activity of immune 
cells that enhance tissue remodelling and thereby wound healing. It exerts 
significant effects on human monocytes cultured in vitro in the presence of 
human serum. Spessotto et al, prepared monocytes from buffer coated and 
assayed monolayer cultures under a microscope for morphology and cell 
density, as well as protein content (Spessotto et al., 1993). Cell density was 
increased in all concentrations of applied Actovegin®, as well as the cell 
protein content. Actovegin® partly acted like a substitute for blood serum 
favours survival and differentiation of monocytes in culture (Spessotto et al., 
1993). 
 
Radiation induced damage in cells and tissues has been regarded as a 
crucial test case for the protective and supportive action of many different 
pharmacologically active substances. Actovegin® has been studied regarding 
the effects of radiation on animals and exerted positive effects. Bauer and 
Locker investigated the effects of Actovegin® on the survival of mice that have 
been irradiated by a lethal dose of gamma radiation (Bauer and Locker, 
1974). The application of Actovegin® led to a concentration-dependent better 
survival of the Actovegin®-treated animals after 30 days following irradiation. 
Barth and colleagues, examined the time-dependence of the injection of 
Actovegin® in relation to the damage produced by irradiation. The results 
revealed an optimal time point for the injection of three hours after the 
irradiation had taken place. Prophylactic treatment with Actovegin® on 6 
consecutive days before the radiation did not reveal any preventive effects of 
Actovegin®. In a similar study, Basu et al, examined the radio-protective 
effects of Actovegin® in adult rats (Basu et al., 1985) ; while control animals 
died within 30 days, the rats treated with Actovegin® 1 hour before irradiation 
had a statistically significant higher survival rate, as already described in the 
study of Bauer and Locker, thereby confirming their results (Bauer and 
Locker, 1974). In contrast, Tamou and Trott, described findings on the 
occurrence of radiation-induced ulcers in the rectum of rats where the results 
in the Actovegin® group did not differ from control conditions (Tamou and 
Trott, 1994).  
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Sigdestad and colleagues, demonstrated the intracellular effects of 
Actovegin® in irradiated cells in culture (Sigdestad et al., 1988). Although, 
there was no difference in cell survival in vitro, the cells treated with 
Actovegin® exhibited much less single-strand DNA breaks as compared to the 
control cells. This also supported the effects described earlier that pointed to a 
beneficial effect of Actovegin® on cell survival, also on the level of the cell 
nucleus. 
 
Actovegin is likely to have membrane stabilising effects in ischaemic 
cells. This may be due to the presence of negatively charged 
oligosaccharides, shifting the cells to the direction of oxidized substrates. In 
the immediate post ischaemic period, these factors may help cellular 
recovery. Its insulin and growth factor synergistic properties could also be 
beneficial and make the initial recovery period more efficient. Therefore, 
Actovegin is assumed to be useful in circulatory disturbances and post 
ischaemic events.  
 
2.6.3 Clinical reports on Actovegin indirectly related to muscle injuries 
 
 Although the active ingredient(s) in Actovegin are yet to be identified, 
many clinical studies have indicated its safety and effectiveness. There has 
been one case report of a possible anaphylactic reaction related to the use of 
intravenous Actovegin injections by an amateur cyclist. In this report, the 
diagnosis of  “anaphylactic reaction” was not confirmed with any biochemical 
testing and the patient improved with broad spectrum antibiotics. The author 
later stated in the communication letter that this patient had used intravenous 
Actovegin once before with no adverse reaction, thus an anaphylactic 
response is unlikely. Although it is possible that the first use of Actovegin had 
predispose or prime the immune cells to react severely following the second 
or subsequent administrations(Maillo, 2008). As the patient improved on 
broad spectrum antibiotics, the most likely cause for this acute shock was due 
to bacterial contamination during injection, not anaphylactic reaction to the 
drug (Maillo, 2008).  
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Pforringer et al, in a double-blinded placebo controlled single centre 
study with 60 recreational athletes, demonstrated that ultrasound guided para-
tendon injection of Actovegin was effective in the treatment of Achilles 
tendinitis (Pforringer et al., 1994). The tendon cross section measurement 
was reduced significantly (p<0.0001), patients’ physical activity and 
perception of pain was also improved (p<0.002) in the treatment group 
(Pforringer et al., 1994). The overall clinical outcome, which is measured by 
patient satisfactory score was significantly better in the Actovegin group 
(p<0.0001) and no adverse events were reported in this study (Pforringer et 
al., 1994). Although it is a relatively small-scale study with limited power, it is a 
well-conducted study that was featured in a Cochrane review.  
 
Ziegler et al 2009, reported a double-blinded multi-centre randomized 
control study with 567 patients with type 2 diabetes, in which 281 patients 
treated with 20 daily high dose intravenous Actovegin infusions followed by 
1800mg of Actovegin daily for 120 days in the treatment of symptomatic 
diabetic polyneuropathy compared to placebo (Ziegler et al., 2009). Total 
Symptom Score (TSS) of the lower limbs, vibration perception threshold 
(VPT), Neuropathy Impairment Score of the Lower Limbs (NIS-LL), and 
quality of life (SF-36) were used as patient reported outcome measures, 
which all show statistically significant differences compared to placebo and 
baseline scores (p<0.05). Furthermore, no anaphylactic reactions were 
reported with this study after 5,620 infusions and the adverse effect profile 
was no different compared to placebo (Ziegler et al., 2009).  
 
2.6.4 Evidence in muscle injuries 
 
The treatment of muscle tears with intramuscular Actovegin was first 
published by Pfister and Koller in 1990 (Pfister and Koller, 1990). Their 
partially blinded case control study with 103 patients, showed a reduction in 
recovery time with the treatment group of 5.5 weeks compared with 8.3 weeks 
for the control group (Pfister and Koller, 1990). However, in this study, 
patients were recruited from various sports and competitive levels and the 
treatment regimen and the rehabilitation protocol were not standardised. The 
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diagnosis of muscle injury was only based on clinical findings and was not 
graded according to MRI. Actovegin was mixed with local anaesthetics before 
injection, therefore its pharmacodynamics and pharmacokinetics were altered. 
The treatment regimen in this study was not standardised; the number of 
injections ranged from 3-8 and the final outcomes were based on patients and 
various clinicians’ subjective observations and there was no pre-injury data to 
compare outcomes. Despite the limitations of the study, it is the first published 
study regarding its use as an intra-muscular injection in the treatment of 
muscle injuries and no adverse events were reported in this paper. Since 
Pfister and Koller (1990), there has not been any published report in the 
medical literature regarding the use of Actovegin in muscle injuries until 
Wright-Carpenter et al in 2004. In this small non-randomised study, 
Autologous Conditioned Serum (ACS) was compared to Actovegin. The 
Actovegin group in this study was created by the retrospective analysis of the 
Pfister and Koller study; therefore it should not be seen as new evidence. 
 
Ziegler et al (2009) reported a double-blinded multicentre randomized 
control study with 567 diabetic patients treated with Actovegin for diabetic 
neuropathies which was discussed above (Ziegler et al., 2009). Although 
muscle assessments were not the primary objective for this study, it was 
measured as a secondary objective to monitor the progression of treatment. 
There was no significant difference in the adverse event rate compared to 
placebo; Actovegin did not improve muscle strength (p = 0.731) or muscle 
reflex (p=0.571) (Ziegler et al., 2009). Therefore, it is reasonable to conclude 
that Actovegin is a safe drug and does not have anabolic or ergogenic effects 
on muscles.   
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2.6.5 Summary 
 
There are many studies confirming the safety and effectiveness of 
Actovegin. It is evident that Actovegin is beneficial to ischaemic cells (2.6.1) 
and wound healing (2.6.2.). Furthermore Actovegin has a good clinical track 
record and good safety profile as discussed in 2.6.3. There has only been a 
single clinical study published in the literature with regards to the use of 
Actovegin in the muscle injuries, however it is a single drug study (2.6.4). 
There are currently no clinical studies reporting the use of Actovegin as a 
single agent in the treatment of muscle injuries.  
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2.7  Research question and Hypothesis 
 
As discussed in sections 2.3 and 2.4, muscle injuries are very common 
sports related injuries. They result in significant morbidity and time lost from 
training and competitions. As discussed in section 2.4.2.3, there have been 
many new potential treatment options available on the market. In 2008, a 
current best practice paper from the British Journal of Sports Medicine “The 
early management of muscle strains in the elite athlete: Best practice in a 
world with a limited evidence basis” (Orchard et al., 2008a) on the treatment 
of muscle injuries by a panel of experts, suggested that injection therapy 
could be potentially useful in treating muscle injuries. For further details, 
please see section 2.4.2.3. With regards to injection therapy, platelet-rich 
plasma (PRP) and Actovegin have attracted significant interest in sports 
medicine. Although the evidence is limited for both of these substances, PRP 
has received many so-called expert opinions and the IOC has encouraged its 
use (Engebretsen et al., 2010). On the other hand, Actovegin, a licenced drug 
that has a good clinical track record for 60 years (further details in section 2.5) 
has caused a lot of controversy and negative media attention.   
 
Section 2.4.2.3 has discussed the limitations with the studies regarding 
PRP; furthermore there are many methods of producing so-called “PRP”. The 
concentration of platelets and growth factors in PRP alter between methods of 
preparation and the brand of equipment. It also differs between individual’s 
blood biochemistry and hydration status. Therefore it is impossible to 
standardise treatment and compare results between studies. Actovegin is a 
deproteinised haemodialysate of ultra-filtered calf serum, although it is 
originally from a different species, it shares a similar principle to the PRP (see 
section 2.5). Due to the issues discussed above, the quality and quantity of 
PRP varies between injections; currently there is no consensus on the 
molecular weight cut off for PRP. On the other hand, Actovegin is 
manufactured through a more robust method with a molecular weight cut of 
point of 6 kD and strict quality control as a licenced drug (For further details 
please see 2.5.1 and 2.5.2). One could view that Actovegin is a fine filtered 
“PRP” from Bovine serum, which is standardised and well regulated by the 
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manufacturer. Through the review of literature in section 2.5, there is good in 
vitro, and clinical evidence suggesting the efficacy of Actovegin in the 
treatment of various conditions. There has only been one published study 
reporting the use of Actovegin in the treatment of muscle injuries, its 
limitations have been discussed in section 2.6.4. Furthermore, there have 
been anecdotal reports from high profile athletes suggesting that Dr. Mueller-
Wohlfahrt’s injection regime produces good clinical results in treating muscle 
injuries. In this injection regime, Actovegin is mixed with Traumeel and local 
anaesthetics for injection, therefore the biochemical properties, 
pharmacodynamics and pharmacokinetics of each drug are altered and 
unpredictable. Although it is possible that a specific quantity mixture of these 
drugs produce the desirable therapeutic effects, it is not practical to 
investigate this effect scientifically as the effect of each of the substances are 
unknown. As demonstrated in the literature review in section 2.6, Actovegin is 
a drug with 60 years of track record and it is beneficial to ischaemic cells and 
wound healing. Therefore Actovegin is the most likely “active” substance in 
Dr. Mueller-Wohlfahrt’s regimen. In this PhD thesis, in order to avoid the 
unpredictable nature of poly-pharmacy, only Actovegin will be investigated.  
 
As discussed in section 2.6, Actovegin is a drug that has good 
published results in the treatment of some medical conditions, but its use in 
the treatment of muscle injuries is limited. No studies have reported its use as 
a single agent to treat muscle injuries. Actovegin contains physiological 
components, electrolytes and essential trace elements (Nycomed). The active 
ingredients in this mixture have yet to be identified (see section 2.5.1). 
Although Actovegin is a licenced drug in Europe, it does not have marketing 
authority in the UK. Therefore it is not possible to obtain this drug in a regular 
pharmacy in the UK. In order to progress with this PhD, the supply of 
Actovegin will have to be established via a specialist route, which will be 
discussed in the method section in 3.2.  
 
The biochemical events following skeletal muscle injuries and repair 
are driven by cytokines, monocytes and leukocytes. The speed and quality of 
muscle healing are dependent on the inflammatory process. As demonstrated 
 59 
in the section 2.3.3, in order to alter the speed or quality of muscle repair, the 
substance must be able to modulate the inflammatory process. Recent 
studies suggest that there are two distinct subpopulations of macrophages 
sequentially involved in the inflammatory process (Garrett, 1996b, Grefte et 
al., 2010, Jarvinen et al., 2000). The balance between the pro-inflammatory 
macrophages (CD68+) and the anti-inflammatory macrophage (CD163+) will 
dictate the progression from the destruction phase to the repair phase of the 
muscle healing process as detailed in section 2.3.3. Therefore, this PhD will 
focus on the role of Actovegin in the inflammatory process, especially in the 
acute phase with the CD163+, CD68+ sub group of macrophages. In vitro 
studies will be performed to establish the appropriate type of cell culture and 
method of analysis, as detailed in section 3.4. Depending on the results of the 
in vitro studies, a treatment regimen will be established and a clinical study 
will be performed to investigate the clinical efficacy of Actovegin. In this PhD, 
a clinical study will only be performed when there are sufficient findings to 
support the use of Actovegin in muscle injury from the in vitro study. Clinical 
assessment, treatment and rehabilitation regimen will be established and 
ethical approval will be sought prior to the commencement of the clinical 
study. The clinical study is detailed in chapter 4. 
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Research question: 
 
There are two elements to this PhD thesis; the objective is to 
investigate the role of Actovegin in the acute muscle injuries. There have not 
been any study investigate the effect of Actovegin to the inflammatory 
process. The in vitro study section in this PhD is to investigate the 
biochemical role of Actovegin in the acute inflammatory process following 
muscle injuries. Further more there as not been any clinical studies report the 
use of Actovegin as a single agent in the treatment of acute muscle injuries. 
The clinical section in this PhD is to investigate the clinical efficacy of the 
Actovegin single agent treatment protocol developed based on the in vitro 
study from this PhD. 
 
 
 
Hypothesis: 
 
1) Actovegin has a biochemical role in the acute inflammatory process 
following muscle injuries. 
 
2) Actovegin treatment regimen developed from this PhD can influence 
clinical outcome in treating acute muscle injuries. 
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Chapter Three 
in vitro study 
 
3.1 Introduction 
 
In section 2.7 the research question and hypothesis is clearly stated. 
The pathophysiology and biochemical events following skeletal muscle 
injuries and repair is complex as discussed in section 2.3.3. This chapter will 
described the in vitro element of the PhD to investigate the role of Actovegin 
in the inflammatory process. Furthermore, standardisation and acquisition of 
Actovegin would be discussed in this chapter.  
 
Hypothesis for the in vitro studies in this PhD: 
 
Actovegin has a biochemical role in the acute inflammatory process 
following muscle injuries. 
 
3.2 Actovegin acquisition 
 
In section 2.4, the background information of Actovegin is discussed. 
Although Actovegin is a licenced drug in Europe, it does not have marketing 
authority in the UK. Therefore it is not possible to import Actovegin directly 
from the manufacturer or purchase it from a standard UK pharmacy. In order 
to progress with this PhD, the supply of Actovegin must first be established. 
 
The Medicines and Healthcare Products Regulatory Agency (MHRA) is 
an executive agency of the Department of Health for the UK government, 
responsible for the regulation of any medicinal product. The MHRA operates a 
system of licensing before the marketing of medicines. Medicines that meet 
the standards of safety, quality and efficacy are granted a marketing 
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authorisation. Under regulation 46 of The Human Medicines Regulations 2012 
(SI 2012/1916), all medicines must have a marketing authorisation before 
they can be prescribed or sold. In addition, the companies that are involved in 
all stages of the manufacture and distribution of the product need to have 
licensed. Applications for marketing authorisation are assessed by medical, 
pharmaceutical and scientific staff at the MHRA, working in multidisciplinary 
functional teams. Usually applications for marketing authorisation come 
mainly from the pharmaceutical industry but anyone with the necessary 
supporting data may apply. The task of evaluating the beneficial effects 
against the possible harmful effects of any medicine is complex.  Evaluation 
takes into account the nature of the active ingredients, the dosage form (for 
example, tablet or liquid), the nature of the disease or condition to be treated, 
the effective dose that needs to be given, the type of patient and the duration 
of treatment.   
 
In order to use Actovegin in the UK, I contacted the MHRA and 
requested the drug to be imported via a specialist prescription route from a 
fully UK GMC registered medical doctor. However, this only partially fulfilled 
the MHRA’s requirement. As Actovegin is a bovine animal product, further 
documentation of terms were needed to demonstrate minimal risk of 
transmitting animal spongiform encephalopahty agents (BSE) via Actovegin 
administered to humans before it could be imported into the UK. Therefore, I 
contacted the manufacturer, Nycomed, and arranged a meeting in their 
headquarters in Zürich with a team of clinicians and scientists involved in the 
development of Actovegin. Through that meeting I was able to obtain a copy 
of the Actovegin European drug license and a copy of the certificate to prove 
that Actovegin is free from BSE (appendix B). After further discussion with the 
MHRA with these documents, the agency gave their approval to import 
Actovegin to the UK through a specialist prescription. In order to comply with 
the regulations and the supply chain, a specialist pharmacy was used to 
import the drug. All the Actovegin was checked by a Royal Pharmaceutical 
Society approved Qualified Person (QP) to ensure quality and compliance. It 
is a legal requirement for a QP to batch certify medicinal products prior to 
clinical use. The involvement of the MHRA, Nycomed, specialist Pharmacy 
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and the QP have ensure the legality and authenticity of the source of 
Actovegin used in this PhD study.  
 
 In section 2.5.1, the manufacturing process and background 
information of Actovegin have been discussed. In this PhD, the clinical study 
could potentially involve high-level professional footballers, therefore further 
in-house testing will be performed to ensure quality and that the Actovegin is 
free from contamination. Further details are described in section 3.3. 
Furthermore, approval from official governing bodies such as WADA, UK 
sports and the FA will be confirmed prior to the clinical aspect of this PhD.(see 
appendix A). 
 
3.3 Standardisation of Actovegin  
 
 
(figure 3.3) 5x5ml packaging of Actovegin for injection 
 
The packaging of injectable Actovegin may vary worldwide. In Western 
Europe, there only 2 sizes and quantities officially produced by Nycomed. 
Actovegin is a light yellow-brown colour clear aqueous solution, its 
concentration is 40 mg/ml, and can be packaged as a box of twenty five 2ml 
ampules or a box of five 5ml ampules. In this PhD, only sealed boxed 2ml 
ampules will be imported to ensure standardisation.   
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3.3.1 MALDI ToF spectrometry 
 
In order to perform standardisation for the Actovegin used in this PhD, 
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-ToF) was used to try to establish a drug profile. 
 
Matrix assisted laser desorption/ionization (MALDI) is a soft ionisation 
technique used in mass spectrometry, allowing the analysis of biomolecules 
such as DNA, proteins, peptides and sugars and large organic molecules 
such as polymers, dendrimers and other macromolecules, which tend to be 
fragile and fragment when ionised by more conventional ionisation methods. It 
is similar in character to electrospray ionisation in that both techniques are 
relatively soft ways of obtaining large ions in the gas phase, though MALDI 
produces many fewer multiply charged ions. 
 
Samples (Actovegin) for analysis by MALDI are embedded in matrix 
crystals (3,5-dimethoxy-4-hydroxycinnamic acid, α-cyano-4-hydroxycinnamic 
acid and 2,5-dihydroxybenzoic acid) deposited on the surface of a sample 
plate that comprises one electrode of an ion accelerator. Desorption is 
triggered by a UV laser pulse. Matrix material heavily absorbs UV laser light, 
leading to the ablation of upper layer of the matrix material. The hot plume 
produced during ablation contains many species: neutral and ionized matrix 
molecules, protonated and deprotonated matrix molecules, matrix clusters 
and nanodroplets. Then the analyte molecules are protonated or 
deprotonated in the hot plume. Ablated species may participate in the 
ionisation of analyte, though the mechanism of MALDI is still debated. Pulsed 
and static electrical fields may be applied to accelerate and focus the ions in 
both space and time. The ideal ion source produces a narrow, nearly parallel 
beam with all ions of each m/z arriving at the detector with a flight time that is 
nearly independent of the initial position and velocity of the ions. The initial 
velocities used are less than 1000m/s and are independent of the mass of the 
ion. The velocity depends on the properties of the matrix and the laser 
fluence.  
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The time of flight (ToF) is measured relative to the time that the 
extraction pulse is applied to the source electrode. The extraction delay, Δt, is 
the time between the application of the laser pulse to the source and the 
extraction pulse. The linear analyser with pulsed acceleration provides 
excellent sensitivity for high-mass ions and can provide nearly constant low 
resolving power over a broad mass range, but an ion reflector is required for 
higher resolving power. This allows the effective length to be increased 
without increasing the other contributions to peak width. The time of flight can 
be calculated exactly depending on the distance and applied voltages. 
 
3 ampules of Actovegin were given to the Cardiff CBS laboratory for 
MALDI-ToF analysis using the ABI 4800 MALDI-TOF/TOF Analyser with 
standard matrix (3,5-dimethoxy-4-hydroxycinnamic acid). A graph of ToF was 
plotted against the molecular mass. In the graphic analysis of all 3 Actovegin 
samples only Matrix (3,5-dimethoxy-4-hydroxycinnamic acid) peaks were 
identified. Therefore, MALDI-Tof mass spectrometry is not an appropriate 
method for drug profiling for Actovegin, as it did not provide any meaningful 
data regarding its components. However, this has also confirmed that there 
are no protein molecules in the Actovegin mixture. 
 
MALDI-TOF is not a useful tool to standardise and batch test Actovegin 
for its composition. Therefore, an alterative method is needed to quantify the 
components in Actovegin.  High Performance Liquid Chromatography (HPLC) 
is a separation technique used to separate components of a mixture; it is 
commonly used in pharmaceutical and toxicology analysis. This could be a 
useful method to create a drug profile and standardise Actovegin. 
 
  
 66 
3.3.2 High Performance Liquid Chromatography (HPLC) 
 
High-performance liquid chromatography (HPLC) is a chromatographic 
technique used to separate a mixture of compounds in analytical chemistry 
and biochemistry with the purpose of identifying, quantifying or purifying the 
individual components of the mixture. Chromatography can be described as a 
mass transfer process involving adsorption. A mixture of various components 
enters a chromatography process, and the different components travel 
through the system at different rates. These differential rates of migration 
occur as the mixture moves over absorptive materials providing separation. 
The smaller the affinities a molecule has for the stationary phase, the faster it 
travels, hence it travels further in the given time. 
 
HPLC relies on pumps to pass a pressurized liquid and a sample 
mixture through a column filled with a sorbent, leading to the separation of the 
sample components. The active component of the column, the sorbent, is 
typically a granular material made of solid particles (e.g. silica, polymers), 2-
50 micrometres in size. The components of the sample mixture are separated 
from each other due to their different degrees of interaction with the sorbent 
particles.  
 
The pressurised liquid is typically a mixture of solvents (e.g. water, 
acetonitrile and/or methanol) and is referred to as "mobile phase". Its 
composition and temperature plays a major role in the separation process by 
influencing the interactions taking place between sample components and 
sorbent. These interactions are physical in nature, such as hydrophobic 
(dispersive), dipole-dipole and ionic, most often a combination thereof. 
 
HPLC is distinguished from traditional ("low pressure") liquid 
chromatography because operational pressures are significantly higher (50-
350 bar), while ordinary liquid chromatography typically relies on the force of 
gravity to pass the mobile phase through the column. Due to the small sample 
amount separated in analytical HPLC typical column dimensions are 2.1 - 4.6 
mm diameter, and 30 - 250 mm length. Also HPLC columns are made with 
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smaller sorbent particles (2- 5 micrometre in average particle size). This gives 
HPLC superior resolving power when separating mixtures, which is why it is a 
popular chromatographic technique. 
 
The sampler brings the sample mixture into the mobile phase stream, 
which carries it into the column. The pumps deliver the desired flow and 
composition of the mobile phase through the column. The detector generates 
a signal proportional to the amount of sample component emerging from the 
column, hence allowing for quantitative analysis of the sample components. A 
digital microprocessor and user software control the HPLC instrument and 
provide data analysis. Some models of mechanical pumps in a HPLC 
instrument can mix multiple solvents together in ratios changing in time, 
generating a composition gradient in the mobile phase. The HPLC 
instruments also have a column oven that allows for adjusting the temperature 
at which the separation is performed. 
 
Structural properties of the analyte molecule play an important role in 
its retention characteristics. In general, an analyte with a larger hydrophobic 
surface area is retained longer because it is non-interacting with the water 
structure. On the other hand, analytes with higher polar surface areas are less 
retained as they are better integrated into water. Such interactions are subject 
to steric effects in that very large molecules may have only restricted access 
to the pores of the stationary phase, where the interactions with surface 
ligands (alkyl chains) take place. Such surface hindrance typically results in 
less retention. 
 
Retention time increases with hydrophobic (non-polar) surface area. 
Branched chain compounds elute more rapidly than their corresponding linear 
isomers because the overall surface area is decreased. Similarly organic 
compounds with single C-C-bonds elute later than those with a C=C or C-C-
triple bond, as the double or triple bond is shorter than a single C-C-bond. 
 
Another important factor is the mobile phase pH, since it can change 
the hydrophobic character of the analyte. For this reason, most methods use 
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a buffering agent, such as sodium phosphate, to control the pH. Buffers serve 
multiple purposes: control of pH, neutralize the charge on the silica surface of 
the stationary phase and act as ion pairing agents to neutralize analyte 
charge. The effects of acids and buffers vary by application but generally 
improve chromatographic resolution. This chromatography approach 
separates components depending on their molecular weight and solubility; it 
does not require the use of a matrix. Therefore, HPLC could be useful in 
producing a drug prolife for Actovegin and will be used in this PhD.  
 
 
(Figure 3.3.2a) HPLC system used in Cardiff University to analyse Actovegin 
HPLC method:  
 
BLC20G Plus HPLC system (Buck-Chrom, Germany) was used to 
perform HPLC on Actovegin (figure 3.3.2a). A 2500mm x 4.6mm C 18 column 
(Phenomenex Ltd, Germany) was used for the HPLC. 100% Elga UHP water 
and 0.3% formic acid is mixed with 100% Acetonitrile and 0.3% formic acid. 
The mixed solvent ratio is used as per manufacturer recommendation. 20 ul of 
Actovegin (40mg/ml) was injected to the C18 column by an Auto-sampler with 
a flow rate of 1ml/min at 25oC. The peaks were detected using a thermo 
finnigan detector (uv6000LP, spectra system, Germany) at wavelength of 
200-800nm. The results were interpreted via Xcalibur software (ver. 1.2, 
Thermo Scientific, USA). 3 independent samples were tested per ampule of 
Actovegin to ensure the consistency of the results.    
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Time (minute) 
 
(Figure.3.3.2.1) HPLC graph time against absorption of Actovegin sample – Test 1 
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
 
 
Time (minute) 
(Figure.3.3.2.2) HPLC graph time against absorption of Actovegin sample – Test 2 
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
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Time (minute) 
 (Figure.3.3.2.3) HPLC graph time against absorption of Actovegin sample – Test 3 
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
 
Results: 
 
The peaks on the graphs represent separation of Actovegin against 
time (figure 3.3.2.1, 3.3.2.2, 3.3.2.3).  There are consistent peaks at 3 
minutes, 5 minutes and 10 minutes with all the Actovegin samples. The 
amplitude of the peaks was also within 10% of each other. Therefore, a HPLC 
“footprint” for Actovegin is formulated and can be used to standardise all 
future Actovegin batches. 
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3.3.3 Batch testing  
 
In order to standardise the quality of Actovegin, due to the reason 
discussed in 3.2, all imported Actovegin was batch tested against the 
“footprint” drug prolife obtained from the HPLC analysis above, with the same 
equipment and solvent ratio. Only Actovegin matched with all 3 peaks within 
10% in amplitude to the “footprint” will be used in this PhD. 
 
HPLC is a reliable method to separate and identify Actovegin, it can 
provide a graphical prolife of Actovegin; therefore it can be used to compare 
different batches of Actovegin to assure quality and minimise the risk of 
contamination. All the Actovegin used in this PhD will be batch tested with 
HPLC. Batch 13608343, 1608753, 18128753, 02233453 and 18233453 were 
tested as per HPLC method described; all batches demonstrated similar 
results and no contaminates were found.  
 
 
Time (minute) 
Graph to demonstrate the composition of Actovegin batch 10608753 using HPLC. The peaks 
on the graph represent separation of Actovegin against time.  
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
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Time (minute) 
Graph to demonstrate the composition of Actovegin batch 18128753 using HPLC. The peaks 
on the graph represent separation of Actovegin against time.  
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
 
 
 
 
Time (minute) 
Graph to demonstrate the composition of Actovegin batch 02233453 using HPLC. The peaks 
on the graph represent separation of Actovegin against time.  
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
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Time (minute) 
Graph to demonstrate the composition of Actovegin batch 18233453 using HPLC. The peaks 
on the graph represent separation of Actovegin against time.  
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
 
 
 
Time (minute) 
Graph to demonstrate the composition of Actovegin 13608343 batch using HPLC. The peaks 
on the graph represent separation of Actovegin against time.  
3 large peaks, 3.49 minutes, 4.75 minutes, 9.43 minutes 
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3.4 In vitro study: 
 
The biochemical events following skeletal muscle injuries and repair is 
driven by cytokines, monocytes and leukocytes. The speed and quality of 
muscle healing are dependent on the inflammatory process as discussed in 
section 2.3.3. Therefore, this PhD is focused on the role of Actovegin in the 
inflammatory process. In this section, an in-vitro cell culture model will be 
used to explore the role the hypothesis stated in section 2.7. 
 
In order to investigate the role of Actovegin in muscle injuries, a cell 
culture model must first be established. To identify the type of cells can be 
used for cell culture, preliminary cell culture experiments were performed. As 
detailed in section 2.6, Actovegin is a biological drug, manufactured from 
Bovine Serum. Therefore, the cell culture in this PhD would ideally be cultured 
under a serum free environment. Many cell culture protocols involve the use 
of Fetal Bovine Serum (FBS), which could potentiality invalidate the study.  
 
FBS is produced from blood collected at commercial slaughterhouses 
from cattle bred via needle cardiac puncture to the calf right atrium. The 
collected blood was allowed to clot and separate under gravity. The 
centrifugation process was then performed to remove the red blood cells and 
fibrin clot; the serum was then passed through a series of filters dependent on 
the manufacturer. The manufacturing process of FBS is similar to the 
manufacturing process of Actovegin as detailed in 2.5.1. Depending on the 
batch and manufacturer of the FBS, its effect on the cell culture is 
unpredictable, therefore a serum free cell culture is needed for the 
biochemical investigation in this PhD. 
 
Serum free skeletal muscle cell culture of chick embryos was 
attempted, however without FBS the cell culture failed to mature and was not 
viable for further experiments. Primary human muscle cell line culture (Promo 
Cell) was also considered for this PhD, however after detailed discussion with 
the manufacturer, it was not recommended to be used as a FBS free culture. 
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It is not possible to culture eukaryotic muscle cells without the presence of 
FBS; therefore alterative cell types must be identified for serum free culture in 
this PhD.  
 
Section 2.3.3 in this thesis detailed that the speed and quality of 
muscle healing is dependent on the inflammatory process. Serum free 
monocytes cell culture was attempted and the culture results were 
encouraging. Therefore, the cell culture studies in this PhD will be based on 
Monocyte cell lines. 
 
3.4.1 Serum free cell culture 
 
THP-1 cell-line was established as the cell line for in vitro cell cultures 
(European collection of Animal Cell Culture, Salisbury). The cells were 
donated by Dr. Dipak Ramji, Reader, Cardiff School of Biosciences. They are 
derived from the peripheral blood of a 1-year-old human male with acute 
monocytic leukemia. THP-1 cells have Fc and C3b receptors and lack surface 
and cytoplasmic immunoglobulins. These cells also stain positive for alpha-
napthhyl butyrate esterase, produce lysozymes and are phagocytic. They can 
be differentiated into macrophage cells using TrypLE. Cells were supplied at -
80oC with the cell ampule immersed in glycerol as a cryoprotectant. 
 
Resuscitation of Frozen Cell Lines 
 
In a microbiological safety cabinet, the frozen ampoule was cleaned 
with a tissue soaked in 70% alcohol. The cap was turned a quarter turn to 
release any residual liquid nitrogen trapped during the storage process. The 
cap was then retightened, and the ampoule quickly (minimising the damage to 
the cell membrane) transferred to a 37°C waterbath. In order to reduce the 
risk of contamination, the ampoule was not totally immersed into the 
waterbath. The cell suspension was then centrifuged at low speed for 5 
minutes. The suspenstant was removed and cells were re-suspended in fresh 
medium with 2mM Glutamine and 20% of Fetal Bovine Serum. It was then 
incubated at 37 °C with 5% CO2. Cells were checked daily and the medium 
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was refreshed when required according to the colour change to the medium. 
Cell counts were performed after each medium change to ensure that growth 
was monitored. The culture flasks were kept at a vertical position until the 
cells reached 6x105 cells/ml. Once the culture was established, cells were 
incubated in a serum free environment with RMPI-1640 medium.  
 
Establishing THP-1 culture 
 
The THP-1 cells were then washed twice with complete medium RPMI-
1640, supplemented with 2 mM l-glutamine, 100 U of penicillin per ml, 100 µg 
of streptomycin per ml, 25 mM HEPES and 1% L-glutamine, using a 50 ml 
Flacon tube and 20 ml medium to wash, spun down for 5 min at 1500 rpm. 
Cells were then placed in T75 flasks to expand cell numbers with 10 ml RPMI-
1640 and later in T150 flasks in 50 ml RPMI -1640. Sub-cultures were 
established by centrifugation with subsequent re-suspension at 2-5 x 105 
viable cells/ml, every 2-3 day. Cells reached a density of 8 x 105 cells/ml 
within this period of time. In order to ensure quality control, cells did not 
exceed 1x106 cells/ml before sub-culturing. Cell cultures were incubated at 
37°C and 5% CO2 in a certified human tissue laboratory.  
 
Establishing Macrophage culture 
 
The macrophages used in this PhD study were differentiated from 
THP-1 cells. The differentiation process was triggered by the addition of 
phorbol 12-myristate 13-acetate (PMA) in Dimethyl Sulfoxide (DSMO). In 
order to differentiate 1.6 x 105 cells, a 0.16µM solution of (PMA) was added. 
Cells were then incubated for another 16 hours (overnight) for the THP-1 to 
fully differentiate into macrophages. After incubation at 37°C and 5% CO2 in a 
certified human tissue laboratory, non-attached cells were removed by 
aspiration. The macrophages had readily attached to the bottom of the dishes 
during the incubation process. The culture flask was then washed 3 times with 
Phosphate buffered saline. 
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1 ml of TrypLE Express solution was then added to the dish, and 
incubated for 10min at 37 °C in an atmosphere of 5% CO2- 95% air. 9 ml of 
the growth medium RPMI-1640 was then added to the culture dish and the 
macrophages were then gently scraped off with a cell scraper. The cells were 
then transferred into a 15 ml conical tube and centrifuged at 180 x g for 5 min 
at 25°C. The supernatant was then discarded and the cells were dissociated 
into single cell pellets by vigorous pipetting. The cell number was confirmed 
by haemocytometer-counting. THP-1 cells in the same passage with no PMA 
were used as control cells during the differentiation process. 
 
Culture medium 
 
Roswell Park Memorial Institute medium (RPMI-1640) was developed 
by Roswell Park Memorial Institute. The formulation is based on the RPMI-
1630 series of media utilizing a bicarbonate buffering system and alterations 
in the amounts of amino acids and vitamins. RPMI-1640 medium has been 
used in many published in vitro studies and described by many textbooks as a 
standard method of cell culture medium.  
 
Penicillin and streptomycin (100ug/ml) were also used in the culture 
medium to minimise the risk of bacterial contamination during the incubation 
process. Fetal bovine serum (FBS) was used in the quantity of 20% at the 
initial resuscitation of frozen THP-1 cell-lines. FBS was an essential ingredient 
for the resuscitation process as previous experience demonstrated that initial 
cell line failure to survive in a serum free environment. As discussed in 
previous chapters, Actovegin is manufactured from fetal bovine serum, 
therefore in order to reduced the potential error and noise from the final 
outcome, all sub-cultures were performed in a serum free environment. Once 
the THP-1 culture density was established, cells were washed 3 times with 
PBS and transferred to a serum free culture environment with RMPI-1640 
culture medium only for sub-culture.   
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Cell culture experiment 
 
THP-1 and macrophage cultures were established with the method 
described above. For the main experiment, after centrifugation, cells were re-
suspended in 5ml of medium. 0.5 ml was then pipetted from the cell mixture 
into one of the wells in a 12-well cell culture plate (BD falcon, California, 
USA). This process was repeated 10 times in order to established 10 sets of 
cell cultures. 0.05ml of Actovegin (40mg/ml) was added to 5 independent 
wells to establish culture with 10% Actovegin. 0.05ml of RPMI 1640 was 
added to each of the other 5 independent wells to establish the control 
culture. All cultures were mixed independently via repeated pipetting with 
independent sterile tips. A sample of 100ul of each cell mixture was collected 
into a 96 well plate in order to perform MTS cell proliferation assays (cellTiter 
96, Promega, USA) and manual haemocytometer counts (further details of 
MTS cell Proliferation assay will be explained in following sections).  The 12-
well cell culture plate was incubated at 37.5ºC in a humidified cell incubator in 
an atmosphere of 95% air and 5% C02, for 24 hours. The MTS cell 
proliferation assays and manual haemocytometer counts were then repeated. 
 
3.4.2 Cell proliferation assay  
3.4.2.1 Method 
 
 The CellTiter 96 Aqueous non-radioactive cell proliferation assay 
(Promega,USA) is a colourimetric method for determining the number of 
viable cells in proliferation assays. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), is a tetrazolium 
compound with an electron coupling reagent which can be uptaken and bio-
reduced by living cells into a bluish-green coloured formazan product that is 
soluble in tissue culture medium. This assay measures cellular metabolic 
activity via NAD(P)H-dependent cellular oxidoreductase enzymes (cell 
proliferation). The quantity of formazan product is measured by the amount of 
490nm absorbance and is directly proportional to the metabolic rate and 
hence the number of living cells in culture. 
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 The MTS assay was prepared according to the manufacturer’s protocol 
from Promega. MTS Solution and the PMS Solution were defrosted in a water 
bath for 10 minutes at 37°C. The entire content of the 1ml PMS solution was 
transferred into the 20ml bottle of MTS Solution. 2.0ml of the MTS/PMS 
mixture was pipetted into a test tube and mixed with a further 1ml of PMS 
Solution. 20 ul of the final mixture was pipetted into each well of a transparent 
96 well assay plate (Invitrogen). Cell culture experiments were established as 
described above. 100 ul of cell mixture was pipetted into one of the wells in a 
96 well plate from each cell culture. The cells and MTS/PMS mixture was 
mixed with a repeated pipetting technique with new sterile pipette tips. The 96 
well plate was when incubated for 2 hours at 37oC in a 5%CO2 incubator. 
BMG labtech FLUOstar optima (Germany) Fluorescence plate reader was 
used to determine 490nm absorbance in each well. The results were then 
calibrated and confirmed with the haemocytometer count. 
 
3.4.2.2 Results 
 
Five sets of THP-1 and Macrophage cell cultures were completed in 
triplicate (in total 15 samples) according to the study protocol. The mean cell 
density was 0.156×104cells/100 µl/well. According to the manufacture 
guidance MTS cell assay produced normal destitution data, therefore 
parametric data analysis such as t test were used for data analysis. There 
were no significant differences in cell count between the Actovegin treated 
cells compared to the control cells before incubation in both THP-1  (Table 
3.4.2.2.nT.1) and macrophage (Table 3.4.2.2.nM.1) groups. The mean 
absorbance value of 1.829 and 1.825 from the MTS assays for both THP-1 
groups (Table 3.4.2.2.aT.1). This is confirmed by the haemocytometer manual 
counting. The starting cell number of the macrophages would also be the 
same as the cells were differentiated from the THP-1 cell line confirmed by 
the MTS absorbance (Table 3.4.2.2.aM.1) and manual counting (Table 
3.4.2.2.nM.1). 
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THP-1 cells before incubation (Absorbance) 
 THP control  control  control  Actovegin  Actovegin  Actovegin  
1 1.83 1.85 1.87 1.87 1.78 1.83 
2 1.87 1.84 1.83 1.84 1.94 1.69 
3 1.80 1.86 1.77 1.89 1.84 1.74 
4 1.76 1.84 1.90 1.81 1.89 1.64 
5 1.81 1.98 1.64 1.83 1.99 1.81 
Mean   1.829     1.825 
S.D.     0.075     0.090 
 
        p value 0.905 
(Table 3.4.2.2.aT.1). Absorbance of the cell proliferation assay at 490nm before incubation 
in THP-1 cells. Absorbance assays show no difference between control and Actovegin group 
prior to incubation in THP-1 cell line. P = 0.905 
 
THP-1 cells before incubation (cell count) 
 THP control  control  control  Actovegin  Actovegin  Actovegin  
1 0.16 0.16 0.16 0.15 0.15 0.16 
2 0.16 0.16 0.16 0.16 0.17 0.15 
3 0.15 0.16 0.15 0.15 0.16 0.15 
4 0.15 0.16 0.16 0.16 0.17 0.14 
5 0.16 0.17 0.14 0.16 0.17 0.16 
Mean   0.156     0.155 
S.D.     0.006     0.008 
T- test         0.694 
(Table 3.4.2.2.nT.1). Cell count before incubation in THP-1 cells (104 cells/100µl) Cell 
counts show no difference between control and Actovegin group prior to incubation THP-1 
cell line. (p=0.694) 
 
Macrophages cells before incubation (Absorbance) 
Mac control  control  control  Actovegin  Actovegin  Actovegin  
1 2.69 3.03 2.76 2.99 2.62 3.50 
2 3.15 3.33 2.69 2.98 2.96 3.33 
3 2.65 2.74 3.22 2.41 2.94 2.57 
4 2.64 2.25 2.79 2.67 2.18 2.39 
5 2.41 2.89 2.41 2.69 2.93 2.48 
Mean   2.777     2.776 
S.D.     0.306     0.360 
T- test         0.992 
(Table 3.4.2.2.aM.1). Absorbance of the cell proliferation assay at 490nm before incubation 
in Macrophages. Absorbance assays show no difference between control and Actovegin 
group prior to incubation in differentiated macrophages cell line (p=0.992) 
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Macrophages cells before incubation (cell count) 
Mac control  control  control  Actovegin  Actovegin  Actovegin  
1 0.23 0.26 0.24 0.26 0.23 0.31 
2 0.27 0.29 0.23 0.24 0.25 0.29 
3 0.23 0.24 0.28 0.21 0.26 0.22 
4 0.23 0.19 0.24 0.23 0.19 0.22 
5 0.21 0.25 0.21 0.23 0.26 0.23 
Mean   0.241     0.241 
S.D.     0.027     0.029 
T- test         0.986 
(Table 3.4.2.2.nM.1). Cell count before incubation in Macrophages (104 cells / 100 µl). Cell 
counts show no difference between control and Actovegin group prior to incubation in 
differentiated macrophage cell line (p=0.986) 
 
After 24 hours of incubation, both the Actovegin and control groups 
showed increased numbers of cells in the THP-1 cultures. The mean 
absorbance value of 1.994 and 2.803 from the MTS assays between the 
Control and Actovegin groups respectively (Table 3.4.2.2.aT.2.AC). This is 
confirmed by haemocytometer manual counting. The mean cell count in the 
control group was 0.168 x 104 and the Actovegin group was 0.233 x 104 
(Table 3.4.2.2.nT.2.AC). There was a significant increase (p=0.0001) in the 
cell count between the groups compared to their pre incubation cell counts. In 
the control group, the cell count increased from 0.156 to 0.168. (Table 
3.4.2.2.nT.12.c) In the Actovegin group, the cell count increased from 0.155 to 
0.233 (Table 3.4.2.2.nT.12.c). The Actovegin group showed an additional 
39% increase in THP-1 cell count compared to control after 24 hours of 
incubation (p=0.0001).  
THP-1 cells after incubation (Absorbance) 
THP control  control  control  Actovegin  Actovegin  Actovegin  
1 2.15 1.95 1.87 3.06 2.57 3.47 
2 2.12 1.74 2.29 2.15 1.98 2.78 
3 1.84 1.87 2.04 3.31 2.22 2.12 
4 1.97 1.91 2.18 3.68 3.14 2.86 
5 2.01 2.13 1.84 2.79 3.35 2.58 
Mean     1.994     2.803 
S.D.     0.155     0.532 
 
          p value 0.00004 
(Table 3.4.2.2.aT.2.AC) Absorbance of the cell proliferation assay at 490nm after 24 hours 
of incubation in THP-1 cells. Absorbance assays show significant difference between control 
and Actovegin group after 24 hours of incubation in THP-1 cell line. p=0.00004 
  
 82 
THP-1 cells after incubation (cell count) 
THP control  control  control  Actovegin  Actovegin  Actovegin  
1 0.18 0.16 0.16 0.26 0.22 0.29 
2 0.20 0.15 0.19 0.15 0.18 0.26 
3 0.15 0.17 0.16 0.28 0.19 0.18 
4 0.17 0.16 0.18 0.30 0.25 0.27 
5 0.17 0.18 0.15 0.24 0.26 0.20 
Mean     0.168     0.233 
S.D.     0.014     0.046 
 
          p value 0.0001 
(Table 3.4.2.2.nT.2.AC) Cell count after 24 hours of incubation in THP-1 cells. Cell count 
shows significant difference between control and Actovegin group after 24 hours of 
incubation in THP-1 cell line. p=0.0001 
 
THP-1 cell count in control group pre and post incubation 
 pre  pre pre Con 24 hr  Con 24 hr Con 24 hr 
1 0.16 0.16 0.16 0.18 0.16 0.16 
2 0.16 0.16 0.16 0.20 0.15 0.19 
3 0.15 0.16 0.15 0.15 0.17 0.16 
4 0.15 0.16 0.16 0.17 0.16 0.18 
5 0.16 0.17 0.14 0.17 0.18 0.15 
Mean   0.156   0.168 
S.D.     0.006   0.014 
 
        p value 0.005 
(Table 3.4.2.2.nT.12C) THP-1 cell count shows significant difference between pre and post 
24 hours incubation in control group p=0.005 
 
THP-1 cell count in Actovegin group pre and post incubation 
 pre  pre pre Acto24 hr  Acto24 hr Acto24 hr 
1 0.15 0.15 0.16 0.26 0.22 0.29 
2 0.16 0.17 0.15 0.15 0.18 0.26 
3 0.15 0.16 0.15 0.28 0.19 0.18 
4 0.16 0.17 0.14 0.30 0.25 0.27 
5 0.16 0.17 0.16 0.24 0.26 0.20 
Mean   0.155     0.233 
S.D.     0.008     0.046 
 
        p value 0.005 
(Table 3.4.2.2.nT.12A) THP-1 cell count shows significant difference between pre and post 
24 hours incubation in Actovegin group p=0.005 
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Macrophages 
 
After 24 hours of incubation, both the Actovegin and control groups 
showed increased numbers of cells in the macrophage cultures. The mean 
absorbance value of 2.823 and 3.473 from the MTS assays between the 
Control and Actovegin groups respectively (Table 3.4.2.2.aM.2.AC). This is 
confirmed by the haemocytometer manual counting. The mean cell count in 
the control group is 0.244 x 104 and the Actovegin group is 0.320 x 104 (Table 
3.4.2.2.nM.2.AC). There was a significant increase (p=0.00006) in the cell 
count between the groups compared to its pre incubation cell count. In the 
control group the cell count has increased from 0.241 to 0.244. (Table 
3.4.2.2.nM.12.A) In the Actovegin group the cell count has increased from 
0.241 to 0.320 (Table 3.4.2.2.nM.12.A). The Actovegin group showed an 
additional 31% increase in macrophage cell count compared to control after 
24 hours of incubation (p=0.00006).  
 
 
Macrophages cells absorbance between control and Actovegin post incubation 
 
control  control  control  Actovegin  Actovegin  Actovegin  
1 2.64 2.39 2.33 3.76 3.16 3.24 
2 3.54 3.52 2.89 3.27 2.64 2.99 
3 2.26 2.98 2.32 4.07 3.20 3.14 
4 2.42 3.21 3.35 4.38 3.73 4.23 
5 2.47 3.59 2.43 3.58 3.79 2.91 
Mean     2.823     3.473 
S.D.     0.501     0.509 
 
          p value 0.004 
(Table 3.4.2.2.aM.2.AC) Absorbance of the cell proliferation assay at 490nm after 24 hours 
of incubation in Macrophages cells. Absorbance assays show significant difference between 
control and Actovegin groups after 24 hours of incubation in Macrophage cell line. p=0.004 
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Macrophages cell count between control and Actovegin post incubation 
 
Con24  Con24 Con24 Acto24  Acto24 Acto24 
1 0.24 0.22 0.22 0.35 0.29 0.30 
2 0.33 0.20 0.26 0.30 0.24 0.35 
3 0.21 0.23 0.21 0.37 0.25 0.29 
4 0.22 0.26 0.29 0.40 0.34 0.39 
5 0.23 0.33 0.22 0.33 0.35 0.27 
Mean     0.244     0.320 
S.D.     0.041     0.049 
  
       p value 0.00006 
(Table 3.4.2.2.nM.2.AC) Cell count after 24 hours of incubation in Macrophage cells. Cell 
count shows significant difference between control and Actovegin groups after 24 hours of 
incubation in Macrophage cell line. p=0.00006 
 
Macrophages cell count in control group pre and post incubation 
Mac pre  pre pre 24 hr  24 hr 24 hr 
1 0.23 0.26 0.24 0.24 0.22 0.22 
2 0.27 0.29 0.23 0.33 0.20 0.26 
3 0.23 0.24 0.28 0.21 0.23 0.21 
4 0.23 0.19 0.24 0.22 0.26 0.29 
5 0.21 0.25 0.21 0.23 0.33 0.22 
Mean   0.241   0.244 
S.D.     0.027   0.041 
 
       p value 0.720 
(Table 3.4.2.2.nM.12.C) Macrophage cell count shows no significant difference between 
pre and post 24 hours incubation in control group p=0.72 
 
Macrophages cell count in Actovegin group pre and post incubation 
 pre  pre pre 24 hr  24 hr 24 hr 
1 0.26 0.23 0.31 0.35 0.29 0.30 
2 0.24 0.25 0.29 0.30 0.24 0.35 
3 0.21 0.26 0.22 0.37 0.25 0.29 
4 0.23 0.19 0.22 0.40 0.34 0.39 
5 0.23 0.26 0.23 0.33 0.35 0.27 
Mean     0.241     0.320 
S.D.     0.029     0.049 
         p value 0.0002 
(Table 3.4.2.2.nM.12A) Macrophage cell count shows significant difference between pre 
and post 24 hours incubation in Actovegin group p=0.0002 
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Results Summary : 
 
After 24 hours of incubation, both Actovegin and Control groups in the 
THP-1 cell culture showed significant increases in cell counts. The Actovegin 
group showed 39% additional increase in THP 1 cell count compared to 
control, p= 0.0001 (Table 3.4.2.2.nTM.2S).  In comparison to the 
Macrophages, the control group failed to demonstrate a significant increase in 
cell count after 24 hours of culture. On the other hand, the Actovegin group 
showed significant increase in cell count. The Actovegin group showed 39% 
additional increase in macrophage cell count compared to control after 24 
hours of culture, p=0.00006 (Table 3.4.2.2.nTM.2S). Figure 3.4.2.2.nTM.S 
shows a graphical representation of the results discussed in this section.  
 
   mean S.D. mean diff t-test 
THP-1   Actovegin 24 0.233 0.046 +39% 0.0001* 
Macrophages Actovegin 24 0.320 0.041 +31% 0.00006* 
(Table 3.4.2.2.nTM.2S) Summaries of the cell count changes after 24 hours of cell culture in 
THP-1 and macrophage cells. 
 
 
(Figure 3.4.2.2.nTM.S) con = control group pre-incubation, acto = Actovegin group pre-
incubation,  con 24 = control group after 24 hour of incubation, acto 24 = Actovegin group 
after 24 hours of incubation.  
Graph to summarise the overall changes in cell counts between the Actovegin and control 
groups before and after 24 hours of cell cultures.  
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3.4.2.3 Discussion  
 
The MTS assay and cell count in the in-vitro study confirmed that 
Actovegin has significant proliferative effects on THP-1 and Macrophages. 
This findings are in keeping with other in-vitro studies reported in the literature 
with different cell types, detailed in Section 2.6.1. In-vitro cell cultures of 
human origin are uncommon in the published literature related to Actovegin; 
this could be due to the fact that most human cell types require the use of 
FBS. As discussed in Section 3.4.1, FBS will potentially affect the outcome 
and interpretation of the results when investigating the role of Actovegin in an 
in-vitro setting. FBS -free human THP-1 cell cultures are a well-established 
cell culture method used to investigate haematological and immunological 
diseases and malignancy as detailed in Section 3.4.1. This study is the first 
study reporting the proliferative effect of Actovegin in these cells of human 
origin.   
 
Besides the proliferative effect of Actovegin demonstrated in this study, 
I have also identified a suitable serum free human cell in-vitro model to 
investigate the biochemical role of Actovegin in the inflammatory process. 
Section 2.3.3 has detailed the pathophysiology of the muscle healing process, 
further in vitro experiment will be discussed in Section 3.4.3, attempting to 
identify the role of Actovegin in muscle injuries.  
 
3.4.3 Polymerase chain reaction (PCR) 
 
In Section 3.4.1, a serum free in-vitro human cell culture system was 
identified; Section 3.4.2 demonstrated the efficacy of this in-vitro model and 
also suggested that Actovegin has a significant proliferative effect on these 
inflammatory cells. As discussed in Sections 2.3.3 and 2.3.4, the speed and 
quality of muscle healing are dependent on the inflammatory process. 
Cytokines and inflammatory cells govern the inflammatory process. Although 
Section 3.4.2 demonstrated the proliferative effects of Actovegin on these 
cells, it is not possible to identify its subtype and function with the MTS assay. 
In this section, polymerase chain reaction will be used to identify the subtype 
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of these inflammatory cells and further explore the role of Actovegin, as stated 
in the hypothesis in Section 2.7. 
 
PCR is a laboratory technique used to makes many copies of a piece 
of DNA. The copies of DNA double with every cycle, hence it can reliability 
detect a very small amount of change in the total amount of DNA. The 
principle of PCR is based on the use of DNA polymerase to make a copy of a 
single stranded DNA. Therefore, double standard DNA must first be melted to 
single stranded DNA via the denaturation process with a set temperature. A 
short piece of single stranded DNA (gene of interest), called the primer is 
added to the mixture. A forward primer binds to one strand and a reverse 
primer binds to the opposite strand. The DNA polymerase enzyme forms a 
double stranded DNA between the single stranded DNA and the primer. This 
annealing process is achieved by cooling the PCR mixture. After the 
annealing process, the mixture is then heated up again to a specific 
temperature depending on the DNA polymerase to facilitate the extension 
process. In this process, the DNA polymerase enzyme copies the single 
stranded molecule, starting at the bound primer region and makes a 
complementary copy of the single stranded DNA (cDNA). The only DNA that 
is copied is the region between the forward primer binding location and the 
reverse primer binding location. Both single strands of the original double-
stranded DNA molecule are copied. Therefore, the result is two double 
stranded molecules each identical to the original double-stranded DNA 
fragment. The three steps of the PCR process, denaturation, annealing and 
extension are repeated. After 30 cycles, 1x109 copies of double stranded 
cDNA are produced from a single double stranded DNA. If there were 2 
double strands of DNA, 1x1018 copies of double stranded cDNA are produced. 
After the amplification process, agarose gel electrophoresis is employed for 
size separation of the PCR products, which can be quantified by 
Fluorescence light absorptiometry, similar to the MTS assay described in 
Section 3.4.2. This method is useful in determining the presence of a specific 
gene, however it will only give a semi-quantitative result as gel 
electrophoresis fluorescence light absorptiometry can only indirectly measure 
the end product of the PCR. As technology advanced, real time PCR was 
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developed over recent years to improve the accuracy and efficiency of PCR. 
 
Real time quantitative PCR (qPCR) 
qPCR is based on the same principles as PCR, as discussed above. 
qPCR enables both detection and quantification of one or more specific 
sequences in a DNA sample. With this method, the quantity can be either an 
absolute number of copies or a relative amount when normalised to DNA 
input or additional normalising genes. This offers distinct advantages over 
traditional PCR, as it can detect the magnitude of changes in a specific gene 
real time. Estimation errors can arise from variations in the quantification 
method and can be the result of DNA integrity, enzyme efficiency and many 
other factors. Instead of quantifying the absolute amount of the total gene 
expression, the quanitification of a specific gene being studied in relation to a 
housekeeping gene is used instead in qPCR. As the housekeeping gene and 
the specific gene of interest are measured at the same time, it reduces the 
estimation errors. Instead of the absolute quantity of a specific gene, a ratio 
for the expression of the gene of interest divided by the expression of the 
selected housekeeping gene is reported. 
 
qPCR utilizes the same PCR steps, denaturation, annealing and 
extension process. In qPCR a fluorophore is added to this mixture in a 
thermal cycler that contains sensors for measuring the fluorescence of the 
flurophore after it has been excited at the required wavelength, allowing the 
generation rate to be measured for one or more specific products. This allows 
the rate of fluorescence generation by the amplified product to be measured 
at each PCR cycle by a specially designed qPCR machine. The fluorescence 
generated by a sample of DNA during real-time PCR is plotted over time, 
rather then PCR cycle number. The middle of its curve represents the 
exponential phase of PCR (Figure 3.4.3.a), when the levels of generated 
fluorescence exceeds the background fluorescence, but reagents have not 
nearly begun to reach limiting factors. This specific value is referred to as the 
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threshold cycle (Ct) or it could also be called the threshold time (Cq) (Figure 
3.4.3.a). Genes with the highest starting target amount will also have the 
highest values of amplified target in a given PCR cycle number. This means 
their fluorescence curves will exceed background earlier and cross the 
threshold at an earlier cycle number; thus, the more abundant the starting 
quantity of gene, the lower the Ct value of that sample. The plateau stage 
(Figure 3.4.3.a) of the qPCR curve represents the endpoint of that reaction as 
at one or more reaction components is depleted. At the plateau stage the 
amplification curves of qPCR are no longer exponential, which means that the 
association of a two-fold increase in quantity from one cycle number to the 
next has come to an end.  
 
After the plateau stage, it is important to establish a melt graph for the 
qPCR. This is due to the fact that SYBR Green will detect any double 
stranded DNA including primer dimers, contaminating DNA, and PCR 
products from mis-annealed primer. The melt graph analysis can identify 
contamination, as contaminating DNA or primer dimers will show up as an 
additional peak separate from the desired peak. 
 
 
(Figure 3.4.3.a) demonstrates a typical graph for qPCR, fluorescence generated by a sample 
of DNA against time, the threshold time (Ct) is when the levels of generated fluorescence 
exceed background fluorescence Reference: qPCR manual  
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Cells in all organisms regulate gene expression by turnover of gene 
transcripts via messenger RNA (mRNA). The amount of an expressed gene 
by a cell can be measured by the number of copies of its mRNA transcripted. 
qPCR can robustly detect and quantify gene expression, however it is limited 
to DNA detection. Therefore, mRNA in cell culture is needed to be reverse-
transcribed to DNA with reverse transcriptase prior to qPCR. In order to 
analyse the cell’s genetic expression, mRNA must first be extracted. Once the 
quality of extraction is confirmed, it can then be reverse-transcribed to 
complementary DNA (cDNA), which can then be used for qPCR. cDNA is a 
much more stable form of nucleic acid compared to mRNA, therefore mRNA 
should be reverse-transcribed to cDNA before storage.  
As discussed in Section 2.3.4, the speed and quality of muscle healing 
are dependent on the inflammatory process. The inflammatory process is 
governed by cytokines and inflammatory cells. Although Section 3.4.2 has 
demonstrated the proliferative effect of Actovegin in these cells, it is not 
possible to identify its sub type and function with the MTS assay. Therefore, 
qPCR will be used to identify the role of Actovegin on the CD68+ and CD163+ 
subtypes of THP-1 and Macrophages, furthermore inflammatory cytokines 
MCP-1, TNF∝, CD163+, CD68+ and IL1 will also be analysed. The 
housekeeping gene used for this qPCR is GAPDH. 
 
 
3.4.3.1 Method 
 
Cell culture 
 
THP-1 and macrophage cell cultures in the same format as described 
in the cell proliferation experiment with control and 10% Actovegin. 6 
biological replications of each group were performed at separate time points. 
After 24 hours incubation, cells were lysed with TRIZOL Reagent (Invitrogen, 
USA) and stored as cell pellets at -20oC until RNA extraction and cDNA 
conversion. Once all 24 individual culture samples were collected, RNA 
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extraction, cDNA conversion and qPCR for all experiments were performed 
on the same day.  
 
RNA extraction: 
 
Frozen TRIZOL cell pellets were put into a 37oC water bath for 2 
minutes to rewarm. The samples were then incubated for 5 minutes at room 
temperature to permit the complete dissociation of nucleoprotein complexes. 
All work surfaces, equipment and sample bottles were cleaned with RNAaway 
solution prior to RNA extraction. 0.2 ml of chloroform was added and samples 
were vortexed vigorously for 15 seconds and incubated at room temperature 
for 2 minutes. The samples were centrifuged at 12,000 RPM for 15 minutes at 
40C. Following centrifugation, the mixture was separated into lower red, 
phenol- chloroform phase, an interphase, and a colorless upper aqueous 
phase. RNA remains exclusively in the aqueous phase. The upper aqueous 
phase was transferred carefully without disturbing the interphase into a fresh 
tube. The RNA was precipitated from the aqueous phase by mixing with 0.5ml 
isopropyl alcohol. Samples were incubated at room temperature for 10 
minutes and centrifuged at 12, 000 rpm for 10 minutes at 4oC. The RNA 
precipitate, formed a gel-like pellet on the side and bottom of the tube, the 
supernatant was then completely removed and washed with 1ml of 75% 
ethanol. The sample was mixed by vortexing and centrifuging at 7,500 RPM 
for 5 minutes at 4 oC. The RNA pellet was air-dried for 5 minutes and then 
dissolved in DEPC-treated water by passing the solution a few times through 
a pipette tip. The RNA quality control was performed immediately with RNA 
6000 LabChip. Once quality was confirmed, cDNA synthesis was performed 
to minimise the RNA degradation. 
  
RNA quality control: 
 
The Agilent 2100 Bioanalyzer (Agilent Technologies) was used in 
conjunction with the RNA 6000 LabChip (Caliper Technologies Corporation) 
to provide detailed information about the condition of RNA samples including 
integrity, concentration and purity. This method of automated system RNA 
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analysis only required small amounts of RNA as compared to the traditional 
agarose gel method.  
 
Agilent 2100 Bioanalyzer was switched on and set up, as per manufacturer’s 
guidance, and 2100 expert software was loaded. RNA 6000 LabChip was 
removed from 4oC storage to the bench to equilibrate at room temperature for 
30 minutes. The ladder aliquot (standardized manufacture control) was taken 
out of the freezer at –70 0C and thawed on ice.  A dummy chip was introduced 
to the cumber and filled with 350ul of RNAseZAP and left for 1 minute to 
decontaminate the machine. A second dummy chip was introduced to the 
cumber and filled with 350ul of fresh Milli-Q water and left for 10 minutes with 
the lid closed. The dummy chip was then removed and the electrode was 
allowed to dry.  
 
The RNA 6000 chip was placed onto the chip priming station and each well 
was primed with 9ul of Gel Dye Mix. 5ul of RNA 6000 Nano Marker was 
pipetted into each well and 1ul of each sample was also introduced to each 
well. 1ul of ladder was pipetted to the ladder well. The chip was then placed 
on an adapter and vortexed for 1 minute. The sample loaded chip was then 
introduced to the Agilent 2100 Bioanalyzer for RNA analysis. Once RNA 
quality was confirmed, it could be transcribed to more stable cDNA. 
 
cDNA synthesis: 
 
Complementary DNA (cDNA) was reverse transcribed from total RNA 
samples using High Capacity cDNA Reverse Transcription Kit with 
SuperScript® VILO™ Master Mix (Invitrogen, USA). 4 µl of SuperScript® 
VILO™ Master Mix was mixed with 2 µg of RNA generated from the RNA 
extraction process described above. All samples were then incubated at 42oC 
for 90 minutes. Then the temperature was increased to 85oC for 5 minutes to 
terminate to process. Once the cDNA was produced, it was stored in -80 oC 
until the qPCR process  
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qPCR 
 
Polymerase Chain Reaction (PCR) products were synthesized from 
cDNA samples using the PCR master mix, SYBR GREEN PCR Master Mix 2 
X 10µl, dH2O 4.8µl, Forward primer (100µM)  0.6µl, Reverse primer (100µM) 
0.6 µl.  Forward and reverse primer of GAPDH, TNF∝, CD163+, CD68+, IL1 
and MCP1 from e-Bioscience (UK) were used (Table 3.4.3.1). All the above 
steps were performed in a certified biotechnology laboratory, ABI 7900HT 
Real-Time PCR system was used for the Real time PCR. The reaction was 
carried out at 25°C for 5 minutes followed by another 60 minutes at 42°C and 
was terminated by the deactivation of the enzyme at 70 °C for 5 minutes. All 
samples were analyzed twice with and without reverse transcriptase, and no 
amplification was seen in the samples in the absence of reverse transcriptase. 
Comparisons of Actovegin treated cells with the control in the proliferation 
assay, qPCR gene expression, two tailed t-test was used to determine mean 
difference, using SPSS version 20 (IBM Corp.). 
 
 
Gene Forward primers Reverse primers 
GAPDH,  5' CGCTCTCTGCTCCTCCTGTT 3' 5' CCATGGTGTCTGAGCGATGT 3'  
TNF∝,  5′ CTCTTCTCCTTCCTGATCGTGGCA 3’ 5′ GAAAGCATGATCCGGGACGTGGA 3’ 
CD163+,  5′ CCAGTCCCAAACACTGTCCT 3’ 5′ ATGCCAGTGAGCTTCCCGTTCAGC 3′ 
CD68+ 5′ GGGAGAAGGGAGGGAGAGAA 3′ 5′ GGAAAACCCCGTCAAAGATT 3′ 
IL1  5' AGTAGCAACCAACGGGAAGG 3',  5' TGGTTGGTCTTCATCTTGGG 3' 
MCP1 5’ CTGGATCGGAACCAAATGAG 3’ 5’ CGGGTCAACTTCACATTCAA 3’ 
Table 3.4.3.1 for the gene of the primers 
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Calculation:  
 
All data were expressed as arbitrary units in relation to GAPDH mRNA 
(housekeeping gene). The number of mRNA “threshold cycle” difference of 
each gene compared to the control was expressed as “∆Ct”, the “threshold 
cycle” of each gene compared to the Actovegin group was expressed as 
“∆∆Ct”. As per international standards, relative quantity (RQ) values were 
calculated to express changes in the Actovegin group in relation to control.  
 
Example for calculation for Macrophage CD68+ gene expression:  
 
Threshold cycle (ct) for GAPDH in Control  = 16.63 
Threshold cycle (ct) for CD68+  in Control  = 20.95 
∆Ct  for CD68+  in Control= 20.95 - 16.63 = 4.32 
(table 3.4.3.2.h, page 106) 
 
Threshold cycle (ct) for GAPDH in Actovegin = 16.93 
Threshold cycle (ct) for CD68+   in Actovegin  = 20.61 
∆Ct  for CD68+   in Actovegin= 20.61 – 16.93 = 3.68 
(table 3.4.3.2.h, page 106) 
 
“∆∆Ct” of CD68+   between Actovegin and control = 3.68 – 4.32 =-0.64 
(table 3.4.3.2.i, page 106) 
 
RQ vale = 2 to the power of – ( - 0.64 ) = 1.56 
(table 3.4.3.2.j, page 1067) 
 
In this specific example, CD68+ gene expression in the Actovegin 
group is 156% compare to control.  
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3.4.3.2 Results: 
 
Six sets of independent samples were used for each gene of interest 
and qPCR was carried out as triplicate according to the protocol described in 
4.3.4.1 of the method section. In total, 216 samples were analysed for each 
cell type. All samples were stored at -80 oC until qPCR, as per protocol. The 
quality of mRNA was excellent, the RNA integrity number ranged between 9.9 
-10. According to the previous studies and text book(Acharyya et al., 2007, 
Shen et al., 2005, Sulahian et al., 2000, Cory et al., 1991, Tsuchiya et al., 
1980), all qPCR data could be assumed to produce normal destitution data, 
therefore parametric data analysis such as t test were used for data analysis. 
 
RNA quality 
The graphs in this section demonstrate the extracted RNA ratio and the 
quality of the RNA, suggesting that the highest possible quality of RNA was 
extracted from all of the samples of Macrophages and THP-1 cells. 
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Melt Curve 
 
Melt curve analysis suggested that all the reaction was free from 
contamination; only single peaks were detected in each of the gene analysis.  
 
 
 
Melt curve analysis showing that the IL1 gene qPCR reactions are free from 
contamination for all of the samples. 
 
 
 
Melt curve analysis showing that the GAPDH gene qPCR reactions are free 
from contamination for all of the samples. 
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Melt curve analysis showing that the CD163+ gene qPCR reactions are free 
from contamination for all of the samples. 
 
 
 
Melt curve analysis showing that the CD68+ gene qPCR reactions are free 
from contamination for all of the samples. 
 
 
 
Melt curve analysis showing that the TNF α gene qPCR reactions are free 
from contamination for all of the samples 
 102 
 
Melt curve analysis showing that the MCP-1 gene qPCR reactions are free 
from contamination for all of the samples 
 
THP-1 Cell line 
 
There were significant changes in RQ values for CD68+, CD163+, 
MCP-1 and TNF α compared to control after 24 hours of incubation for THP-1 
cells. Mean CD68+ was 73% in the Actovegin group, CD163+, MCP-1 and 
TNF α were significantly higher in the Actovegin group, 147%, 133% and 
137% respectively (Table 3.4.3.2.a). There were no significant changes for 
IL1 gene expression compared to the control group. Two tailed t-test was 
used to compare the RQ values; there were significant changes (p<0.05) in 
the gene expression of CD68+, CD163+, MCP1 and TNF∝ in the Actovegin 
group compared to control (Table 3.4.3.2.e).  
 
THP CD68+RQ CD163+ RQ IL1B RQ MCP1 RQ TNFα RQ 
Actovegin  73% 147% 99% 133% 137% 
Statistical sig. Yes Yes No Yes Yes 
(Table 3.4.3.2.a) Results summary for THP-1 cells after 24 hours of incubation. Actovegin 
group showed statistical difference in CD68+, CD163+, MCP-1 and TNF α 
 
The threshold cycle (Ct) is shown in Table 3.4.3.2.b and the ∆∆Ct values are 
shown in Table 3.4.3.2.c. Table 3.4.3.2.d shows the relative quantity of each 
gene in the Actovegin group compared to control in THP-1 cell line after 24 
hours of incubation. 
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THP GAPDH Ct  CD68+Ct  CD163+ Ct  IL1B Ct  MCP1 Ct  TNF α Ct  
control 1 16.44 20.78 30.74 28.70 25.58 24.06 
control 2 16.34 20.31 30.86 28.72 26.00 24.26 
control 3 16.08 20.52 30.47 28.19 25.29 24.49 
control 4 15.94 20.49 31.33 25.32 25.13 25.34 
control 5 16.02 20.58 31.51 25.90 26.05 26.53 
control 6 16.62 20.89 32.30 26.59 26.72 27.03 
mean 16.24 20.60 31.20 27.24 25.80 25.29 
acto 1 16.09 20.83 31.57 25.70 25.18 24.87 
acto 2 16.50 21.15 31.37 26.66 25.92 26.06 
acto 3 16.05 20.94 31.59 26.27 26.06 26.30 
acto 4 16.71 21.20 30.23 28.66 25.31 23.90 
acto5 16.37 21.39 30.31 28.54 25.51 23.92 
acto 6 16.36 21.76 29.75 28.44 25.05 24.81 
mean 16.35 21.21 30.80 27.38 25.51 24.98 
(Table 3.4.3.2.b) Q- PCR Ct of each gene in control vs Actovegin group in THP-1; the value 
of each cell represents the average of the triplet per experiment, in total 216 sets of pPCR 
were performed. 
 
THP CD68+ CD163+  IL1B  MCP1  TNF α 
  ∆∆ Ct ∆∆ Ct ∆∆ Ct ∆∆ Ct ∆∆ Ct 
acto 1 0.19 0.08 0.23 -0.11 -0.63 
acto 2 0.09 -0.62 0.27 -0.62 -0.95 
acto 3 0.62 -0.16 0.24 -0.10 -0.17 
acto 4 0.14 -0.79 -0.31 -0.54 -0.43 
acto5 1.04 -0.58 -0.22 -0.52 -0.38 
acto 6 0.96 -1.00 -0.03 -0.52 0.04 
            
mean 0.51 -0.51 0.03 -0.40 -0.42 
s.d. 0.43 0.40 0.26 0.23 0.35 
(Table 3.4.3.2.c) ∆∆Ct value for each gene of interest in qPCR in THP-1 
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THP CD68+RQ CD163+ RQ IL1B RQ MCP1 RQ TNF α RQ 
acto 1 0.88 0.94 0.85 1.08 1.54 
acto 2 0.94 1.54 0.83 1.53 1.94 
acto 3 0.65 1.11 0.84 1.07 1.13 
acto 4 0.91 1.73 1.24 1.46 1.35 
acto5 0.49 1.50 1.16 1.43 1.30 
acto 6 0.51 2.00 1.02 1.43 0.97 
            
mean 0.73 1.47 0.99 1.33 1.37 
s.d. 0.20 0.39 0.18 0.20 0.34 
(Table 3.4.3.2.b) Relative quantity of each gene in the Actovegin group compared to control 
in THP-1. RQ values for each gene of interest in qPCR in reference to control group which is 
= 1. 
 
 
THP t-test for Equality of Means (Equal variances not assumed) 
t df Sig.  
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% C.I of 
 the Difference 
Lower Upper 
CD68+ 3.22 5 0.024* 0.27 0.084 0.054 0.486 
CD163+ -2.94 5 0.032* -0.47 0.160 -0.880 -0.060 
IL1 0.14 5 0.896 0.01 0.073 -0.178 0.198 
MCP-1 -4.01 5 0.001* -0.33 0.083 -0.547 -0.120 
TNF α -2.68 5 0.004* -0.37 0.139 -0.728 -0.015 
(Table 3.4.3.2.e) t-test confirmed that there was statistical difference in RQ values between 
control and Actovegin treated cells in CD68+, CD163+, MCP-1 and TNF α. There was no 
statistical difference in RQ values found in IL1 between the groups  *= Statistically significant  
 
Macrophage Cell line 
 
There were significant changes in RQ values for CD68+, CD163+, 
MCP-1 and TNF α compared to control after 24 hours of incubation of the 
Macrophage cells. Mean CD163+ was 63% in the Actovegin group. CD68+, 
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MCP-1 and TNF α were significantly higher in the Actovegin group, 177%, 
310% and 410% respectively (Table 3.4.3.2.f). Student t-test confirmed 
statistical significance. There were no significant changes for IL1 gene 
expression in the parametric test compared to the control group. (Table 
3.4.3.2.g) 
 
Mac 
CD68+ 
 RQ 
CD163+ 
RQ IL1B RQ 
MCP1 
RQ 
TNF α 
RQ 
Actovegin  177% 63% 120% 310% 410% 
Statistical 
significant 
Yes Yes No 
 
Yes Yes 
 
(Table 3.4.3.2.f) Results Summary for macrophage cells after 24 hours of incubation. 
Actovegin group showed statistical difference in CD68+, CD163+, MCP-1 and TNF α 
 
 
mac t-test for Equality of Means (Equal variances not assumed) 
t df Sig.  
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% C.I. of 
 the Difference 
Lower Upper 
CD68+ -2.91 5 0.034* -0.77 0.266 -1.457 -0.089 
CD163+ 2.73 5 0.041* 0.37 0.137 0.022 0.725 
IL1 -1.18 5 0.291 -0.20 0.166 -0.625 0.231 
MCP-1 -2.96 5 0.032* -2.10 0.708 -3.917 -0.276 
TNF α -2.59 5 0.049* -3.13 1.209 -6.236 -0.020 
(Table 3.4.3.2.g)  t-test confirmed that there was statistical difference in RQ values between 
control and Actovegin treated cells in CD68+, CD163+ MCP-1 and TNF α. There was no 
statistical difference ib RQ values found in IL1 between the groups. *= Statistical significant  
 
 
The threshold cycle (Ct) is shown in Table 3.4.3.2.h and the ∆∆Ct 
values are shown in Table 3.4.3.2.i. Table 3.4.3.2.j shows the relative quantity 
of each gene in the Actovegin group compared to control in the macrophage 
cell line after 24 hours of incubation. 
 
 106 
mac 
GAPDH 
Ct  CD68+Ct  CD163+Ct  IL1B Ct  
MCP1 
Ct  
TNF α 
Ct  
control 1 16.63 20.95 20.54 17.50 20.32 22.93 
control 2 17.88 21.12 20.95 18.00 21.35 22.91 
control 3 15.97 20.92 20.68 18.07 21.13 22.93 
control 4 15.39 19.66 20.56 14.92 19.33 21.64 
control 5 15.80 19.08 21.30 15.02 19.65 21.93 
control 6 16.07 20.08 21.62 15.26 19.59 22.17 
Mean 16.29 20.30 20.94 16.46 20.23 22.42 
acto 1 16.93 20.61 21.06 17.58 18.80 20.23 
acto 2 16.63 20.00 21.60 17.56 19.02 20.23 
acto 3 16.81 20.44 21.28 18.02 19.31 20.80 
acto 4 16.72 19.62 22.70 16.09 19.04 21.81 
acto5 15.87 18.39 22.57 14.78 18.62 20.89 
acto 6 15.72 19.25 22.47 14.59 18.71 20.96 
Mean 16.45 19.72 21.95 16.44 18.92 20.82 
(Table 3.4.3.2.h) Q- PCR Ct of each gene in control vs Actovegin group in the Macrophage 
cell line, the value of each cell represents the average of the triplet per experiment, in total 
216 set of pPCR were performed. 
 
 
mac CD68+ CD163+ IL1B  MCP1  TNF α 
  ∆∆ Ct ∆∆ Ct ∆∆ Ct ∆∆ Ct ∆∆ Ct 
acto 1 -0.64 0.22 -0.23 -1.81 -3.00 
acto 2 0.14 1.91 0.81 -1.07 -1.42 
acto 3 -1.32 -0.24 -0.89 -2.66 -2.98 
acto 4 -1.38 0.81 -0.15 -1.62 -1.16 
acto5 -0.76 1.20 -0.32 -1.10 -1.11 
acto 6 -0.47 1.20 -0.31 -0.53 -0.86 
  
    
  
mean -0.74 0.85 -0.18 -1.47 -1.76 
s.d. 0.56 0.77 0.55 0.74 0.97 
(Table 3.4.3.2.i) “Threshold cycle” difference in Actovegin group compared to control in 
Macrophages. ∆∆Ct value for each gene of interest in qPCR in Macrophages 
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mac CD68+RQ CD163+ RQ IL1B RQ MCP1 RQ TNF α  RQ 
acto 1 1.56 0.86 1.17 3.51 8.00 
acto 2 0.91 0.27 0.57 2.11 2.68 
acto 3 2.49 1.18 1.85 6.30 7.87 
acto 4 2.59 0.57 1.11 3.07 2.24 
acto5 1.70 0.44 1.24 2.15 2.16 
acto 6 1.39 0.44 1.24 1.44 1.82 
  
    
  
mean 1.77 0.63 1.20 3.10 4.13 
s.d. 0.65 0.34 0.41 1.74 2.96 
(Table 3.4.3.2.j) Relative quantity of each gene in the Actovegin group compared to control in 
Macrophages. RQ value for each gene of interest in qPCR in reference to control group which 
is = 1. 
 
Overall results summary: 
 
qPCR demonstrated Actovegin significantly up regulated the THP-1 
cell subtype CD163+ to 147% and suppressed the CD68+subtype to 73%. It 
also up regulated the gene expression of the inflammatory cytokine MCP-1 to 
133% and TNF α to 137% (Table 3.4.3.2.k). In Macrophages, it significantly 
up regulated the CD68+subtype to 177% and suppressed the CD163+ subtype 
to 63%. It also caused a 3 fold MCP-1 and 4-fold increase in TNF α gene 
expression (Table 3.4.3.2.k). Figure 3.4.3.2 summaries the results in 
graphical format.  
 
 
CD68+RQ CD163+ RQ IL1B RQ MCP1 RQ TNF α RQ 
THP-1 73%* 147%* 99% 133%* 137%* 
Macrophages 177%* 63%* 120% 310%* 410%* 
(Table 3.4.3.2.k) Results summary - qPCR Relative Quantity value (RQ) results summary, 
Blue = reduced, Red = increased *= Statistical significance 
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(Figure 3.4.3.2) Graph to show mean Relative Quantity (RQ) of gene expression from qPCR 
for THP-1 and Macrophage cells compared to control after 24 hours of incubation. There 
were significant changes in CD68+, CD163+, MCP-1 and TNF α gene expression in the 
Actovegin Group compared to control.  
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3.4.3.3 Discussion  
 
The in vitro study in this PhD confirmed that Actovegin havs a role in 
the inflammatory process. It can significantly affect the cell genotype 
expression of the acute inflammatory cells such as THP-1 and macrophages. 
Actovegin up regulates the CD68+ subtype of  “phagocytic” macrophages, 
characterized by the expression of the CD68+cell surface marker and lacking 
the CD163+ marker. These CD68+ subtypes of macrophages are pro-
inflammatory phagocytes and were thought to be responsible for the removal 
of necrotic debris during the initial phase of the inflammatory process 
following muscle injury. It also down regulates the CD163+subtype of “non-
phagocytic” macrophages, which was thought to contribute to the termination 
of the destruction phase and initiate the repair phase of the muscle healing 
process (Ciciliot and Schiaffino, 2010, Chazaud et al., 2009) (Figure 
3.4.3.3.a). Further details are explained in Section 2.3. Therefore, the change 
of macrophage subtype suggests that Actovegin could significantly increase 
the acute inflammatory process, which is also confirmed by the expression of 
the inflammatory cytokines MCP-1 and TNF α. Figure 3.4.3.3.b explain the 
finding in a graphical format. 
 
 
TNF α = tumor necrosis factor, IL-1 =interleukin-1, SLPI = secretory leukocyte protease 
inhibitor, TGF-A=transforming growth factor, IL-10= interleukin 10, PPAR =peroxisome 
proliferator activated receptor 
 
Figure 3.4.3.3.a Switch of macrophage phenotype upon phagocytosis. In vitro, phagocytosis 
of both apoptotic and necrotic debris switches the phenotype of pro-inflammatory 
macrophages into anti-inflammatory macrophages, which is associated with the resolution of 
inflammation and tissue repair (Arnold et al., 2007). 
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(Fig. 2) (21). It has been recently demonstrated in myocar-
dium that two waves of monocyte subsets are subsequently
recruited into the injured tissue (17). Nevertheless, this also
leads to a switch of the macrophage phenotype present in the
tissue from an inflammatory profile to an anti-inflammatory
profile.
These results show that postinjury muscle regeneration is
characterized by sequential macrophage populations. First in
the tissue are inflammatory macrophages, which are associ-
ated with monocyte recruitment and removal of necrotic
material. Next, anti-inflammatory macrophages appear and
are associated with healing and tissue repair.
MACROPHAGES AND SKELETAL MUSCLE REPAIR
We have shown that the specific depletion of intramus-
cular F4/80hi (a monocyte/macrophage marker whose expres-
sion increases with differentiation) macrophages during the
phase of muscle repair (using CD11b-DTR mouse) results in
a decrease in the diameter of regenerating myofibers. This
result indicates that these anti-inflammatory macrophages
are involved in muscle cell differentiation and/or fiber
growth (2).
With the exception of regulation of inflammation, studies
documenting a direct role of macrophages on modulating cell
behavior are scant and include intestinal progenitor pro-
liferation (19), erythroblast proliferation and maturation
(20), and oligodendrocytic differentiation and myelination
(8). In vitro studies have shown that the macrophage acti-
vation state may direct neural progenitor differentiation
toward either neurogenesis or oligodendrogenesis (5).
We have performed a series of in vitro experiments using
human myogenic cells and macrophages aimed at identifying
the role of macrophages on myogenic cell behavior (2,6,24).
We first identified that macrophages stimulate in a dose-
dependent way the growth of myogenic cells. They are more
efficient when the two cell types are allowed to contact each
other. We showed that this stimulating effect is caused by: 1)
the release of mitogenic factors for myogenic cells, which are
likely growth factors known to be secreted by macrophages
and to which myogenic cells respond efficiently (10); and 2)
the establishment of cell-cell contacts that protect myogenic
cells from apoptosis. We have identified four molecular
systems involved in these cell contacts: vascular cell
adhesion molecule 1Yvery late antigen 4, intercellular cell
adhesion moleculeYleukocyte functionYassociated molecule
1, platelet-endothelial cell adhesion molecule 1 (PECAM-
1YPECAM-1), and CX3CL1-CX3CR1. These systems are
more strongly expressed by myotubes (multinucleated differ-
entiated myogenic cells) that are more protected from
apoptosis compared with undifferentiated myoblasts. This
suggests that macrophages could help protect these cells until
they establish a final association with the matrix.
We further analyzed the effects of differentially activated
macrophages.We used proinflammatory and anti-inflammatory
activated human macrophages, the counterparts of inflam-
matory and anti-inflammatory cells observed in vivo during
muscle regeneration in mouse, respectively (9). Our results
substantiate the view that macrophage function may be
related to activation state. In coculture experiments, inflam-
matory macrophages stimulate myogenic cell proliferation and
inhibit their differentiation. Conversely, anti-inflammatory
macrophages exhibit a strong differentiating influence on myo-
genic cells as assessed by both stimulation of the myogenic
program and increased myoblast fusion (2). These results
strongly suggest that the activation state of macrophages may
modulate the myogenic process.
The in vitro process of myogenesis involves three main
steps including cell differentiation per se (cell cycle with-
drawal and expression of the myogenic program), migration
of cells toward each other, and eventually fusion into
multinucleated structures. We have analyzed the effects of
macrophage-conditioned medium and showed that these
three steps are differentially regulated by proinflammatory
and anti-inflammatory macrophages (B. Chazaud, and H.
Yacoub-Youssef, unpublished data, 2008). Medium from pro-
inflammatory macrophages exerts negative effects on both
myogenic differentiation and fusion while stimulating myo-
genic cell motility, which may be detrimental for cell fusion
(3). Conversely, medium from anti-inflammatory macro-
phages stimulates both the myogenic differentiation and
fusion processes (Fig. 3).
The molecular mechanisms involved in these processes are
currently under investigation. It is likely that cytokines
released by activated macrophages influence myogenic cell
behavior. For example, tumor necrosis factor-> (TNF->) is
mitogenic for myoblasts and inhibits their differentiation
Figure 2. Switch of macrophage phenotype upon phagocytosis. Macrophages that invade skeletal muscle soon after injury present an inflammatory
phenotype, characterized by high expression of tumor necrosis factor-> (TNF->), interleukin-1A (IL-1A), and secretory leukocyte protease inhibitor (SLPI),
which are expressed y macrophages that have received proinflammatory cues. n vitro, phagocytosis of both apoptotic and n cr tic debris switches the
phenotype of proinflammatory macrophages into anti-inflammatory macrophages, which express high levels of transforming growth factor-A (TGF-A),
interleukin 10 (IL-10), and peroxisome proliferatorYactivated receptor-F (PPAR-F) that have been shown to be expressed by macrophages associated with
resolution of inflammation and tissue repair (for details on these markers of inflammation, see Arnold et al. [2]).
20 Exercise and Sport Sciences Reviews www.acsm-essr.org
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Inflammatory Phase (destruction) 
 
 
Anti Inflammatory Phase (repair) 
 
 
 
cd163 = CD163+anti -inflammatory macrophages neu = neutrophils, MAC CD68= CD68+ pro-
inflammatory macrophages, TNF α = Tumour Necrosis Factor, MCP-1 = Monocyte 
Chemotactic Protein -1 
 
(Figure 3.4.3.3.b) explained the in vitro study findings. Actovegin up regulated the CD68+ 
macrophages in the initial destruction phase, this leads to increase in cell number as well as 
increase the inflammatory responds by increase the inflammatory cytokines MCP-1 and TNF 
α. In the repair phase Actoveign up regulated THP-1 cell, which matured to become CD163+ 
macrophages and speed up repair.  
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The role of Actovegin in the acute inflammatory process following 
muscle injury is not limited to its effects on the CD68+ macrophages. It also 
exhibits an effect on THP-1 cells and up regulates a specific sub group of 
THP-1 cells. Although THP-1 cells have a limited role in the inflammatory 
process, they differentiate into macrophages. The qPCR results demonstrated 
that Actovegin could significantly up regulate the CD163+ subtype of THP-1 
cells, which will differentiate into the CD163+ subtype of macrophage. The 
differentiation process, which depends on other biochemical factors, was 
believed to take place approximately 48 hours after acute muscle injuries. 
Once the CD163+ subtype of THP-1 cells differentiates into the CD163+ 
subtype of “non-phagocytic” Macrophages, they will have an impact on the 
repair phase of the inflammatory process. (figure 3.4.3.3.b) 
 
The qPCR study in this PhD is based on high quality RNA extracted 
from 216 samples for each cell type. As demonstrated by gene chip analysis, 
the RNA integrity is the highest possible grade (range between 9.9 -10). The 
cDNA transcription and the primer used were also free from contamination as 
the melt cure for all 432 samples only demonstrated a single peak. Therefore 
the qPCR study in this PhD is high quality and reliable. 
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3.5 Summary for in vitro study 
 
 
The aim of the in vitro study in this chapter was to investigate the 
biochemical role of Actovegin in the acute inflammatory process as stated in 
Section 2.7. The cell proliferative studies (Section 3.4.2) from this PhD 
suggested that Actovegin could significantly (p=0.00006) increase 
macrophage proliferation (+33%) after 24 hours of incubation compared to 
control. This increase in cell number could theoretically increase the initial 
inflammatory response if this increase is specific to the pro-inflammatory 
subtype of macrophages. The qPCR gene analysis from this PhD (Section 
3.4.3) confirmed that it specifically up regulated CD68+ pro-inflammatory 
macrophages (+77%, p<0.05) and down regulated CD163+anti-inflammatory 
macrophages (-47%, p<0.05). At the beginning of the inflammatory phase of 
the muscle healing process, up regulation of CD68+ pro-inflammatory 
macrophages could be beneficial as it could increase the chemokine 
signalling pathway and increase subsequent recruitment of circulating 
monocyte cells to the injury site (further details in Section 2.3.3). Furthermore, 
the qPCR gene analysis on the inflammatory mediators suggested a 
significant (p< 0.05) 3 - 4 fold increase in Macrophage specific MCP-1 and 
TNF α Chemo-Cytokines.  These chemo-cytokines are known to be a potent 
chemo-attractant for circulating inflammatory cells (Arnold et al., 2007, 
Acharyya et al., 2007, Chazaud et al., 2009). This demonstrates that the up 
regulation of the pro inflammatory CD68+ macrophage by Actovegin could 
translate to up regulation of the inflammatory process. Table 3.5 summarises 
the significant findings from the in-vitro studies. 
 
Actovegin 
treated cells  
Cell 
number 
qPCR 
CD68+ CD163+ MCP1 TNF α 
THP-1 +39% 
 
+147% 
  Macrophages +31% +77% - 47% + 3-4 fold + 3-4 fold 
(Table 3.5) Results summary – proliferative cell essay results, qPCR results on Actovegin 
treated THP-1 and Macrophages cell line. Actovegin treated cells show significant increase in 
cell number and up regulation of the pro inflammation macrophages CD68+, anti-inflammatory 
THP-1 CD163+ and the pro inflammatory markers TNF α and MCP-1. It down regulates the 
CD163+ anti inflammatory macrophages.  
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This combination of findings demonstrates that Actovegin is an active 
agent, which causes significant up regulation of the initial pro-inflammatory 
response following injury. It may also have a role in the later anti-inflammatory 
phase as the CD163+ THP-1 matures. Figure 3.5 summary the finding in a 
diagram modified form Ciciliot and Schiaffino 2010. This finding confirmed the 
hypothesis, stated in Section 2.7, suggesting that Actovegin is the most likely 
active substance in a pharmacological cocktail used in previous published 
literature. As discussed in Section 2.3.3, modulation of the inflammatory 
process could theoretically alter the speed and quality of the muscle healing 
process. The in-vitro studies confirmed that Actovegin could cause the up 
regulation of the pro inflammatory stage of the inflammatory process; 
therefore a clinical study is needed to investigate this clinical efficacy in the 
treatment of acute muscle injuries. The rationale and methodology of the 
clinical study will be discussed in Chapter 4. 
 
 
 
(Figure 3.5) Diagram above illustrates the biochemical events of the muscle healing process 
including inflammatory, anti-inflammatory, proliferation and maturation phases. The in vitro 
study suggested that Actovegin can speed up stage 2 (red) and 3 (blue) of the muscle healing 
process. 
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Chapter Four 
Clinical Study  
 
4.1 Introduction 
 
  The in-vitro study in Chapter Three confirmed the role of Actovegin in 
the inflammatory process of acute muscle injuries. Actovegin can directly and 
indirectly influence the key players involved in the biochemical process of 
inflammation (CD68+) and repair (CD163+) of the acute inflammatory process. 
As discussed in Section 2.3.3, these subtypes of macrophages can influence 
the quality and speed of muscle healing. Section 2.7 outlined this PhD thesis 
research question, as there was convincing evidence from the in-vitro study 
suggesting a positive role for Actovegin in acute muscle injuries; a clinical 
study was performed to investigate the clinical impact of the in-vitro findings. 
There has been little published evidence on the use of Actovegin in the 
treatment of muscle injuries. There has only been 1 study reporting the use of 
IM Actovegin in the treatment of acute muscle injuries. Besides the fact that it 
was not a single drug study, there were also many limiting factors, which have 
been discussed in Section 2.6.4. There have not been any studies reporting 
the use of Actovegin as a single intramuscular agent in treating muscle 
injuries. Therefore, after ethical approval from Cardiff University Ethics 
Committee (see appendix C), the clinical element of this PhD, as stated in 
Section 2.7, was commenced. 
 
In this Chapter, the clinical efficacy of Actovegin in the treatment of 
acute muscle injuries will be explored. The rationale for patient selection, 
method selected for diagnosis of muscle injuries, Actovegin treatment 
regimen, rehabilitation protocol and functional assessment will be discussed. 
The clinical study protocol and its results will be reported and discussed. 
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Hypothesis for the clinical studies in this PhD: 
 
Actovegin treatment regimen developed from this PhD can influence 
clinical outcome in treating acute muscle injuries. 
 
 
4.2 Patient Selection 
 
Muscle injuries are common in sports, as discussed in Section 2.4.2; its 
treatment regimen and recovery are multifactorial. In the general population, 
muscle injuries may cause some pain and discomfort; they do not usually lead 
to any significant mortality or morbidity and the patient is usually able to carry 
on with daily activities. In contrast to the professional elite athlete, muscle 
injuries are a serious condition as they could significantly affect their 
performance, which could potentially change their career.  Shortened 
recovery time from muscle injuries in professional athletes would enable 
training to be continued, competition demand to be fulfilled and increased 
game played. These consequences have direct influence on the athlete and 
their sponsors, therefore the effect of muscle injuries is much more profound 
in professional athletes. Section 2.4.1 explained the aetiology of muscle 
injuries in professional athletes, it accounted for 15 matches and 80 training 
days lost per club per season in British professional football (Woods et al., 
2004, Ekstrand et al., 2011).  Therefore, high level professional football 
players are an ideal group for the clinical study in this PhD. In order to limit 
other confounding factors in the study, only a single club of high-level football 
players was used. All the players in the club would follow the same pre-
season training, diagnostic method, rehabilitation regimen, physiotherapy 
treatment and return to play assessment.  
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4.3 Method of Clinical Measurement 
 
4.3.1 Diagnosis 
 
As discussed in Section 2.3.1, muscle injuries can be classified into 3 
grades. Traditionally, the assessment of muscle injuries is only based on 
clinical symptoms. Modern imaging techniques such as MRI scanning are a 
useful adjunct for helping the clinician to confirm the diagnosis. 
 
4.3.1.1 Clinical Assessment 
 
Clinical assessment is the most common form of assessment to 
diagnose muscle injuries. Although it is a subjective assessment that could 
vary between clinicians, it can be a powerful tool for identification and grading 
when used appropriately by experienced clinicians. To ensure the reliability 
and reproducibility of this study, 3 independent clinicians, the team doctor and 
the physiotherapists will carry out independent assessments on each injured 
subject to assess the severity of the muscle injuries.  
 
The mechanism of injury was reviewed prior to clinical assessment, 
either by direct questioning of the injured player or from the recorded video 
footage of the event leading to the injury. Each individual clinician performed 
clinical examination on the injured player, including observation, palpation, 
strength testing and evaluation of motion. The clinicians recorded their 
findings independently and summarised the injury to clinical grading according 
to Section 2.2.1. 
 
4.3.1.2 MRI 
 
The classification of muscle injuries should be based on clinical 
assessment by the clinician, however MRI scanning is a useful adjunct to 
confirm clinical findings. Depending on the power of the MRI scanner and its 
selected sequence of signal interpretation, the image quality and its sensitivity 
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to acute muscle injuries varies(Kujala et al., 1997, Ekstrand et al., 2012, Elliott 
et al., 2008, Jarvinen et al., 2007). Although there have been reports 
suggesting that MRI scans could accurately grade muscle injuries and predict 
recovery time, it requires high power MRI machines with a specific 
sequences, which are not commonly available (Ekstrand et al., 2012, Elliott et 
al., 2008, Jarvinen et al., 2007). Therefore MRI scans can only be used as an 
adjunct for diagnosis and grading of muscle injuries. The professional football 
club policy dictated that all suspected injured player should undergo MRI 
scanning and its result to be reported by a consultant radiologist. 
 
Although the MRI scan data is not an essential part for the diagnosis 
and classification of the muscle injuries, it will further validate the clinical 
assessment. However if the clinical assessment and MRI scan do not reveal 
the same diagnosis and grading, further consultation with the radiologist will 
be sought. 
 
4.3.2 Treatment 
 
Section 2.7 has discussed the potential problems with the 
polypharmacy of Dr. Mueller-Wohlfahrt’s injection treatment regimen of 
Actovegin, local anaesthetic and traumeel mixture. Local anaesthetics can 
lead to myonecrosis and Traumeel is a homeopathic substance which 
contains 99% sterile isotonic saline (Schneider, 2011); the only potential 
“active” substance in Dr. Mueller-Wohlfahrt’s regimen may be a drug called 
“Actovegin”. For further details, please see 2.4.2.3.  There have not been any 
studies investigating the role of stand-alone Actovegin intramuscular 
injections in acute muscular injuries. In order to reduce the complex 
pharmacodynamics and pharmacokinetics of drug / substance interaction, the 
aim of this study is to investigate the role of Actovegin as a stand-alone agent 
in treating muscle injuries.  
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4.3.2.1 Actovegin regimen 
 
  Actovegin is a drug that is believed to have positive effects on 
ischaemic cells and wound healing. Its clinical evidence is discussed in 
Section 2.6. The pathophysiological insult on cells following muscle strain 
injuries is a mechanical and physiological process as detailed in 2.3.2. Cells 
that are damaged during the injury need to be debrided by the inflammatory 
process during muscle healing; these “dead” cells do not have an active role 
in muscle healing. On the other hand, the cells in the nearby ischaemic zone 
will influence the pathophysiology of healing. (Figure 2.3.2) Therefore, in order 
to target these cells, treatment agents should be directly delivered to this 
area. As these cells are in the ischaemic zone, the only reliable way of 
delivery is via direct intramuscular injection instead of intravenous injection. 
 
  The pathophysiology of muscle healing is via the inflammatory process; 
it is energy/ATP dependent as discussed in Section 2.3.3.  Actovegin is 
believed to be able to enhance oxidative phosphorylation to improve the cell’s 
ischaemic process and also exhibit a cell membrane stabilising effect, 
therefore could potentially benefit the cells in the ischaemic zone, further 
details can be found in Section 2.3.4. Furthermore, from the in-vitro study 
described in Chapter 3, Actovegin has a direct and indirect effect on the key 
players involved in the biochemical process of the inflammation (CD68+) and 
repair (CD163+) of the muscle healing process. Therefore, in order for 
Actovegin to exhibit the local effect, it has to be injected directly to the nearby 
area of the injury site.  
 
There were two common methods of delivering injection therapy 
described in the published literature - injection to the injury site under direct 
palpation and the multiple needle penetration injection technique (Speed, 
2007, Reurink et al., 2012). One of the major criticisms of the direct palpation 
technique is the accuracy of the injections; however, there have been many 
studies suggesting that accuracy does not correlate with efficacy (Eustace et 
al., 1997, Jaeger and Reeves, 1986, Reeves et al., 1986). With regards to the 
multiple needle penetration injection technique, it was originated from 
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prolotherapy techniques, assuming fresh trauma to the injury site would 
“stimulate” recovery (Speed, 2007, Refai et al., 2011, Topol et al., 2005, 
Reeves and Hassanein, 2000). However, there have been case reports 
suggesting that multiple needle penetration injections could further weaken 
the injured structure and lead to muscle rupture. (Aydemir et al., 2010, Chen 
et al., 2009, Kim et al., 2010, Fitzgerald et al., 2005) There have been no 
studies comparing the efficacy of these two injection techniques. In this 
clinical study, due to the acute nature of the injuries and diagnosis, it is 
fruitless to induce unnecessary trauma by multiple needle penetration 
injection techniques. In order to minimize the potential hazard of sharps 
related injuries and infections, the single direct palpation injection technique 
was used.  
 
According to the manufacturer’s recommendations from Nycomed, 
Actovegin solution is acidic and the intramuscular injection should not exceed 
5ml (400mg) to a single site. Pfister et al 1990, described a five injection site 
technique with a mixture of 3ml (120mg) Actovegin and 2 ml of Traumeel 
around the injured area (Pfister and Koller, 1990). The volume of 
intramuscular injection was based on muscle size, large volume (>5ml) was 
associated with increased complication rate and discomfort (Workman, 1999, 
Wynaden et al., 2005). According to published research from intramuscular 
vaccination programmes, a volume of less then 4 ml is well tolerated in the 
hamstring (Diggle and Deeks, 2000, Wynaden et al., 2005). Only a single 
injection site was used in this clinical study. In order to achieve maximum 
penetration with minimum discomfort, 2ml was chosen to be the most 
appropriate volume for injection.   
 
With regards to the timing of the treatment regimens, initial injection 
would be performed at clinical diagnosis of muscle injury. Two more injections 
would be given 24 hours apart. Therefore, the last dose of Actovegin injection 
would be 48 hours after muscle injury, this regimen is based on the 
pathophysiological response of muscle healing and the in-vitro study results. 
Initial injection of Actovegin could limit the extent of the nearby cells’ 
ischaemic damage from the injury as well as its effects on the inflammatory 
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process. The treatment regimen is terminated at 48 hours, as the 
inflammatory process will start to enter the repair phase and the 
CD163+macrophages will start to have a more dominant role.  The in-vitro 
study suggested that Actovegin can significantly down regulate CD163+ 
macrophages (Section 3.4.3.2), therefore treatment beyond 48 hours does not 
provide any biochemical advantage in the pathophysiological process of 
muscle repair. In order to comply with logistical constraints within professional 
football, injections are 24 hours apart. Figure 4.3.2.1 illustrates the regimen. 
 
Figure 4.3.2.1 Actovegin treatment regimen for the study 
 
The use of ultrasound guidance is unnecessary for Actovegin 
intramuscular injections, the targeted site of drug delivery are cells near to the 
injured site instead of directly to the injured tissue. The site of injury can easily 
be identified following clinical examination and the patient can usually pin 
point the location of the injury site. Ultrasound scanning does not add extra 
value to the Actovegin intramuscular injection technique but may introduce 
potential variables. Therefore, ultrasound scans are not used in this clinical 
study. 
 
4.3.2.2 Control group 
 
As discussed in Section 2.4.2, there is no consensus on the best 
treatment options for muscle injuries. Ideally a placebo injection should be 
used to compare against Actovegin, to minimise the psychological effect of 
the needle and volumetric effect of injection. As the treatment of muscle 
injuries is based on low-level evidence, there has not been any report or 
evidence on intramuscular isotonic saline injection therapy. Therefore, it is 
unethical to assume that intramuscular isotonic saline is a placebo and can be 
used as a control group.  
Day 0 Day 1 Day 2  
Rehabilitation 
 
1st Injection 2nd Injection 3rd Injections Return to play 
Injury confirmed    
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This is the first clinical pilot study using Actovegin as a single agent to 
treat muscle injuries; the target group of participants are high-level 
professional footballers. After consultation with the club, it was decided that 
the best option for the control group was for the injured players to undergo the 
same physiotherapy treatment and rehabilitation protocol without any 
injections. Although this method of selecting control has its limitations, it was 
the safest option for the players and the club medical-legally. Furthermore, in 
order to fulfil the medial-legal obligations of the football club to the 
professional football players, this pilot study has be carried out in a non-
randomised and non-blinded fashion.  
 
4.3.3 Rehabilitation protocol  
 
  The same doctor and physiotherapist will treat all injured players and 
follow the same rehabilitation protocol set out below in Figure 4.3.2. This has 
3 days set for the RICE period for the initial stage of the rehabilitation 
protocol. Following Stage A treatment, Stages B and C are carried out 
simultaneously depending on the progression of the patient. Once Stage B is 
completed, Stage D can begin depending on the patient’s recovery alongside 
with Stage C. Actovegin treatment regimen, as discussed in 4.3.2.1, would be 
used in Stage A of the rehabilitation program. 
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(Figure 4.3.2) Rehabilitation regimen for the study 
 
Stage A: RICE, gentle movement,  
Stage B:  Mobilize hamstring to full range, core stability exercise,  
Stage C: Strengthening exercise, core stability exercise, proprioceptive,  
Stage D:  Sudden movement, stop start, cutting  
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The rehabilitation protocol is designed and set out by the professional football 
club, each of the stages of the rehabilitation protocol are explained below: 
 
Stage A: RICE, gentle movement (3 days) 
Complete rest from routine training 
Compression garments, cold therapy machine, advice on elevation 
Low- to moderate-intensity sidestepping, grapevine stepping 
Single-leg stand progressing from eyes open to eyes closed 
Prone abdominal body bridge   
 
Stage B:  Mobilize hamstring to full range, core stability exercise 
Moderate- to high-intensity sidestepping 
Grapevine stepping (flat surface) 
Single-leg stand windmill touches 
Push-up stabilization with trunk rotation  
Fast feet in place  
Proprioceptive neuromuscular facilitation trunk pull-downs with Thera-Band,  
Symptom-free practice without high-speed manoeuvres  
 
Stage C: Strengthening exercise, core stability exercise, proprioceptive 
High-intensity sidestepping 
Grapevine stepping (with elevation) 
Single-leg stand windmill touches 
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Swiss ball stabilization with trunk rotation  
Proprioceptive neuromuscular facilitation trunk pull-downs with Thera-Band,  
Running with ball  
 
Stage D:  Sudden movement, stop start, cutting 
Swiss ball stabilization with trunk rotation  
Nordic Hamstring curl  
Cutting exercise with ball 
Sudden stop and start running with ball 
  
 125 
4.3.4 Functional assessment  
 
Muscle contractions are classified by how the load is applied or how 
the velocity changes and the directional change in length of the muscle or a 
combination of the two(Herzog, 1988, De Ste Croix et al., 2003, Maffiuletti et 
al., 2007). There are three classifications of muscle contraction, isotonic, 
isometric and isokinetic. Isotonic contraction refers to when the muscle tries to 
move a constant load, thereby having a constant value of tension with the 
length of muscle changing. Isometric testing refers to muscle contraction 
where there is no change in muscle length regardless of the force applied. 
The final type of muscle contraction is isokinetic. For this type, the muscle 
contracts at a constant velocity. Due to the contraction being kept at a 
constant velocity it means the force applied to the muscle will vary as the 
tension the muscle creates varies (Herzog, 1988, De Ste Croix et al., 2003). 
Therefore, the length of the muscles and tension it creates change throughout 
the tested range of motion. This type of muscle testing was therefore used, as 
it best resembles how the muscles are acting during sporting activities 
(Durand et al., 1991). 
 
Assessment of muscle strength is an important component of diagnosis 
and treatment in muscle injuries. A variety of methods have been used to test 
quadriceps strength. The two most common methods used in clinical testing 
are manual muscle testing and Isokinetic testing. Manual muscle testing is 
easier to use, however results are subjective(Herzog, 1988, Durand et al., 
1991). On the other hand, Isokinetic testing offers the benefit of objective 
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measurement, but there is controversy about which is the most clinically 
significant testing speed (Askling C, 2003, Clark et al., 2006).  
 
Isokinetic dynamometry claims to be able to provide objective 
measurement of concentric and eccentric dynamic strength. It provides 
optimal and efficient loading of muscles and joints through range, therefore 
strength evaluation is not limited to the weakest point in the range (Tredinnick 
and Duncan, 1988, Paton et al., 1989, Durand et al., 1991, Garrett, 1996a). It 
can also identify muscle weakness at certain points in the range, which may 
help to pin point injuries. There have been many published studies suggesting 
that hamstring to quadriceps ratio can been used as a measure of muscle 
balance and hence are linked to increased stress and injury susceptibility. 
Therefore, this ratio may be a useful objective measuring tool to monitor the 
progress of treatment.  
 
Previous studies using isokinetic data to try and predict hamstring 
injuries have all followed similar patterns. They have used prospective cohort 
studies in order to determine if isokinetic parameters can identify previous and 
predict future injuries(Paton et al., 1989). Previous literature all appears to 
indicate that a hamstring to opposite hamstring ratio of less than 0.9 and a 
hamstring to quadriceps ratio of less than 0.6 may influence injury(Kujala et 
al., 1997, Woods et al., 2004, Gabbe Bj, 2006). However, there appears to be 
a lot of varied results as to whether the ratio can predict injuries across 
different studies (Durand et al., 1991, Li et al., 1996, Orchard et al., 1997, 
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Funk D, 2001, Maffiuletti et al., 2007, Howatson et al., 2009, Yeung and 
Yeung, 2009). 
 
Owing to the anatomical and histological arrangement of the muscle 
fibres, the lengths of each fibre vary in each muscle (further details in Section 
2.2.). Therefore, the forces provided by the muscle across its working length 
are not constant even at identical joint angles(Kawakami et al., 2002). The 
peak torque has been shown to shift upward in more extended positions with 
increasing angular velocity(Kawakami et al., 2002). There also reports 
suggested that with increased angular velocity, the quality of the results are 
be affected as the participant’s high stress levels could lead to muscle 
inhibition(Aagaard et al., 1997, Baltzopoulos, 1995, Sahin et al., 2011). There 
have been reports suggesting that the uni-planar movement during isokinetic 
testing can cause significant muscle tears during high speed maximal effort 
movements(Orchard et al., 2001). Furthermore, there have been concerns 
that the angular velocity of the isokinetic testing cannot represent the normal 
physiological range of movement in sports especially in high performance 
sports such as football(Newman et al., 2004, Housh et al., 1988). Therefore, 
its role as an overall objective screening tool in high performance football 
players is questionable.  
 
Although there is much uncertainty regarding the use of isokinetic 
testing for muscle function in high performance athletes, it may be able to 
provide some objective method of assessing hamstring function, which may 
help the medical team to decide when a player is ready to return to play. 
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Therefore, after discussion with the football club, pre-season hamstring 
isokinetic testing of all players were preformed in order to obtain baseline 
data. Additionally, all players were encouraged to return for further isokinetic 
testing during the season. 
 
The following study is designed to analyse the suitability of the use of 
isokinetic testing as an objective method of measuring the hamstring function 
in elite footballer players. As suggested by previous literature, Hamstring 
eccentric torque / Quadriceps concentric ratio will be analysed with the 
isokinetic data. Furthermore, total work and torque ratios will be analysed to 
determine the relationship between pre-season and mid season injury data. 
The physiological movement and the angular velocity on the knee joint 
exerted by the hamstring during a football match for professional players 
would be much higher than the upper limit (360 degree/sec) of the isokinetic 
dynamometry. The reliability of the test reduces and the risk of injury 
increases when the angular velocity increases (Newman et al., 2004, Housh 
et al., 1988). In order to minimise injury risk and obtain reliable data, angular 
velocity was chosen to be 60 degrees per second for this study.  
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4.3.4.1 Equipment and method 
 
The machine used to test the subjects was a Kin-Com 125E Isokinetic 
Dynamometer (Chattex Corporation, Chattanooga Group Inc, Tennessee, 
USA). ) (Figure 4.3.4.1.a) 
 
 
 
 
 
 
 
 
 
 
(Figure 4.3.4.1.a) KinCom 125E Dynamometer 
 
In order to determine whether isokinetic data can be used as an 
objective marker for hamstring injury, a baseline test was performed pre-
season. The pre-season testing took place in the physiotherapy laboratory at 
St.Davids House at the University of Wales Heath Hospital Cardiff, under the 
guidance of Dr. Nicola Phillips, Cardiff University.  19 players were tested on 
the Kin-Com Dynamometer machine where the isokinetic variables measured 
were for the movements of hamstrings concentrically, hamstrings 
Dynamometer 
and Motor  
Computer and 
data selection 
touch screen  
Lever Arm  
Load Cell  
Leg Strap  
Seat  
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eccentrically, quadriceps eccentrically and quadriceps concentrically for each 
leg. For this testing, the machine was set at 60 degrees per second.  
 
Method 
 
Prior to the 1st subject’s arrival, the machine was turned on and the 
positioning adjustments were set to the correct location. This included moving 
the lever arm and height adjustments to allow for the knee to be tested. The 
seat was positioned vertically so that the subject would be in an upright 
position. The right leg was tested first for all the subjects.  All subjects had 5 
minutes warm up on the treadmill prior to testing. 
 
The subject was then asked to sit in a comfortable position with the 
knee joint aligned with the centre of rotation of the lever arm. (Figure 
4.3.4.1.b) This involved adjusting the height and orientation of the 
dynamometer so that the two were aligned. This was done via the control 
buttons on the top of the dynamometer. Once aligned, the back rest for the 
subject was positioned to give something to rest against. The subject was 
strapped in via the seat belts around the waist and thigh so that movement 
during testing was reduced. 
 
(Figure 4.3.4.1.b) Knee position to the centre of rotation to the centre lever arm 
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The position of the load cell on the lever arm was then adjusted on the 
distal region of the subject’s leg just above the medial malleolus. It was 
positioned until the subject was happy with the level of comfort. It was then 
tightly secured to the leg using the strap. 
  
The appropriate setting was selected from the Kin-com machine. The 
initial selection was evaluation and then overlay. Subjects’ demographics 
were then entered into the computer.  Knee isokinetic protocol and laterality 
was selected. The protocol was designed to test extension then flexion as the 
knee was already in a flexed position prior to testing. 
 
The distance of the load cell on the lever arm (Figure 4.3.4.1.c) was 
then entered into the computer. The position of the load cell on the lever arm 
was gained from reading the scale on the lever arm.  
 
        
(Figure 4.3.4.1.c) Distance of the load cell on the lever arm 
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The anatomical zero position was then set in full knee extension and 
the thigh and leg were parallel. Therefore, the subject was asked to extend his 
leg until at this position. (Figure 4.3.4.1.d) 
 
The lever arm then needed to be situated in the stop position for 
extension. In the case of extension, this position was the same as the 
anatomical zero position. The machine displayed an angle, which needed to 
be 0. When the lever arm was at this position, enter was selected from the 
machine. The subject was then asked to flex their leg 90 deg. At this location 
the start position on the machine was selected. The angle velocity of 60deg / 
s was then selected and the subject was allowed to warm up and get used to 
the movement while the leg was attached to the machine. The subject was 
informed that the machine would maintain a constant angular velocity, so no 
matter how hard they pushed, it would not result in their leg moving at a faster 
speed. The subject was asked if all the strapping felt comfortable and that the 
movement felt natural before proceed to the next stage of the test. 
  
The subject returned their leg to the flexed position. The start measure 
button was selected from the test screen. The subject was informed to extend 
the leg with maximum force until it was stopped by the machine at the stop 
angle. Once at the stop angle, the subject was informed to resist the machine 
as it was going to apply force in order to return it to the start position. Once 
returned to the start position, the machine displayed the results. Provided the 
subject was happy that they had performed to their maximum ability, the 
results were accepted. The movement of extension gave the quadriceps 
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concentric values for the right leg, and the resistance from an extended 
position to a flexed position gave the quadriceps eccentric values. 
 
The next stage of the testing involved measuring the performance of 
the hamstrings. Whilst the leg was in a flexed position, the load cell strap was 
removed and turned around. This was for safety reasons because if the 
strapping had remained in the same position as for quadriceps testing, then 
the leg would have loosened resulting in possible injury to the subject or 
surrounding people. After the load cell pad was turned around, it was re-
attached to the subject’s leg. 
 
The subject was informed to flex their leg until at approximately 90 
degrees of flexion. At this time, the stop angle was selected from the machine. 
The machine then displayed the stop angle, which needed to be at 
approximately 90 degrees. The subject was informed to move their leg to the 
maximum extended position so that the start angle could be chosen. New test 
was then selected from the machine. On the test page, an angle velocity of 60 
degrees per second was selected. From the test page, warm up was selected 
so that the subject could get used to flexing the leg whilst being attached to 
the machine before data gathering begins.  
 
The subject moved their leg to a fully extended position after being 
given the instruction to do so. Start measure was selected from test page, the 
subject was asked to flex their knee with a maximum force until stopped at the 
stop angle. Whilst the knee was at the stop angle, the subject was informed to 
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resist the machine whilst it applied force, in order to return the leg to start 
angle. At the point where the subject’s leg had been returned to the start 
position, the machine displayed the results. Provided the subject was happy 
that they had performed to their maximum ability, the results were accepted. 
The movement of flexion gave hamstring concentric results and the resistance 
to the machine from a flexed position to an extended position gave the 
hamstring eccentric results. (Figure 4.3.4.1.d)  
 
 
(Figure 4.3.4.1.d) Isokinetic results display on screen of the hamstring following flexion and 
extension movements 
 
The results for the right leg of the machine were now complete, thus the 
subject was unstrapped from the machine and asked to move away from the 
machine. At this point the machine set up was changed. The lever arm and 
dynamometer were moved to the left side of the machine and positioned to be 
facing inward. The procedure for the left leg follows the same procedure as for 
the right.  The KinCom Protocol used in this study can be found in appendix D 
  
 135 
4.3.4.2 Data processing  
 
 
After the data collection on a Kin-com Isokinetic Dynamometer, the 
results needed to be processed to allow for further analysis of the data. The 
data for the 19 players was exported into 76 individual files as ASCII text 
format to a USB storage device and was transferred to a computer.  
 
Each ASCII file contained each individual test record containing 
concentric and eccentric movements for a specific action of each limb.  The 
data collected by the machine was angle (deg), angular velocity (deg/s) and 
force (N) in 0.5-degree interval. ASCII files were labelled with the subjects’ 
initials, action and side to avoid confusion. For example, JB (initial of subject)_ 
R(right)_Flex(flexion). A complete test for each subject should yield 4 ASCII 
files with approximately 1600 data points in total. The ASCII data was 
manually transferred to an XLS spreadsheet (Excel 2003) to create an overall 
profile for each subject. Separate files were created for each limb.  
Hamstring eccentric, hamstring concentric, quadriceps eccentric and 
quadriceps concentric were recorded according to angle and angular velocity. 
The torque was calculated through multiplying the force by the length of the 
lever arm. Data was then summarised into one spreadsheet for further 
processing.  
 
Matlab (matrix laboratory, MathWorks 2008) was used to simulate a 
mathematical model and produce a line best fit for each set of data points. 
After curves were fitted, data could be extracted from the graph. The data 
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extracted and ratios calculated in pre-season testing for each subject can be 
seen in the table below.  
 
Example Calculations 
 
Comparison of the quadriceps concentric and hamstring eccentric movements 
of an individual left leg of a subject, when the knee is moved from 90 degree 
flex to a complete extend position. 
 
For the data in Figure 4.3.4.2.a the quadriceps concentric data was fitted with 
a polynomial curve of order 6 and the hamstring eccentric data was fitted with 
polynomial curve of order 3. 
 
 
(Figure 4.3.4.2.a) Torque versus angle for the quadriceps concentric and hamstring eccentric 
movement of the left leg of a subject. 
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Data extraction from curve fitting 
 
The peak quadriceps concentric torque (Qconmax) = 115Nm 
The peak hamstrings eccentric torque (Heccmax) = 98Nm 
The hamstring eccentric torque at the angle of Qconmax (Hecca)=63Nm 
The quadriceps concentric torque at the angle of Heccmax (Qcona) = 44Nm 
 
The equation for the line for quadriceps concentric was: 
(Where Y refers to the variable on y axis and x the variable on the x axis) 
 
Y= -2.7294e-008x6 + 6.5664e-006x5 -5.9302e-004x4 + 0.0243x3 -0.3966x2 + 
1.7202x +  10.1108 
 
To calculate the work done by the muscles over a range of motion, the area 
under the curve needed to be calculated.  
 
Qwork =        Y dx = 4550.2Nmdeg 
 
Convert to over all work done – ω 
 
Convert from degrees to radians multiply by π/180. 
 
= 4550.2 x (π / 180) = 79.4 Joules (Qw) 
 
  
0 
90 
∫ 
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The equation for the line for hamstring eccentric was: 
 
Y= -2.4552e-004x3 + 0.0132x2 + 0.1485+  87.4752 
Hwork =        Y dx = 7654.675616 Nmdeg 
 
Convert to over all work done - ω 
= 7654.7 x (π / 180) = 133.6Joules (Hw) 
 
Further analysis based on the curve fitting 
 
Peak hamstring eccentric torque / peak quadriceps concentric torque  
Heccmax / Qconmax =98 / 115 = 0.85 (H/Q max) 
 
Hamstring eccentric torque at angle of peak quadriceps torque / Peak 
quadriceps torque. 
Hecca / Qconmax = 63 / 115 = 0.55 (Ha/Qmax) 
 
Quadriceps concentric torque at angle of peak hamstrings eccentric torque / 
peak hamstrings eccentric torque. 
Qcona / Heccmax  44 / 98 = 0.45 (Qa/Hmax) 
 
Hamstrings eccentric work done / Quadriceps concentric work done. 
 
Heccwork / Qconwork = 79.4 / 133.6 = 1.68 (Hw/Qw) 
 
 
0 
90 
∫ 
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4.3.4.3 results 
 
Pre-season testing 
 
Table 4.3.4.3.a, presents the data from the pre-season testing, peak 
quadriceps concentric torque (Qconmax), peak hamstrings eccentric torque 
(Heccmax), hamstring eccentric torque at the angle of Qconmax (Hecca), 
quadriceps concentric torque at the angle of Heccmax (Qcona), work done by 
quadriceps muscle (Qw) and work done by hamstring muscle (Hw) was 
calculated according to the method described in 4.3.4.2. All 19 players from 
the club attended and completed isokinetic testing. Due to computer data 
corruption it is not possible to retrieve the right leg data on subject 17.  Table 
4.3.4.3.b presented the data calculated from Table 4.3.4.3.b. Peak hamstring 
eccentric torque / peak quadriceps concentric torque (H/Q max), Hamstring 
eccentric torque at angle of peak quadriceps torque / Peak quadriceps torque 
(Ha/Qmax), Quadriceps concentric torque at angle of peak hamstrings eccentric 
torque / peak hamstrings eccentric torque (Qa/Hmax) and Hamstrings eccentric 
work done / Quadriceps concentric work done (Hw/Qw) were calculated. 
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Subject Leg 
Qconmax 
(Nm) 
Heccmax 
(Nm) 
Hecca 
(Nm) 
Qcona 
(Nm) 
Qw 
(joules) 
Hw 
(Joules)  
1 Left 115 98 63 44 79 134 
1 Right 142 84 61 32 102 115 
2 Left 214 119 76 100 215 142 
2 Right 220 124 70 27 170 161 
3 Left 101 85 67 10 82 105 
3 Right 117.5 74 59.5 8 109 97 
4 Left 143 75 51 28 107 101 
4 Right 134 107 77.5 46 116 144 
5 Left 127.5 70 43 16 107 94 
5 Right 130 74 55 53 107 102 
6 Left 157 103 74.5 34 131 143 
6 Right 113 96 81 30 101 130 
7 Left 180 86 44 86 156 105 
7 Right 169 115.5 65 109 178 143 
8 Left 102 79 54 49 99 104 
8 Right 130 80 57 58 110 104 
9 Left 145 125 95 94 130 163 
9 Right 123 135 95.5 27.5 114 180 
10 Left 200 120 69 52 124 159 
10 Right 186 117 84 80 143 149 
11 Left 117 78 54 76 106 101 
11 Right 222 130 85 89 183 170 
12 Left 120 78 59 56 96 104 
12 Right 128 66 60 35 107 99 
13 Left 215 124 77 42 156 165 
13 Right 224 121 64 43 158 159 
14 Left 128 75.5 40 40 116 92 
14 Right 155 108 65 30 149 133 
15 Left 156 89 48 45 133 112 
15 Right 175 98 45 7 156 96 
16 Left 187 80 48 58 157 100 
16 Right 182.5 107 69 45 156 143 
17 Left 151 98 50 114.5 155 104 
18 Left 202 84 75 137 191 117 
18 Right 163 88 60 20 151 110 
19 Left 150 81 87.5 95 120 96 
19 Right 119 89 61 73 111 106 
(Table 4.3.4.2.a) Isokinetic data from pre-season testing. 
Peak quadriceps concentric torque (Qconmax), peak hamstrings eccentric torque (Heccmax), 
hamstring eccentric torque at the angle of Qconmax (Hecca), quadriceps concentric torque at 
the angle of Heccmax (Qcona), work done by quadriceps muscle (Qw), work done by hamstring 
muscle (Hw) 
 
NB: Subject 17 Right leg data corrupted and not possible to recover from KinCom source 
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Subject Leg H/Q max Ha/Qmax Qa/Hmax Hw/Qw 
1 Left 0.85 0.55 0.45 1.68 
1 Right 0.59 0.43 0.38 1.13 
2 Left 0.56 0.36 0.84 0.66 
2 Right 0.56 0.32 0.22 0.95 
3 Left 0.84 0.66 0.12 1.28 
3 Right 0.63 0.51 0.11 0.89 
4 Left 0.52 0.36 0.37 0.94 
4 Right 0.80 0.58 0.43 1.24 
5 Left 0.55 0.34 0.23 0.88 
5 Right 0.57 0.42 0.72 0.96 
6 Left 0.66 0.47 0.33 1.09 
6 Right 0.85 0.72 0.31 1.29 
7 Left 0.48 0.24 1.00 0.67 
7 Right 0.68 0.38 0.94 0.81 
8 Left 0.77 0.53 0.62 1.05 
8 Right 0.62 0.44 0.73 0.94 
9 Left 0.86 0.66 0.75 1.26 
9 Right 1.10 0.78 0.20 1.58 
10 Left 0.60 0.35 0.43 1.28 
10 Right 0.63 0.45 0.68 1.04 
11 Left 0.67 0.46 0.97 0.96 
11 Right 0.59 0.38 0.68 0.93 
12 Left 0.65 0.49 0.72 1.08 
12 Right 0.52 0.47 0.53 0.92 
13 Left 0.58 0.36 0.34 1.06 
13 Right 0.54 0.29 0.36 1.01 
14 Left 0.59 0.31 0.53 0.79 
14 Right 0.70 0.42 0.28 0.90 
15 Left 0.57 0.31 0.51 0.84 
15 Right 0.56 0.26 0.07 0.62 
16 Left 0.43 0.26 0.73 0.64 
16 Right 0.59 0.38 0.42 0.91 
17 Left 0.65 0.33 1.17 0.67 
18 Left 0.42 0.37 1.63 0.61 
18 Right 0.54 0.37 0.23 0.73 
19 Left 0.54 0.58 1.17 0.80 
19 Right 0.75 0.51 0.82 0.96 
(Table 4.3.4.2.b) Isokinetic data ratio from pre-season testing 
Peak hamstring eccentric torque / peak quadriceps concentric torque (H/Q max), Hamstring 
eccentric torque at angle of peak quadriceps torque / Peak quadriceps torque (Ha/Qmax), 
Quadriceps concentric torque at angle of peak hamstrings eccentric torque / peak hamstrings 
eccentric torque (Qa/Hmax), Hamstrings eccentric work done / Quadriceps concentric work 
done (Hw/Qw) 
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Mid-season testing 
 
All subjects were encouraged to attend re-testing 4 months after initial 
pre-season testing. Due to logistic and players’ professional commitments, 
only 5 subjects returned for 2nd isokinetic testing following the same testing 
protocol by the same operator. Furthermore, the isokinetic load cell and motor 
was malfunctioning towards the end of the season. This machine was not 
repaired until the season had finished. The same data processing methods 
described in section 4.3.4.2 were used. The results of mid season testing for 
all 5 players is summarised in Table 4.3.4.2.c and the isokinetic data ratio is 
summarised in Table 4.3.4.2.d. 
 
Subject Leg 
Qconmax 
(Nm) 
Heccmax 
(Nm) 
Hecca 
(Nm) 
Qcona 
(Nm) 
Qw 
(joules) 
Hw 
(Joules) 
2 Left 219 182 126 40 214 217 
2 Right 255 157 120 142 262 207 
5 Left 184.5 97.5 71 99 156 131 
5 Right 137 105 26.5 47 116 105 
7 Left 226 109 65 48 200 120 
7 Right 235 126 71 85 213 148 
18 Left 195 104 77.5 89 164 140 
18 Right 185 142 88 78 170 184 
19 Left 180 48 39 124 163 54 
19 Right 150.5 78 70 130 81 90 
 
(Table 4.3.4.2.c) 5 subjects returned for retesting during the mid season. 3 subjects were 
treated for grade 2 hamstring injuries with Actovegin injections, these are highlighted in grey.   
 
Peak quadriceps concentric torque (Qconmax), peak hamstrings eccentric torque (Heccmax), 
hamstring eccentric torque at the angle of Qconmax (Hecca), quadriceps concentric torque at 
the angle of Heccmax (Qcona), work done by quadriceps muscle (Qw), work done by hamstring 
muscle (Hw) 
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Player Leg H/Q max Ha/Qmax Qa/Hmax Hw/Qw 
2 Left 0.83 0.58 0.22 1.01 
2 Right 0.62 0.47 0.90 0.79 
5 Left 0.53 0.38 1.02 0.84 
5 Right 0.77 0.19 0.45 0.91 
7 Left 0.48 0.29 0.44 0.60 
7 Right 0.54 0.30 0.67 0.69 
18 Left 0.53 0.40 0.86 0.85 
18 Right 0.77 0.48 0.55 1.08 
19 Left 0.27 0.22 2.58 0.33 
19 Right 0.52 0.47 1.67 1.11 
 
(Table 4.3.4.2.d) 5 subjects returned for retesting during the mid season. 3 subjects were 
treated for grade 2 hamstring injuries with Actovegin injections, they are highlighted in grey.   
 
Peak hamstring eccentric torque / peak quadriceps concentric torque (H/Q max), Hamstring 
eccentric torque at angle of peak quadriceps torque / Peak quadriceps torque (Ha/Qmax), 
Quadriceps concentric torque at angle of peak hamstrings eccentric torque / peak hamstrings 
eccentric torque (Qa/Hmax), Hamstrings eccentric work done / Quadriceps concentric work 
done (Hw/Qw) 
 
With the 5 subjects that returned for re-testing, 3 had sustained grade 2 
hamstring injuries and were treated with 3x Actovegin injections as per clinical 
study protocol (see Section 4.4). These subjects recovered from injury and 
returned to play at least 34 days prior to mid-season testing. The average 
number of days between pre-season and mid season testing in this sub group 
of players was 267 days. Table 4.3.4.2.c summarises the number of days 
between retest, injury and return to play. 
 
 Subject 
Number of 
days between 
tests 
Number of days 
between  
Injury to re-test 
Number of days 
between  
return to play to re-test 
2 254 131 109 
7 262 47 34 
19 285 84 62 
Avg. 267   
(Table 4.3.4.2.c) Number of days between pre and mid season isokinetic testing in the injury 
subgroup.  
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Pre season isokinetic data and ratios are compared to mid season 
testing for the injured limb in Table 4.3.4.2.d and Table 4.3.4.2.e respectively. 
The uninjured limb of the injured players was also analysed, Tables 4.3.4.2.f 
and 4.3.4.2.g. The isokinetic data of the uninjured players is shown in Tables 
4.3.4.2.h and 4.3.4.2.i. Due to the limited data set it is not possible to identify 
any meaningful trend in the results. 
 
There have not been any specific trends observed in this limited data set.   
Subject  Leg 
Qconmax 
(Nm) 
Heccmax 
(Nm) 
Hecca 
(Nm) 
Qcona 
(Nm) 
Qw 
(joules) 
Hw 
(Joules) 
2 pre Right 220 124 70 27 170 161 
2 mid Right 255 157 120 142 262 207 
7 pre Left 180 86 44 86 156 105 
7 mid Left 226 109 65 48 200 120 
19 pre Left 150 81 87.5 95 120 96 
19 mid Left 180 48 39 124 163 54 
(Table 4.3.4.2.d) Pre and Mid season isokinetic Data for injured limbs.  The mid season 
results are highlighted in grey. 
 
Subject  Leg H/Q max Ha/Qmax Qa/Hmax Hw/Qw 
2 pre Right 0.56 0.32 0.22 0.95 
2 mid Right 0.62 0.47 0.90 0.79 
7 pre Left 0.48 0.24 1.00 0.67 
7 mid Left 0.48 0.29 0.44 0.60 
19 pre Left 0.54 0.58 1.17 0.80 
19 mid Left 0.27 0.22 2.58 0.33 
(Table 4.3.4.2.e) Pre and Mid season isokinetic Data ratio for the injured limbs. Mid season 
results are highlighted in grey. 
 
Subject  Leg 
Qconmax 
(Nm) 
Heccmax 
(Nm) 
Hecca 
(Nm) 
Qcona 
(Nm) 
Qw 
(joules) 
Hw 
(Joules) 
2 pre Left 214 119 76 100 215 142 
2 mid Left 219 182 126 40 214 217 
7 pre Right 169 115.5 65 109 178 143 
7 mid Right 235 126 71 85 213 148 
19 pre Right 119 89 61 73 111 106 
19 mid Right 150.5 78 70 130 81 90 
(Table 4.3.4.2.f) Pre and Mid season isokinetic Data for uninjured limbs in the 
injured subjects. Mid season results are highlighted in grey. 
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Subject  Leg H/Q max Ha/Qmax Qa/Hmax Hw/Qw 
2 pre Right 0.56 0.36 0.84 0.66 
2 mid Right 0.83 0.58 0.22 1.01 
7 pre Left 0.68 0.38 0.94 0.81 
7 mid Left 0.54 0.30 0.67 0.69 
19 pre Left 0.75 0.51 0.82 0.96 
19 mid Left 0.52 0.47 1.67 1.11 
(Table 4.3.4.2.g) Pre and Mid season isokinetic ratios for the injured limbs. Mid season 
results are highlighted in grey. 
 
 
Pre and Mid season KinCom Data for uninjured subjects 
Subject  Leg 
Qconmax 
(Nm) 
Heccmax 
(Nm) 
Hecca 
(Nm) 
Qcona 
(Nm) 
Qconmax 
(joules) 
Heccmax 
(Joules) 
18 pre Left 202 84 75 137 191 117 
18 mid Left 195 104 77.5 89 164 140 
18 pre Right 163 88 60 20 151 110 
18 mid Right 185 142 88 78 170 184 
5 pre Left 127.5 70 43 16 107 94 
5 mid Left 184.5 97.5 71 99 156 131 
5 pre Right 130 74 55 53 107 102 
5 mid Right 137 105 26.5 47 116 105 
(Table 4.3.4.2.h) Pre and Mid season isokinetic ratios for the uninjured subjects. Mid season 
results are highlighted in grey. 
 
Pre and Mid season Data ratio for the uninjured subjects 
Subject  Leg H/Q max Ha/Qmax Qa/Hmax Hw/Qw 
18 pre Left 0.42 0.37 1.63 0.61 
18 mid Left 0.53 0.40 0.86 0.85 
18 pre Right 0.54 0.37 0.23 0.73 
18 mid Right 0.77 0.48 0.55 1.08 
5 pre Left 0.55 0.34 0.23 0.88 
5 mid Left 0.53 0.38 1.02 0.84 
5 pre Right 0.57 0.42 0.72 0.96 
5 mid Right 0.77 0.19 0.45 0.91 
(Table 4.3.4.2.i) Pre and Mid season isokinetic ratios for the uninjured subjects. Mid season 
results are highlighted in grey. 
 
  
 146 
Table to show total hamstring eccentric power difference between 
injured and uninjured limbs and between un-injured subjects 
 
 Mid season - pre season 
 Subject Leg Difference in Hw (Joules) % 
Injured 
limb 
2 Right 45.3 28.0 
7 Left 15.3 14.6 
19 Left -42.4 -44.2 
Injured 
subject 
uninjured 
limb 
2 Left 74.5 52.5 
7 Right 4.4 3.1 
19 Right -16.6 -15.7 
Uninjured 
subject 
18 Left 23.4 20.1 
18 Right 73.8 66.9 
5 Left 36.9 39.4 
5 Right 3.0 3.0 
(Table 4.3.4.2.j) Hamstring eccentric power (Hw) difference between injured and uninjured 
limbs on injured subjects and between un-injured subjects. 
 
4.3.4.4 Discussion 
 
Detailed analysis is demonstrated in Table 4.3.4.2.j on Hw with the pre 
and mid season data between the injured and uninjured limb of the injured 
players and also the data from the uninjured players. There were large 
discrepancies between pre and mid season hamstring eccentric power data 
on the uninjured players between each leg. Due to the limited data set, no 
meaningful trends can be identified with the isokinetic data.  
Due to the logistical constraints and the poor compliance for re-testing 
by the players, isokinetic testing is not a practical method for functional 
assessment in a professional football club. Furthermore, from the limited data 
collected in this study there were large discrepancies between pre and mid 
season testing data. Therefore, isokinetic testing was not a suitable method 
for me to use as a functional assessment tool to predict recovery and was not 
used in the clinical study in this PhD. 
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4.3.5 Return to play 
 
The decision to return to play following a muscle injury is a 
multifactorial process involving both physical and psychological parameters. 
There are many functional tests and scoring systems claiming to be able to 
help clinicians to determine this process. As discussed in Section 4.3.4, 
functional assessment in the form of isokinetic testing is not a reliable tool in 
this setting with this specific group of patients. Besides the compliance issue 
with the professional football players, introducing a new form of functional 
outcome measure to the professional football club would expose the club and 
the medical team to unnecessary potential medico-legal issues. After 
discussing with the football club, it was decided that the only form of outcome 
measure for the players to return to play was clinical assessment by the team 
doctor and physiotherapist. Therefore, in order to make the subjective clinical 
assessment for return to play more robust and more objective, each player 
would need to be assessed by 3 clinicians independently before they returned 
to play.  
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4.4 Clinical Study Protocol 
 
  The rationale for the clinical study, based on the in-vitro findings are 
discussed in Section 4.1. Patient selection, diagnosis, treatment regimens, 
rehabilitation protocol and return to play assessment were discussed in 
Section 4.3. This section focuses on describing the procedure of the clinical 
study.  
   
After initial assessment and diagnosis by the team physician and team 
physiotherapists, all injured players underwent MRI to confirm the diagnosis. 
Actovegin injection therapy was initiated immediately once muscle tears were 
defined and concurred clinically by 3 independent practitioners. The muscle 
injuries were then graded as per Jarvinen et al 2000 detailed in Section 2.3.1. 
Players with normal clinical examination and normal MRI findings or grade III 
tears were excluded from this study. All players were given a patient 
information sheet (see appendix E) Players who refused Actovegin treatment 
were allocated to the control group. All players in the Actovegin treatment 
group followed the same injection regimen of 3 intramuscular injections as 
described in Section 4.3.2.1. There was no blinding or randomization in this 
study. 2ml of Actovegin (80mg) was injected into the injury site under direct 
palpation. The injection process was repeated after 24 hours. Players who 
opted-out of the injection therapy followed the same rehabilitation protocol. All 
players were discouraged from taking any anti-inflammatory (NSAIDs) or oral 
supplements. All players followed the same rehabilitation protocol as 
described in 4.3.3. Players were able return to train with the first team once 
they had completed the rehabilitation program and passed the assessment by 
the team physiotherapist as per stage D in the rehabilitation program and 
return to play assessment as described in Section 4.3.5. Figure 4.4.a and 
Figure 4.4.b summarized the clinical study protocol in a graphical format. The 
study has been ethically reviewed and approved by Cardiff University (see 
appendix C). For further study protocol, please see appendix F. 
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(Figure.4.4a) Injection and rehabilitation regimen, 1st injection at diagnosis, 2nd injection at 
24 hours, 3rd injection at 48 hours. Further information on the rehabilitation stages can be 
found in Section 4.3.3 
 
(Figure.4.4b) Work flow diagram of the clinical study  
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Statistical analyses: 
 
Statistical analyses were performed using SPSS version 20.0 (IBM), p 
value <0.05 was considered to be significant. Non- parametric data analysis in 
the form of Mann-Whitely U test was used to compare the number of days lost 
between control and Actovegin treatment groups. This is due to the sub 
special group of subjects in this PhD and the large variation of number of days 
lost following hamstring injuries in literature. Furthermore, as discussed in 
Sections 2.4 and 4.3.5, the decision of return to play following muscle injuries 
are multifactorial, therefore normal distribution of data cannot be assumed 
and parametric analysis is not suitable to be used in this study.  
 
4.5 Results  
 
All players involved in this study were given patient information sheets 
and gave their informed consent demonstratively recorded as a signed 
consent form (Appendix G). All injured players followed the same study 
protocol described in Section 4.4. All players in the Actovegin group 
experience minor muscle clamp immediately after the injection, which 
recovered within 5 minutes. All MRI scans were carried out in a local private 
hospital with a 1.5 Tesla MRI machine and was reported by the same Senior 
Musculoskeletal Consultant Radiologist on the same day as injury occurred.  
 
4.5.1 Clinical Results  
 
During the study period, 11 players sustained hamstring injuries that 
qualified for this study. All 11 players were examined by 3 clinicians on the 
same day as injury occurred, as discussed in Section 4.3.1.1. The results of 
injury grading were unanimous as demonstrated in Table 4.5.1.a. The mean 
age of injured players was 23, mean weight was 76 kg and mean height was 
178 cm. 3 strikers, 3 midfielders, 2 wing forwards, 2 defenders and 1 wing 
backs sustained the injuries (Table 4.5.1.b). 3 injuries occurred during routine 
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training and 8 injuries during match day. All the grade 2 injuries occurred 
during match day in the second half of the game. 
 
 Clinical Diagnosis 
Clinician 1 Clinician 2 Clinician 3 Overall 
Player 1 Grade 1 Grade 1 Grade 1 Grade 1 
Player 2 Grade 2 Grade 2 Grade 2 Grade 2 
Player 3 Grade 1 Grade 1 Grade 1 Grade 1 
Player 4 Grade 1 Grade 1 Grade 1 Grade 1 
Player 5 Grade 1 Grade 1 Grade 1 Grade 1 
Player 6 Grade 1 Grade 1 Grade 1 Grade 1 
Player 7 Grade 2 Grade 2 Grade 2 Grade 2 
Player 8 Grade 1 Grade 1 Grade 1 Grade 1 
Player 9 Grade 1 Grade 1 Grade 1 Grade 1 
Player 10 Grade 1 Grade 1 Grade 1 Grade 1 
Player 11 Grade 2 Grade 2 Grade 2 Grade 2 
(Table 4.5.1.a) Summary of 3 clinicians’ assessments of injured players. 
 
 Injury grade Player’s position Event 
Player 1 Grade 1 Midfielder Training 
Player 2 Grade 2 Defender Match, 2nd half 
Player 3 Grade 1 Striker Match, 1st half 
Player 4 Grade 1 Wing forward Training 
Player 5 Grade 1 Midfielder Match, 1st half 
Player 6 Grade 1 Midfielder Match, 2nd half 
Player 7 Grade 2 Striker Match, 2nd half 
Player 8 Grade 1 Wing back Match, 1st half 
Player 9 Grade 1 Defender Match, 1st half 
Player 10 Grade 1 Striker Training 
Player 11 Grade 2 Wing forward Match, 2nd half 
(Table 4.5.1.b) Summary of injured players’ positions and event during which injuries 
occurred. 
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There were 6 right and 5 left sided injuries, 3 grade II injuries and 8 
grade I injuries identified from the clinical examination. MRI scans on all 
players confirmed clinical diagnosis and defined the anatomical location of the 
injuries. 4 players had previous hamstring injuries but had been symptom free 
for at least 6 months. All players were able to progress through the 
rehabilitation program pain free. No recurrent muscle strains or injuries were 
recorded during rehabilitation. None of the players had any further injuries to 
the hamstrings during the remaining season. No adverse reactions were 
reported with Actovegin injections and all players in the Actovegin group 
received 3 doses of Actovegin as stated in the treatment protocol. 
 
7 players had Actovegin treatment and 4 players opted-out of the 
injection therapy. In the Actovegin group, 3 players had grade II injuries and 4 
players had grade I injuries. All 4 players in the control group had grade I 
injuries. (Table 4.5.1.c) The mean number of days lost in the control group 
was 20, with a range from 16 to 26 days. In the Actovegin group, the mean 
number of days lost with grade I injuries was 12, with a range from 9 to 15 
days. Overall player’s rehabilitation protocol summary can be found in Table 
4.5.1.d. Player specific rehabilitation progress can be found in Figures 4.5.1.a 
to 4.5.1.k.  
 
 Rehab Stage (days)  
 Injury treatment A B C D Overlapped day(s) Total 
Player 1 Grade 1 Actovegin 3 2 4 1 1 9 
Player 2 Grade 2 Actovegin 3 3 6 2 1 13 
Player 3 Grade 1 Actovegin 3 5 8 3 4 15 
Player 4 Grade 1 Control 3 6 6 2 1 16 
Player 5 Grade 1 Actovegin 3 4 3 1 1 10 
Player 6 Grade 1 Actovegin 3 2 10 3 4 14 
Player 7 Grade 2 Actovegin 3 5 14 2 3 21 
Player 8 Grade 1 Control 3 7 12 4 0 26 
Player 9 Grade 1 Control 3 6 10 4 2 21 
Player 10 Grade 1 Control 3 5 8 1 0 17 
Player 11 Grade 2 Actovegin 3 7 12 2 2 22 
(Table 4.5.1.d) Summary of the rehabilitation stages for each player 
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(Figure 4.5.1.a) Player 1 rehabilitation progress 
 
 
 
(Figure 4.5.1.b) Player 2 rehabilitation progress 
 
 
3	  days 2	  days 4	  days 1	  day 
Stage	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  B 
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  C Stage	  D 
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  9	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1	  day	  overlapped	   
3	  days 3	  days 6	  days 2	  days 
Stage	  A Stage	  B 
Stage	  C Stage	  D 
Total	  13	  days 
1	  day	  overlapped	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(Figure 4.5.1.c) Player 3 rehabilitation progress 
 
 
 
 
 
 
(Figure 4.5.1.d) Player 4 rehabilitation progress 
 
 
3	  days 5	  days 8	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3	  days 6	  days 6	  days 2	  days 
Stage	  A Stage	  B 
Stage	  C Stage	  D 
Total	  16	  days 
1	  day	  overlapped	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(Figure 4.5.1.e) Player 5 rehabilitation progress 
 
 
 
 
(Figure 4.5.1.f) Player 6 rehabilitation progress 
 
 
3	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  days 3	  days 1	  day 
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  B 
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  C Stage	  D 
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  14	  days 
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  day	  overlapped	   3	  day	  overlapped	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(Figure 4.5.1.g) Player 7 rehabilitation progress 
 
 
 
(Figure 4.5.1.h) Player 8 rehabilitation progress 
 
 
3	  days 5	  days 14	  days 2	  days 
Stage	  A Stage	  B 
Stage	  C Stage	  D Total	  21	  days 
2	  days	  overlapped	   1	  day	  overlapped	   
3	  days 7	  days 12	  days 4	  days Stage	  A Stage	  B Stage	  C Stage	  D 
Total	  26	  days 
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(Figure 4.5.1.i) Player 9 rehabilitation progress 
 
 
 
 
 
(Figure 4.5.1.j) Player 10 rehabilitation progress 
3	  days 6	  days 10	  days 4	  days 
Stage	  A Stage	  B 
Stage	  C Stage	  D Total	  21	  days 
1	  day	  overlapped	   1	  day	  overlapped	   
3	  days 5	  days 8	  days 1	  day Stage	  A Stage	  B Stage	  C Stage	  D 
Total	  17	  days 
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(Figure 4.5.1.k) Player 11 rehabilitation progress 
 
Mann-Whitney U non-parametric statistical analysis shows significant 
median difference between the Actovegin and the control group (p<0.05) in 
grade I hamstring injuries (Table 4.5.1.e). Players in the Actovegin treatment 
group were able to return to play 7 days earlier compared to physiotherapy 
alone (Table 4.5.1.f). For Grade II injuries, the median number of days lost in 
the Actovegin group was 21, with a range from 13 to 26 days. Statistical 
analysis cannot be performed, as there were no subjects with grade II injuries 
in the control group. Figure 4.5.1.L demonstrates the results for grade 1 
injuries in a graphical format.  
 
SPSS 20 data output 
 days 
Mann-Whitney U 0.00 
Wilcoxon W 10 
Z -2.31 
Asymp. Sig. (2-tailed) 0.021* 
Exact Sig. [2*(1-tailed 
Sig.)] 0.029* 
 
(Table 4.5.1.e) Mann-Whitney U-test confirmed that there was statistical difference in days 
lost between control and Actovegin groups for grade 1 hamstring injuries *= Statistical 
significance 
 
3	  days 7	  days 12	  days 2	  days 
Stage	  A Stage	  B 
Stage	  C Stage	  D 
Total	  22	  days 
2	  day	  overlapped	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Age Treatment Injury Days lost Median 
26 Actovegin Grade II tear 22 21 
S.D. 4.93 
S.E.M. 2.85 
24 Actovegin Grade II tear 21 
18 Actovegin Grade II tear 13 
22 Actovegin Grade I tear 10 12* 
S.D. 2.94 
S.E.M. 1.47 
 
25 Actovegin Grade I tear 9 
19 Actovegin Grade I tear 14 
26 Actovegin Grade I tear 15 
19 Control Grade I tear 26 19* 
S.D. 4.54 
S.E.M 2.27 
28 Control Grade I tear 16 
22 Control Grade I tear 21 
24 Control Grade I  tear 17 
(Table 4.5.1.f) There was significant difference* between the Actovegin and Control groups 
for individuals with grade 1 hamstring injuries. The median days lost for grade 1 injuries in the 
control group was 19 days compared to 12 in the Actovegin treatment group. *= Statistical 
difference between groups 
 
 
 
(Figure 4.5.1.L) Graph to show significant difference between number of days lost between 
Control and Actovegin groups for grade 1 hamstring injuries. 
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Due to the nature of the rehabilitation protocol with simultaneous 
progression of rehabilitation stages, it is not possible to completely isolate 
each stage and compare between players. Therefore, in-order to further 
analyse the data, it is assumed that once the next stage of the rehabilitation 
protocol is commenced the previous stage is terminated. This assumption 
enables the rehabilitation stage to be separated into 4 independent stages. 
Although this method of data manipulation may introduce bias into the 
following data analysis, this could help further distinguish the Actovegin and 
control group in the rehabilitation process.   
 
It is important to note that in the data manipulation process, 3 days 
have been combined in the grade 1 control group, 10 days have been 
combined in the grade 1 Actovegin group and 6 days have been combined 
from the grade 2 Actovegin group. (Table 4.5.1.g) 
 
 
 
 Rehab stage (days)  
 Injury Treatment A B C D Total 
Player 1 Grade 1 Actovegin 3 1 4 1 9 
Player 2 Grade 2 Actovegin 3 2 6 2 13 
Player 3 Grade 1 Actovegin 3 2 7 3 15 
Player 4 Grade 1 Control 3 5 6 2 16 
Player 5 Grade 1 Actovegin 3 3 3 1 10 
Player 6 Grade 1 Actovegin 3 1 7 3 14 
Player 7 Grade 2 Actovegin 3 3 13 2 21 
Player 8 Grade 1 Control 3 7 12 4 26 
Player 9 Grade 1 Control 3 5 9 4 21 
Player 10 Grade 1 Control 3 5 8 1 17 
Player 11 Grade 2 Actovegin 3 5 12 2 22 
 
(Table 4.5.1.g) Modified rehabilitation data, boxes in grey highlight the data that has been 
modified.  
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On further analysis of the modified data, as shown in Table 4.5.1.h, the 
median time of stage A remained the same in all groups, there was significant 
difference, p=0.029, in the Stage B rehabilitation protocol between control and 
Actovegin groups in grade I injuries. There were no significant difference in 
stage C and stage D of the rehabilitation programme between Actovegin and 
control groups for grade one-hamstring injuries. Table 4.5.6.1.i summarises 
the statistical analysis. Furthermore, injured players in the Actovegin group 
seem to spend less time in stages B and D with grade II injuries compared to 
the players in the control group with grade I injuries. (Figure 4.5.1.L) 
  
 
 
Age Treatment Injury A B C D Total Days lost 
18 Actovegin Grade II tear 3 2 6 2 13 
24 Actovegin Grade II tear 3 3 13 2 21 
26 Actovegin Grade II tear 3 5 12 2 22 
 Median 3 3 12 2  
19 Actovegin Grade I tear 3 1 7 3 14 
22 Actovegin Grade I tear 3 3 3 1 10 
25 Actovegin Grade I tear 3 1 4 1 9 
26 Actovegin Grade I tear 3 2 7 3 15 
 Median 3 1.5 5.5 2  
19 Control Grade I tear 3 7 12 4 26 
22 Control Grade I tear 3 5 9 4 21 
24 Control Grade I  tear 3 5 8 1 17 
28 Control Grade I tear 3 5 6 2 16 
 Median 3 5 8.5 3  
(Table 4.5.6.1.h) Breakdown of the median data for each stage of the rehabilitation 
programme with the modified data.  
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(Table 4.5.6.1.i) Non-parametric analysis from SPSS with Mann-Whitney U test and 
Kolmogorov-Smirnov test for number of days spent in each stage of the rehabilitation 
programme with the modified data.  
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(Figure 4.5.1.L) Graph to show independent sample median test generated from SPSS for 
the difference between control and Actovegin group in the stage B rehabilitation protocol. 
 
On further interpretation of the data, the control and treatment group of 
players who sustained grade I injuries were closely matched with age.  
Therefore further data analysis was performed for grade I injured players. 
There seems to be a trend to suggest that the total number of days lost is 
substantially reduced in a younger age group. There was a 12 day difference 
between the Actovegin treatment and control in the 19 year old injured players 
with very similar demographics. On the other hand, there was only 1 day of 
difference between the 26 and 28 years old players between the Actovegin 
and control group. Spearman’s Rho correlation test performed in SPSS 
suggested that there was significant correlation -0.852 (p=0.015) between the 
age of the players and the number of days lost between control and treatment 
groups. This suggests that Actovegin treatment is associated with a reduced 
number of total days lost in a younger age group of professional football 
players with grade I muscle injuries. On further analysis of the individual 
stages of the rehabilitation process between players matched with age, there 
was no specific trend identified between the rehabilitation stages.  
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Age Treatment Injury A B C D Total Days lost 
19 Control Grade I tear 3 7 12 4 26 
19 Actovegin Grade I tear 3 1 7 3 14 
 Difference  0 6 5 1 12 
22 Control Grade I tear 3 5 9 4 21 
22 Actovegin Grade I tear 3 3 3 1 10 
 Difference  0 2 6 3 11 
24 Control Grade I  tear 3 5 8 1 17 
25 Actovegin Grade I tear 3 1 4 1 9 
 Difference  0 4 4 0 8 
28 Control Grade I tear 3 5 6 2 16 
26 Actovegin Grade I tear 3 2 7 3 15 
 Difference  3 -1 -1 1 
 
(Table 4.5.6.1.j) Breakdown of the median data of each stage of the rehabilitation programme 
with the modified data and total number of days lost matched with the age of the players. 
 
 
Sample size and power calculation: 
 
In order to calculate the power of this pilot study and predict a sample size, 
the observed effect size of this study would need to be established by 
Cohen’s d formula below: 
 
 
 
d = Cohen’s d,  X1 = mean of group 1, X2 = mean of group 2, S = pooled 
Standard deviation. 
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Pooled standard deviation can be calculated as: 
 
 
S = !!! !.!"!! !!! !.!"!!  
S = 3.312 
 
Therefore Cohen’s d formula 
d = !"!!"!.!"#  
 
d = 2.11 
 
The Cohen’s d value in this study is 2.11, which is larger than 1.3, which 
means that the effect size in this study is “Very Large”. In order to determine 
the β value, to calculate the power of this study the formula below is used: 
n = 2σ
2 (Zβ +Zα /2 )2
d 2  
n = total number, d = Cohen’s , δ = standard deviation difference, Zβ = z  
 
Score for β value, Z α/2  = z score for α/2 value = 1.96 
Total number of players who sustained hamstring injuries = n = 8 
Standard deviation difference between groups = δ =1.6 
8 = ! !.! !(!!!!.!")!!.!!!  
Zβ = 0.985 
 
According to the Z table, 0.985 is equal to a β value of 0.168, the power of the 
study is equal to 1 - β = 84%.  
 
The effect size of this study is very large according to Cohen’s d and 
the power is more than 80% with only 5% of alpha error level. Therefore, this 
pilot study is of a high standard and subsequent studies can be based from 
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this data. Furthermore, based on the data collected from this study, in order to 
produce a study with 95% power and 95% statistical significant, a sample size 
of 10 subjects (5 in each group) would be needed. 
 
4.5.2 MRI   
 
According to the study protocol detailed in Section 4.4 and in appendix 
F, all injured players underwent MRI scanning to confirm clinical diagnosis. As 
discussed in Section 4.3.1.2, MRI is not essential for the diagnosis and 
grading of muscle injuries. It is use as a diagnosis adjunct to support clinical 
findings and also document the injury in graphical format.  
 
  In this study, all injured players had an MRI scan within 24 hours of the 
injury, all scans were performed with a 1.5 tesla machine with Proton Density 
Fat Saturation (PD FS) and T1 spin echo (SE). Figure 4.5.2.a demonstrates 
an example of the MRI image of grade II hamstring injuries of one of the 
players in this study. The muscle oedema is demonstrated by the increased 
signal (white colour) in the muscle.  
 
 
 
Axial PD FS 
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Axial T1 SE 
 
 
Coronal t1 SE 
 
Coronal t1 SE  
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Sagittal PF FS 
 
 
Sagittal t1 SE 
(Figure 4.5.2.a) Selected images from the MRI images of grade II hamstring 
injuries of one of the players in this PhD.  
 
 
  Images were analysed in axial, coronal and sagittal planes by a 
certified Senior Consultant Radiologist. Out of the 11 players, 10 were 
reported to have sustained an injury to the biceps femoris (90%). 63% of the 
player’s injuries arose from the musculotendinous junction. (Table 4.5.2.a) All 
MRI findings matched the clinical diagnosis made by the clinicians. (Table 
4.5.2.b) Examples of MRI reports can be found in appendix H. 
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MRI findings Treatment Side 
Grade II tear MTJ Biceps Femoris Actovegin Right  
Grade II tear Biceps Femoris Actovegin Left 
Grade II tear Biceps Femoris Actovegin Left 
Grade I MTJ tear Biceps Femoris Actovegin Left 
Grade I tear lateral Biceps Femoris Actovegin Right 
Grade I tear distal Biceps Femoris Actovegin Right 
Grade I tear MTJ Biceps Femoris Actovegin Right 
Grade I MTJ tear Biceps Femoris Control Right 
Grade I tear MTJ Semimembranosis Control Left 
Grade I tear MTJ Biceps Femoris Control Left 
Grade I MTJ tear Biceps Femoris Control Right 
(Table 4.5.2.a) Report on location of hamstring injuries from MRI findings. 
MTJ - Musculotendinous junction 
 
 Clinician 1 Clinician 2 Clinician 3 MRI 
Player 1 Grade 1 Grade 1 Grade 1 Grade 1 
Player 2 Grade 2 Grade 2 Grade 2 Grade 2 
Player 3 Grade 1 Grade 1 Grade 1 Grade 1 
Player 4 Grade 1 Grade 1 Grade 1 Grade 1 
Player 5 Grade 1 Grade 1 Grade 1 Grade 1 
Player 6 Grade 1 Grade 1 Grade 1 Grade 1 
Player 7 Grade 2 Grade 2 Grade 2 Grade 2 
Player 8 Grade 1 Grade 1 Grade 1 Grade 1 
Player 9 Grade 1 Grade 1 Grade 1 Grade 1 
Player 10 Grade 1 Grade 1 Grade 1 Grade 1 
Player 11 Grade 2 Grade 2 Grade 2 Grade 2 
(Table 4.5.2.b) Summary of 3 clinicians’ assessments and MRI findings for injured players 
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4.6 Discussion  
 
The clinical study in this PhD confirmed the hypothesis stated in 
Section 2.7, demonstrating that the Actovegin treatment regimen developed 
from the in vitro study (details in Section 4.3.2.1) could influence clinical 
outcome in treating acute muscle injuries. It is also the only study using 
Actovegin as a single agent in the treatment of muscle injuries.  
 
The Actovegin treatment group returned to play in a median of 7 days 
earlier compared to physiotherapy alone in grade I hamstring injuries (further 
details in Section 4.5.1). For Grade II injuries, the median number of days lost 
in the Actovegin group was 2; unfortunately statistical analysis could not be 
performed, as there were no subjects with grade II injuries in the control 
group. However, it is only 2 days longer compared to grade I hamstring 
injuries treated in the control group. The results from the clinical study are 
comparable to literature. The physiotherapy protocol used in the clinical study 
was developed from the progressive agility and trunk stabilization exercises 
and icing (PATS) protocol described by Sherry and Best 2004. They reported 
that the average length for athletes to return to sport was 22.2 days (Sherry 
and Best, 2004), which is comparable to the median of 19 days in the control 
group (physiotherapy only) in the clinical study. For the Actovegin group, there 
has been no study in the literature reporting the use of the single Actovegin 
treatment for muscle injuries. The only Actovegin related study was reported 
by Pfister et al, its weaknesses and limitations have been discussed in 
Section 2.6.4; with their pharmacological cocktail of Actovegin and Traumeel 
mixture, the mean for return to sport was 22.2 days for grade 1 hamstring 
injuries (Pfister and Koller, 1990). Although it is not reasonable to perform 
direct comparison and statistical analysis between the clinical study in this 
PhD to the “active” treatment group described in Pfister et al, as there are 
many potential factors to influence recovery, the stand alone Actovegin 
treatment regimen described in this PhD seems to produce better results.   
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On further interpretation of the data, the control and treatment groups 
of players who sustained grade I injuries were closely matched with age.  
Spearman’s Rho correlation test suggests that Actovegin treatment is 
associated with a reduced number of total days lost in a younger age group of 
professional football players with grade I muscle injuries. In this study the 
younger players seemed to take longer to return to play compared to the older 
players with grade 1 injuries, the effect of Actovegin treatment is more 
pronounced in terms of the reduction of number of days lost compared to the 
age matched control group. This suggests that the Actovegin treatment 
regimen has a larger effect in younger players. This could be due to the fact 
that younger players theoretically have a high metabolic rate compared to the 
older players; hence their cells would have a high-energy demand and are 
more dependent on ATP. Younger cells are also believed to have a better 
regeneration potential and therefore would require more ATP during the repair 
process. As discussed in 2.3.2, muscle strain injuries cause mechanical as 
well as biochemical damage to the cells, the speed and extent of muscle 
necrosis are dependent on the amount of ATP available and also the cellular 
metabolic rate.  Hence cells that have a higher cellular metabolic rate would 
be more susceptible to ischaemic and metabolic insults following muscle 
strain injuries. Actovegin is thought to have a membrane stabilizing effect and 
improved energy balance in mitochondria and ATP production in ischaemic 
cells (further details in Section 2.5.4). Therefore, the younger cells with higher 
metabolic rate would have more benefit from Actovegin treatment as it could 
theoretically limit and contain the initial ischaemic and metabolic insult from 
the injury. Besides the effect of damage limitation, Actovegin could also be 
more beneficial to the younger cells in the biochemical process of muscle 
healing as discussed in Section 2.3.3. These facts could theoretically 
contribute to and explain the larger clinical effect with Actovegin treatment in 
younger patients.   
 
All players in the study followed the same rehabilitation protocol and 
the results were further analysed according to the player’s progression in 
each stage of the protocol. The Actovegin treatment group has a significantly 
shorter duration in stage B of the rehabilitation (p<0.05). This observation 
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further confirms the in vitro findings and hypothesis; Actovegin modulates the 
inflammatory process, which enhances the biochemical process of muscle 
healing. As the cells’ recovery and repair becomes quicker, the effect of 
Actovegin treatment is seen in the early stages of the rehabilitation process. 
 
The clinical findings supported the hypothesis developed from the 
results of the in vitro study. Actovegin can modulate the inflammatory process 
and influence the genotype expression of THP-1 and macrophages, therefore 
it can influence the healing process; further details can be found in Sections 
3.4.2.3 and 3.4.3.3. The clinical study has demonstrated that the biochemical 
effects of Actovegin can be translated to influence clinical outcome in the 
treatment of acute muscle injuries.  
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Chapter Five 
Discussion, Conclusion and Future Work  
 
5.1 Discussion: 
 
The aim of this PhD is to provide information on the role of Actovegin in 
muscle injuries and its efficacy as an injection therapy in the treatment of 
hamstring muscular injuries in professional footballers (Section 1.3). The in-
vitro study in this PhD thesis was the first study to investigate the role of 
Actovegin in the inflammatory process and demonstrated significant results to 
support the hypothesis. It confirmed that Actovegin could modulate the 
inflammatory process by influencing the CD68+ and CD163+ macrophages 
and CD163+ THP-1 cells, which could influence the muscle healing process 
(Chapter 3). Based on the findings from the in vitro studies and data from 
previous literature, a stand alone single drug intramuscular Actovegin injection 
therapy regimen was developed to treat acute muscle injuries. The first 
clinical study using this stand-alone Actovegin treatment regimen was 
conducted in this PhD in professional footballer players and translated the in 
vitro findings to clinical practice, which confirmed the second hypothesis that 
Actovegin can influence clinical outcome in treating acute muscle injuries. 
 
Overall, this PhD has suggested that Actovegin has an active role in 
the treatment of muscle strain injuries biochemically and clinically. Although 
the studies in this thesis were logical and performed to a high standard, there 
were some limitations and uncontrollable constraints. The in-vitro cell studies 
were based on well-established isolated THP-1 and Macrophage cell-lines 
and the highest standard of qPCR analysis. It does not fully represent the 
biochemical environment in the muscle injury site in the human body. The 
inflammatory vs anti-inflammatory muscle healing model was based on 
published literature on cell line based studies. Although it is currently the most 
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widely acceptable theory, again it may not fully represent the biochemical 
environment in the muscle injury site in the human body. Furthermore, the 
qPCR data confirmed a change of mRNA, hence gene expression but it may 
or may not translate to final protein changes and effects in the complex 
muscle healing environment. Ideally, more complex cell types such as skeletal 
muscle cells should be used and mixed cells co-culture could further simulate 
the complex biochemical environment in the human body. Owing to the 
similarity of standard cell culture solution (FBS) and Actovegin, as discussed 
in Section 3.4, serum free cell culture models would be required for cellular 
investigation of the role Actovegin. Perhaps an animal model could be used 
as an  study to simulate the complex biochemical environment of muscle 
healing. On the other hand, an animal  model may not be reliable as 
Actovegin is a biological drug with bovine origin, the cross species effect may 
not translate to human muscle injuries. Therefore, a human clinical model is a 
more appropriate investigation for this drug. Owing to the logistical constrains 
and compliance with the professional football club and players, muscle biopsy 
following Actovegin treatment was not possible, otherwise it would have been 
the ideal opportunity to further understand the biochemical role of Actovegin in 
the treatment of muscle injuries.  
 
Although the clinical results provided encouraging results, it is a non-
blinded and non-randomised observational pilot study with subjective 
assessments for return to play. The potential psychological effects of injection 
therapy and placebo effect cannot be ruled out in this study; ideally a placebo 
injection should be used alongside Actovegin. As the treatment of muscle 
injuries is based on low-level evidence, there has not been any report or 
evidence on intramuscular isotonic saline injection therapy. Therefore, it is 
unethical to assume that intramuscular isotonic saline is a placebo and can be 
used as a control group. Alternatively, dry needling to the injury site could be 
used as a control to reduce the psychological effect of the needle entering the 
skin, but it will not mimic the injection effect of Actovegin. Furthermore, all 
players in the Actovegin group experienced minor muscle cramp immediately 
after injection, this effect may not be possible to mimic by any placebo 
substances. Psychological and placebo effects are important issues in all 
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medical therapies, researchers should always consider their potential impact 
and interpret the results with caution.  
 
In the clinical study, the same diagnosis and grading of muscle injuries 
were recorded by three independent qualified practitioners, this provided a 
robust and reliable diagnostic method. As discussed in Section 4.3.1.2, MRI is 
not an essential tool for diagnosis or grading with the method used in this PhD 
described in Section 2.3.1. Therefore, the purpose of the MRI scan in this 
PhD was to document the injuries in a graphical format and was also used as 
a diagnosis adjunct to confirm the clinical findings. (For further details, please 
see Section 4.3.1.2) For future research, if any MRI grading methods were 
used for the diagnosis of muscle injuries, it would be advisable for the 
researcher to have at least two qualified radiologists to interpret the MRI 
findings. Furthermore, the patient should have at least 2 MRI scans by 
different machines to ensure reliability.  
 
The number of subjects in the clinical study is relatively small, due to 
the competitive nature of the sport. It is not possible to standardise the 
rehabilitation regimen between clubs, therefore only a single football club was 
used, and hence the patient numbers in each group were small. On the other 
hand, these limitations could be seen as a strength for the study, as players in 
a professional football club are often closely matched with age and physical 
ability, they can be matched and produce a higher quality result. All players in 
the club are contracted to follow the same rehabilitation protocol and treated 
by the same team of physiotherapists, which significantly reduced the 
variability of the rehabilitation process. Therefore, a high quality clinical study 
can be performed with this subgroup of patients as demonstrated in the 
clinical study. The power calculation demonstrated in Section 4.5 suggested 
that the power of the clinical study is 84%m, which is a high standard (>80%) 
for a clinical study. In order to improve the number of subjects available in the 
clinical study, amateur athletes or college athletes could be used. However, 
the compliance and variation in the rehabilitation process with these groups of 
athletes could affect the reliability of the study as demonstrated by Pfister et al 
during a similar studies (Pfister and Koller, 1990). Furthermore, the clinical 
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impact of a grade I muscle injury to an amateur athlete may not be as 
pronounced compared to a professional footballer. These footballers were in a 
different psycho-social and socio-economic group, therefore the clinical 
results may not translate.  
 
Return to play and functional assessment following injury in the clinical 
study were based on clinical assessment by 3 clinicians independently. 
Although it is a powerful and reliable method of assessment, where all 
clinicians agreed with the outcome and the player could return to play, the 
study can be improved by using an objective assessment method to monitor 
the rehabilitation process. Isokinetic analysis has been tried, as described in 
Section 4.3.4. Due to the logistical constraints and the poor compliance for re-
testing by the players, isokinetic testing is not a practical method for functional 
assessment in a professional football club. However, it may be a useful 
technique if the club had made this assessment compulsory for all the players 
and had a dedicated team of technicians for the isokinetic analysis. Traditional 
imaging techniques such as MRI may not be useful in monitoring the 
rehabilitation process, as currently there are no radiological benchmarks to 
monitor the muscle healing process. Therefore, clinical assessments remain 
as the gold standard of functional assessment in muscle injuries. 
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5.2 Conclusion: 
 
The in vitro studies described in this PhD have provided essential 
evidence that Actovegin could affect the phenotype of macrophages and 
modulate the inflammatory process. These effects have translated to the 
clinical study and suggest that Actovegin intramuscular injection therapy could 
improve clinical outcome in the treatment of grade I hamstring injuries.  
 
This thesis summarises the current evidence on Actovegin.  Compared 
with conventional conservative RICE and NSAID therapy, Actovegin proposes 
an exciting and legal alternative for high performance athletes. From the 
studies, Actovegin injection therapy seems safe and well tolerated. More 
objective evidence is needed before further conclusions can be drawn for this 
new treatment of muscle injuries. Despite the positive experience with 
Actovegin in this PhD, Actovegin injection therapy should be reserved within 
elite professional athletes. Further evidence and clinical studies should be 
performed in different subgroups of populations to further investigate its 
efficacy. Although it may not be possible due to the limitations discussed in 
Section 5.1, a double-blinded multicentre randomised control trial could help 
to confirm its clinical efficacy in the general population.  
 
Medicine is a form of science as well as an art.  As modern sports 
physicians, we must apply the principles of Evidence Based Medicine when 
considering new therapies. Physicians should process this evidence carefully 
and pay attention to detail, especially when the published medical literature is 
limited. Further in vitro and clinical research must be encouraged to 
investigate the effects of Actovegin on muscle injuries before it can be 
labelled as effective treatment. Injection therapy could potentially be useful in 
the treatment of muscle injuries. 
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5.3 Future work: 
 
The In vitro study in the PhD is the first study to investigate the role of 
Actovegin in the inflammatory process and demonstrated significant results. 
Future research could continue to explore this route by looking at different 
inflammatory cytokines with qPCR and micro array gene chip expression to 
further understand the mechanism of action. Protein expression studies such 
as western blotting should be used to confirm the geneotype and phenotype 
expression changes demonstrated by qPCR. Furthermore, a time course 
experiment should be set up with the macrophages and THP-1 cell line to 
further analyse the effect of Actovegin in 48 and 72 hours of cultures. This can 
further identify the role of Actovegin in different stages of the inflammatory 
process. Finally, a human clinical muscle injection and biopsy model would be 
most beneficial to confirm all the in vitro findings.  
 
Actovegin is a physiological mixture of bovine origin, further details can 
be found in Section 2.5. The HPLC experiment described in Section 3.3.2 has 
demonstrated peaks of contents in Actovegin. With the HPLC technique, each 
peak could be separated and be used to the same bioassays either as 
individual or as a mixture to identify the active ingredient(s). However, this 
approach may be difficult as there could be one or more active ingredient and 
the optimum concentration of these ingredient(s) may also have to be refined. 
Further studies can explore the compound with the peaks with bioassay and 
Nuclear magnetic resonance, in order to identify single or combined active 
ingredients within Actovegin.  
 
In regards to the clinical aspect of the use of Actovegin in the treatment 
of muscle injuries, with the limitations of discussed in 5.1, future work should 
be focused on the duration and effective dose of Actovegin therapy. In order 
to minimise the placebo and psychological effect of injection therapy, a 
standard placebo substance needs to be established for injection therapy in 
muscular injuries. Further clinical studies should be done in a different 
subgroup of patients and ensure the clinical effect from this PhD is not group 
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specific and can be translated across different spectrums of patients. Finally, 
a double-blinded multicentre randomised control trial would be useful to 
confirm its efficacy. 
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Appendix B 
Actovegin drug EU licence 
Reference to page 60 
Bundesamt fur Sicherheit 
im Gesundheitswesen Schnlrchgasse 9, 1030 Wien 
GMP-ZERTIFIKAT I CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER 
Zertifikat Nr.: jCertificate No.: INS-4800S0-0011-002 
Teil11 Part 1 
Ausgestellt auf Basis einer Inspektion in Ubereinstimmung mit / 
Issued following an inspection in accordance with 
[8J Art. 111(5), Directive 2001/83/EC 
[8J Art. 80(5), Directive 2001/82/EC 
DArt. 15 of Directive 2001/20/EC 
Die zustiindige BehOrde Osterreichs bestiitigt wie folgt: / 
The competent authority of Austria confirms the following. 
Nycomed Austria GmbH 
St.-Peter-StraBe 25 
A-4020 Unz 
wurde im Rahmen des nationalen Inspektionsprogramms inspiziert, in Verbindung mit der 
Geschaftszahl (Hersteller-Lizenznummer) j 
has been inspected under the national inspection programme In connection with manufacturing 
authorisation no. 480050 
in Obereinstimmung mit / in accordance with 
[8] Art. 40 of Directive 2001j83/EC 
[8J Art. 44 of Directive 2001/82/EC 
DArt. 13 of Directive 2001/20/EC 
umgesetzt in folgende nationale Gesetzgebung / 
transposed In the following national legislation: 
"Verordnung der Bundesministerin fUr Gesundheit und Frauen betreffend Betriebe, die Arzneimitte! 
herstellen, kontrollieren oder in Verkehr bringen (Arzneimittelbetriebsordnung 2005 - AMBO 2005), 
BGBI. II Nr. 479/2004, zuletzt geandert durch das BGB!. II Nr. 156/2007".* 
und/ and * 
1st ein Wirkstoffhersteller, insplziert in Obereinstimmung mit / 
Is an active substance manufacturer that has been Inspected in accordance with 
[8] Art. 111(1) of Directive 2001j83/EC 
[8] Art. 80(1) of Directive 2oo1/82jEC 
CER99K22367DM 14.0 
Bundesamt fOr Sicherheit 
im Gesundheitswesen Schnlrchgasse 9,1030 Wien 
GMP-ZERTlFIKAT I CERTIFICATE OF GNP COMPLIANCE OF A MANUFACTURER 
Zertifikat Nr.: jCertificate No.: INS-480050-0011-002 
umgesetzt in folgende nationale Gesetzgebung / 
transposed in the following national legislation: 
"Verordnung der Bundesministerin fUr Gesundheit und Frauen betreffend Betriebe, die Arzneimittel 
herstellen, kontrollieren oder in Verkehr bringen (Arzneimittelbetriebsordnung 2005 - AMBO 2005), 
BGB!. II Nr. 479/2004, zuletzt geandert durch das BGB!. II Nr. 156/2007".* 
Aus der wahrend der Inspektion des betreffenden Herstellers gewonnenen Kenntnis, zuletzt durchgefUhrt 
amI 
From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 
16th - 17th April 2008, 
kann angenommen werden, dass I 
it is conSidered that it complies with 
l8l den RichtJinien der Guten Herstellungspraxis entsprochen wird, festgehalten in / 
The principles and guidelines of Good Manufacturing Practice laid down in 
r8J Directive 2003/94/EC1/ 
o Directive 91/412/EEC1/ 
[gJ der Richtlinie der GMP fUr Wirkstoffe / The principles of GMP for active substanceS. * 
Dieses Zertifikat spiegelt den Zustand der Betriebsstatte zum oben erwahnten Inspektionszeitpunkt 
wieder, falls mehr als drei Jahre verstrichen sind, sollte die ausstellende BehOrde kontaktiert werden. 
This certificate reflects the status of the manufacturing site at the time of the inspection noted above and 
should not be relied upon to reflect the compliance status if more than three years have elapsed since 
the date of that inspection, after which time the issuing authority should be consulted. 
Die Richtigkeit der Angaben kann bei der ausstellenden Behorde i.iberprGft werden / 
The authenticity of this certificate may be verified with the issuing authority. 
171lese requirements fulfil the GMP recommendations of WHO. 
(*): Nichtzutreffendes streichen / delete that which does not apply 
CER99X22367DM 14.0 
GOltig ab: 13.06.2008 
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a Bundesamt fOr Sicherheit 
'. ' im Gesundheitswesen Schnirchgasse 9,1030 Wfen 
GMP-ZERTIFIKAT I CERnFICATE OF GMP COMPUANCE OF A MANUFACTURER 
Zertifikat Nr.: jCertificate No.: INS-480050-0011-002 
GMP Zertifikat, Teil 2 
GMP-Certificate, Part 2 
Aseptisch hergestellt (uste der Darreichungsformen) / Aseptically prepared 
(List of dosage forms) 
1.1.1.4 Kleinvolumige f1Ussige Darreichungsformen I Small volume liquids: 
Ampullen / Ampoules 
1.1.2 Im Endbehaltnis sterilisiert (Uste der Darreichungsformen) / Terminally 
sterilised (list of dosage forms) 
CER99X.22367DM 14.0 
1.1.2.3 Kleinvolumige flUssige Darreichungsformen I Small volume liquids: 
Ampullen, Flaschchen / Ampoules/ Vials/ 
1.1.2.5 Andere endsterilisierte Produkte I Other terminally sterilised 
prepared products: 
Augentropfen / Eye Drops 
1.2.1.6 Flussige Darreichungsformen zur inneren Anwendung I liquids for 
internal use: 
Losungen / Solutions 
1.2.1.13 Tabletten Tablets 
G(l1tig ab: 13.06.2008 3von 5 
.:-.~ .. : .. -- _.': :'-: ... - .. _--_ ... _--_ .. .... __ .. _ . . 
-':'-.--,' 
Bundesamt fUr Sicherheit 
im Gesundheitswesen Schnirchgasse 9, 1030 Wien 
GMP-ZERTIFlKAT I CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER 
Zertifikat Nr.: / Certificate No.: INS-480050-0011-002 
1.2.2 
Biologische Arzneimittel/ Biological medicinal products 
1.3.1.1 Blutzubereitungen / Blood products: 
Resorbierbare Wundauflage (KolJagen, humanes Fibrinogen, Thrombin, 
Aprotinin) / absorbable wound dressing (co//agenf fibrinogen human, 
thrombin, aprotinln) 
1.3.1.6 Produkte menschlicher oder tierlscher Herkunft / Human or animal 
extracted products: 
Entproteinislertes Kalbsbluthamoderivat / deproteinized hemoderivative 
of calf blood 
1.4.1 Herstellung von: / Manufacture of: 
1.4.1.4 Anderen / Others: 
• Wlrkstoff (Bulk, Endprodukt) / API, Drug Substance (Bulk): 
Aprlndine hydrochloride, Azlntamide, Bamlfylline hydrochloride, Celiprolol 
hydrochloride, Distigmine bromide, Etamivan, Hexobendine dihydrochloride, 
Hexoprenaline sulfate, Lornoxicam, Midodrine hydrochloride, Morphine-6-
glucuronide, Podophyllotoxin, Sulfametrole, Suxamethonium chloride, 
Thonzonium bromide, Warfarin sodium 
• Hochtoxische Stoffe / specifica//y toxic substances 
• Wirkstoff (Ausgangsmaterial, Zwischenprodukt) / API statting material (raw 
material intermediate) 
• Arzneimittel fOr Klinische Versuche / Drugs for clinical trials: 
Tabletten, Ampullen, Schwamme / tablets, ampoules, sponge 
• Salbengrundlage, Lebensmittelzusatze / oinment base, food supplements 
1.4.3 Andere / Others: 
Verblindung / Blinding: Tabletten, AmpuJlen , Schwamme / tablets, ampoules, 
Mikrobiologisch: Sterilitat / Microbiological: sterility 
Mikrobiologisch: PrOfung nicht steriJer Produkte / Microbiological: non-sterility 
CER99X22367DM 14.0 
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Bundesamt fOr Sicherheit 
im Gesundheitswesen Schnlrchgasse 9,1030 Wlen 
GMP-ZERTIFIKAT I CERTIFICATE OF GMP tiJ'MI?{i"'~I!I"-E OFA'HANUFAcTuRER' 
Zertifikat Nr.: /Certificate No.:J~S-4~!-J.~~~'0l1~do2 
\. i' '. t' '\';;''ii~:,: .. 
'. 
, 
Wirkstoffherstellung: siehe 1.4.1.4. / Manufacture of active substance: referring to item 1.4.1.4. 
Mogliche Einschrankungen oder Erklarungen bezilglich des vorIiegenden Zertifikats / 
Any restrictions or darlfying remarks related to the scope of this certificate: . . ' . 
Keine/None 
Fur das Bundesamt fur Sicherheit im Gesundheitswesen / 
For the Federal Office for Safety in Health care 
~\).v., ~ -, t.::">:J. 
CER99X.22367DM 14.0 
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Actovegin 
solution for injection 
3.2.R 
Regional Information 
E rope an Directorate for the 
Quality of Medicines & HealthCare COUNCil CONSEIL OF EUROPE DE L'EUftOPE 
Certification of Substances Division 
Certificate of suitability 
No. RO-CEP 2004-235-Rev 02 
1 Name of the substance: 
2 DEPROTEINISED HEMODERIVATIVE OF CALF BLOOD 
3 Actovegin concentrate 
4 Name of holder: 
5 NYCOMED AUSTRIA GMBH 
6 St Peter-Strasse 25 
7 Austria-4020 Linz 
8 Site(s) of production: 
9 NYCOMED AUSTRIA GMBH 
10 St Peter-Strasse 25 
11 Austria-4020 Linz 
12 THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE 
13 RO·CEP 2004·235·REV 01 
14 After examination of the information provided on the origin of raw material(s) and type of 
15 tissue(s) used and on the manufacturing process for this substance on the site(s) of 
16 production mentioned above, we certify that the substance DEPROTEINISED 
17 HEMODERIVATIVE OF CALF BLOOD meets the criteria described in the current 
18 version of the monograph Products with risk of transmitting agents of animal spongiform 
19 encephalopathies no. 1483 of the European Pharmacopoeia, current edition including 
20 supplements. 
21 - countries of origin of source materials: 
22 
23 
24 
25 - nature of animal tissues used in manufacture: 
Germany, France, Austria , Italy, 
Poland, Belgium, Spain, 
Luxembourg, The Netherlands, 
Lithunia, Latvia, Denmark, Ireland 
Bovine calf blood 
26 The submitted dossier must be updated after any significant change that may alter the 
27 quality, safety or efficacy of the substance, or that may alter the risk of transmitting 
28 animal spongiform encephalopathy agents. 
29 Manufacture of the substance shall take place in accordance with a suitable quality 
30 assurance system such as GMP, and in accordance with the dossier submitted . 
3.2.R Regional Information 
Document ID: 000008218 
Addres'7 7. "lice Kastne r. CS :10026 · F - 67081 Strasbourg (Frdncc) 
Telephone: 33 (0) 3 8841 30 30 Fa~: 33 (0) 3 8841 2771 e mail: cep(g edqm.eu 
Internet: http ://wwlV.cdqm.cu 
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Actovegin 
solution for injection 
3.2.R 
Regional Information 
31 Failure to comply with these provisions will render this certificate void. 
32 The certificate is valid provided there has been no deterioration in the TSE status of the 
33 country(ies) of origin of the source material. 
34 This certificate is granted within the framework of the procedure established by the 
35 European Pharmacopoeia Commission [Resolution AP-CSP (93) 5 as amended] for a 
36 period of five years starting from 16 December 2004. Moreover, it is granted according 
37 to the provisions of Directive 2001/83/EC and Directive 2001/82/EC and any 
38 subsequent amendment, and the related guidelines. 
39 This certificate has: 
40 lines. 
Strasbourg, 28 September 2007 
DECLARATION OF ACCESS (to be filled in by the certificate holder under their own responsibility) 
Nycomed Austria GmbH. as holder of the certificate of suitability 
RO-CEP 2004-235-Rev 02 for DEPROTEINISED HEMODERIVATIVE OF CALF BLOOD 
hereby authorises .......... ..... . 
(name of the pharmaceutical company) 
to use the above-mentioned certificate of suitability in support of their application(s) for the following 
Marketing Authorisation(s) : (name of produc/(s) and marketing number(s). if known) 
The holder also certifies that no significant changes to the operations as described in the CEP dossier 
have been made since the granting of this version of the certificate 
Date and Signature (of the CEP holder) : 
3.2.R Regional Information 
Document ID: 000008218 
Address: 7. al lee Kastncr, CS 30026 - F - 67081 Strasbourg (Francc) 
Telephone: 33 (0) 3 88 4 1 30 30 - fax: 33 (0) 3 884' 27 7 1 - e-mai l: .:cper! cdqm.cu 
Internet : http://www.cdqm.eu 
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Actovegin 
solution for injection 
3.2.R 
Regional Information 
To whom it may concern 
Nyoomed Austria CmbH 
St_-l\:tcr .. Strasse 25 
A-4020 Lin~, Austria 
Postal address: 
P.O. Box 122 
A·4O'll Lill:<, Au:slri. 
T H3 (732) 6919·0 
F +t3 (732) 655568 
July 20th, 2006 PQS/Emau 
Eva Maurhart, DI 
Tel: (+43-70) 6919-4147 
Fax: (+43-70) 6919- 4109 
Email: emau@nycomcd.com 
Compliance with the TSE Guideline 
To the best of our cur:rent knowledge, it is hereby confirmed that all exipients used for the 
manufacturing of the medical product 
ACfOVEGIN SOLUTION FOR INJECfION 200MG PER 5ML 
manufactured at ~lYCOMED Austria GmbH, arc in compli=ce with the Note for GlIidance on 
minimin'ng th. risk of IranI11lilting spongiofrmn m(~halopathy ag'IIII via hllman and Ilttmnary m.dicinal prodllcts 
(EMEA 410/01 Rev. 2), referred to in the Directive 2001/83/EC. 
We confirm that the used exipients (water for injection as well as hydrochloric acid) aie of non-
animal origin. 
Nycomed Austria GmbH 
'1. A . Ca.. ha....... Lo-"L 
DI Eva Maurhart 
Quality Assurance Biological Products 
3.2.R Regional Information 
Document ID: 000008218 
Quality Assurance Biological Products 
DVR0491592 
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Appendix C 
Ethical approval 
Reference to page 112, 146 
Cardiff School ot Engtnee'1ng 
o rt:. ( Of St t t, " 1( ":~ H P "'"IN" ~ • I:. j , 
ReC;Pdfch Offlc E-
o- "'ut, L ft O· If:-, ~"') , ~.,<" r~' f \. f ". r. < l'r,' r 
To whom it may concern, 
RE: ETHICAL APPROVAL 
Title of Project: A Pilot to Study an Intramuscular Injection Therapy of 
Traumeel and Actovegin in Elite Football Players with 
Muscular Injury 
Researcher: Paul Lee 
Supervisor: Prof. Len Nokes 
CAR..DIFF 
U NIVERSITY 
PRI FYSGOL 
(AER..DY@ 
I confirm that the above project has been subject to the School's ethical approval 
process. 
On behalf of the Cardiff School of Engineering Research Committee, I approve the 
attached application . 
.i \ f 'I 
f' 
Professor P J Tasker, Chair, Research Committee 
Deputy Director of School, Research 
2nd July 2009 
Appendix D 
Kincom Protocol 
Reference to page 132 
KinCom Protocol 
5 players per session 
Wearing shorts for the hamstring testing 
Barefooted on ankle testing 
1. Age 
2. Weight 
3. Height 
4. Position of play 
5. Previous injuries 
Warm up - 5 minutes on treadmill at their own speed 
HAMSTRING and Quadriceps 
RIGHT side first 
Players to KinCom, Strapped in, sitting position 
Knee to pivot point 
Strapped load cell just above medial malleolus 
Set up machine 
-Overlay 
- Knee 
- Flex (concentric / eccentric) 
- Anatomical 0 = full extension knee 
- Direction of movement = down 
- Stop angle = Flex 90 
- Start angle = Ext 0 
Angle velocity 60 Is, Flex 50N, Ext 50N, min 20N, Max 2000N 
Gravity correction off 
Instructions: 
"This test is not like a weight machine, the machine will have a fixed speed, it will not 
move faster if you pull harder. It will record your power." 
"Pull the machine by bending your knee" (Flex) 
"Pull the machine by bending your knee, and resist it as your knee extends" 
1 x learning 
2 x sub max testing 
Rest for 30 seconds 
Best of 3 for measurement, Save data 
Reverse the settings for Quadriceps (2 sub max, then best of 3) 
LEFT side test 
2 x sub max testing 
Rest for 30 seconds 
Best of 3 for measurement, Save data 
Reverse the setting for Quadriceps(2 sub max, then best of 3) 
Appendix E 
Patient information sheet 
for clinical study 
Reference to page 146 
ActoFC Study Paul Lee version: 1.1.3 
Study information sheet 
A pilot study of'intramuscular injection therapy with Actovegin on elite 
football players with muscular injuries. 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. Talk to others about the 
study if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
All players in Cardiff City Football Club are being invited to take part. 
It is up to you to decide. We will describe the study and go through this information 
sheet, which we will then give to you. We will then ask you to sign a consent form to 
show you have agreed to take part. You are free to withdraw at any time, without 
giving a reason. This would not affect the standard of care you receive from the 
medical team. 
Background 
Muscle injuries are one of the most common sport related injuries. Currently, the most 
common treatment option is rest, ice, compression and elevation. 
In 2008, an article in the British Journal of Sports Medicine summarised that currently 
almost all our knowledge in the treatment of muscular injuries is very poor. Tt 
highlighted the importance of injection therapies and called for further studies into 
Traumeel and Actovegin. 
Study Drug: 
Actovegin: It is believed to improve the utilization of oxygen and promote uptake 
of nutrients into the cells. 
We have written confirmation from the WADA, FA and UK sport that Actovegin are 
not prohibited via intra-muscular injection. 
What the study involves 
As we don' t know what treatment is the best for muscular injuries. To find out, we 
need to compare different treatments. We put people into groups and give each group 
a different treatment. The results are compared to see if one is better. To try to make 
sure the groups are the same to start with, each participant is put into a group by 
chance (randomly). 
Following clinical examination by the club doctor and MRI confirmation of a muscle 
tear that does not require surgical repair, you will be randomised into two groups. You 
will either receive a course of 3 Actovegin injections, if you would like to op out for 
the Actovegin injection, you will be invited to joint the control group. You will 
undergo standard physiotherapy provided by the club. 
- 1 -
ActoFC Study Paul Lee version: l.l.3 
Safety 
Actovegin have been used for over 60 years in Europe. There are no known reports of 
allergy associated with Traumeel available in the medical literature. 
GMC registered doctors who are trained in life support and are able to deal with 
anaphylactic reactions will perform the injection therapies. Oxygen and adrenaline 
will be available at all times. 
After the study 
All information collected will be anonymous and treated confidentially. All 
participants" personal data and results will be stored in a password protected database. 
All data will be anomymised before publishing. 
Taking part 
Please note that taking part in the study is entirely voluntary. You are free to withdraw 
at any time. Choosing not to take part in the study will not in any way affect your 
medical management. No money is offered for taking part in the study. 
This research is looked at by an independent group of people, called a Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has 
been reviewed and given favourable opinion by Cardiff University's Research Ethics 
Committee. 
If you have any more question please feel free to ask any of the research doctors. We 
hope that the findings of this study will be of benefit to muscular injuries in the future. 
Thank you for considering taking part. 
Jf you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (contact number). Jfyou 
remain unhappy and wish to complain formally, you can do this through the Cardiff 
City Football club or Cardiff University Complaints Procedure (or Private 
Institution). Details can be obtained from the Club or University. 
Investigators 
Chief investigator - Prof. Len Nokes 
Principal investigator - Dr. Paul Lee 
- 2 -
Appendix F 
Clinical Study protocol 
Reference to page 146,164 
3.0.0 ActoFC Obs 
Cardiff University Protocol 
A pilot study into intramuscular injection 
therapy with Actovegin® on elite football 
players with muscular injuries. 
Prospective Observational Study 
Short title 
ActoFC study 
Protocol version number and date: 3.0.0 
EudraCT number: 2008-014603-31 
Sponsor: Cardiff University 
Protocol authorised by: 
Professor Len Nokes, Dr. Paul Lee 
Name and Role I Date I Signature 
ActoFC Protocol 1 
3.0.0 ActoFC Obs 
Study Management Group 
Chief Investigator: 
Principal Investigator: 
Princioal site: 
Collaborators: 
Cardiff City football club 
CardiffUniversity 
Healthcare Studies 
Professor Len Nokes, BEng, MSc, PhD, MB,BCh, 
MD, FIMechE, Ceng, DipSEM, FFSEM 
Director of Medical Engineering 
Medical Engineering Research Unit, Cardiff University 
Tel: 029 2087 5907 Fax: 029 2087 5907 
Email : Nokes@cardiff.ac.uk 
Dr. Paul Lee, MB BCh, PgDip(SEM), MRCS, MFSEM 
PhD student 
Medical Engineering Research Unit, Cardiff University 
Tel: 0776461 4688 
Email: paul@medtaste.co.uk 
Cardiff City Football Club (medical centre) 
Responsible physician: Chief and Principal Investigator 
Mr. Sean Connely 
Chief Physiotherapist 
Cardiff City football club 
Mr. Adam Rattenberry MCSP SRP 
Physiotherapist 
Cardiff City Football Club 
Tel: +44 (0)29 2034 8054 Fax: +44 (0)2920233531 
Dr. Nichola Phillips, PhD 
Senior Lecturer in Sports Physiotherapy 
Director Postgraduate Healthcare Studies, 
Cardiff University 
Tel: 029 206 87557 
Email :PhillipsN@cardiff.ac.uk 
ActoFC Protocol 2 
3.0.0 ActoFC Obs 
Sponsor 
Cardiff University is the research Sponsor for the study. For further 
information regarding Sponsorship related information please contact the 
Research and Commercial Division at: 
Cardiff University 
RACD 
6th Floor 
30-36 Newport Road 
Cardiff 
CF24 ODE 
Tel: +44(0)29 20879277 
Fax: +44(0)2920879280 
Email: bettyn1@cardiff.ac.uk 
Funder 
Cardiff City Football Club 
ActoFC Protocol 3 
3.0.0 ActoFC Obs 
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ActoFC Protocol 4 
3.0.0 ActoFC Obs 
List of Abbreviations 
BNF British Nation Formula 
BSE Bovine Spongiform Encephalopathy 
Cl Chief investigator 
FA Football association 
lA Intra arterial injection 
IM Intra muscular Injection 
IV Intra venous injection 
IPO Inositol phosphate oligosaccharides 
PI Principal investigator 
NSAIDS Non-steroidal anti inflammatory drug 
TSE Transmissible spongiform encep_halopathies 
WADA World Anti-Doping Agency 
ActoFC Protocol 5 
3.0.0 ActoFC Obs 
Brief Summary 
Muscle injuries are one of the most common sport related injuries. In 2008, an 
article in the British Journal of Sports Medicine entitled "The early 
management of muscle strains in the elite athlete: Best practice in the world 
with a limited evidence" summarised that currently almost all our so-called 
knowledge has a basis of level 4 or level 5. The panel continued to highlight 
the importance of injection therapies and called for further studies into 
Actovegin®. 
Actovegin® is manufactured by NYCOMED Austria. It is believed to improve 
the utilization of oxygen and to promote the uptake of nutrient media into the 
cell, hence promote wound healing. It is used as an intravenous infusion to 
treat acute stroke, postpartum haemorrhage and as a topical form to treat skin 
ulcers over 40 years in Europe. Its safety and efficiency has been proven by 
many published studies. We have confirmed with UKsport, World Anti Doping 
Agency and The Football Association (FA) that intramuscular injection of both 
of our study drugs are not prohibited for either in or out of competition use in 
the UK. 
The aim of our study is to provide high quality and objective evidence for this 
combination of injection therapy in muscular injuries. Our hypothesis is that 
this combination of injection therapy can reduce the number of days required 
for players return to play after muscular injuries and also reduce the 
subjective perception of pain. 
Lay summary 
Muscle injuries are the most common sport related injuries. Currently almost 
all the treatment methods were based on very poor scientific evidence. 
Injection therapy for treating muscle injuries was considered by the panel of 
experts in the Royal College of Surgeon Faculty of Sport and Exercise 
Medicine to be the current best practice. Actovegin® - a drug that has been 
used by clinicians across Europe, China and Russia for over 60 years, was 
recommend by this panel for injection therapy. 
Nevertheless very little is known regarding the effects of Actovegin® on 
muscle injuries. Therefore, this study will compare the clinical outcome of two 
groups of elite football players who sustain muscle injury and are treated with 
Actovegin® or Placebo. Scientific laboratory based experiment with also be 
performed to supplement clinical findings. 
ActoFC Protocol 6 
3.0.0 ActoFC Obs 
Background 
Muscle injuries are one of the most common sport related injuries, their 
incidence varying form 30-55%(Noonan and Garrett, 1999, Verrall et al., 
2001, Jarvinen et al., 2000). According to the World Health Organization 
musculoskeletal injuries are the most common cause of long term pain and 
physical disability, which affects hundreds of millions of people in the 
world(Woolf and Pfleger, 2003). In an audit published by The Football 
Association (FA) in 2004 it suggested that 12% of all injuries were hamstring 
injuries, it is 2.5 times more common than quadriceps injuries(Woods et al., 
2004). In the 2 seasons from 1997 to 1999, 749 hamstring injuries were 
reported across the 91 British football clubs(Woods et al., 2004). It was 
accounted for loss of 90 training days and 15 matches per club per 
season(Woods et al., 2004). 
Muscle injury is often assessed and diagnosed by clinical examination. 
Ultrasonography and Magnetic Resonance Imaging can be useful in 
confirming the diagnosis and aid the clinician in making treatment decisions. 
Muscle strains can be classified into three categories according to severity: 
Grade 1 (mild) a tear of few muscle fibres, minor swelling and discomfort with 
no or minimal loss of strength and restriction of movement. Grade 2 
(moderate) a greater damage of muscle with clear loss of strength. Grade 3 
(severe) a tear extending across the whole muscle belly, result in total loss of 
function . 
Current management: 
Rest, immobilization(Jarvinen et al., 2000), physical therapy(Cibulka et al., 
1986) and non-steroidal anti-inflammatory drugs (NSAI DS)(Reynolds et aI., 
1995) have been the mainstay of therapy for grade 1 and 2 muscle injuries 
(Kasemkijwattana et al. , 2000). For Grade 3 muscle injuries, surgical repair 
was essential (Jarvinen et al., 2000, Taimela et al., 1997). 
Immobilization can lead to improved granulation of the injured muscle and 
promote healing, but it will cause significant atrophy of healthy myofibers and 
joint stiffness(Jarvinen et al., 2000). Although some studies have shown that 
the administration of NSAIDS promotes muscle healing by reducing 
degeneration and inflammation (Abramson and Weissmann, 1989, Cheung 
and Tidball, 2003) other research has demonstrated that NSAIDS are 
detrimental to the entire healing process (Obremsky et al., 1994, Mishra et al., 
1995, Almekinders and Gilbert, 1986, Shen et al., 2005). Recently new 
treatment options such as growth factors injection therapy have shown good 
therapeutic results. However, its performance enhancing properties, growth 
factors, autologous blood and autologous conditioned serum was prohibited 
by World Anti-Doping Agency (WADA) under section M1 and S2 from the 
WADA prohibited list(WADA, accessed 03/08/09). 
Proposed treatment: 
The damage caused by the strain of the skeletal muscle is classified as 
shearing injury(Jarvinen et al., 2000). The mechanical force tears the entire 
myofiber, damages its plasma membrane and leaving the sarcoplasm open at 
the end of the stumps and initated necrosis. It will extend along the whole 
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length of the ruptured myofiber which causes inflammation and further cell 
damage(Jarvinen et al., 2000). Actovegin® believed to improve the utilization 
of oxygen and to promote the uptake of nutrient media into the cell (Hoyer and 
Betz, 1989, Kanowski et al., 1995, Schoenwald et al., 1991), therefore was 
thought to improve wound healing and prevent further necrosis. Clinically, it is 
used as an intravenous infusion to treat acute stroke(Derev'yannykh et al., 
2008, Boyarinov et al., 1998), postpartum haemorrhage(Appiah, 2002) and as 
a topical form to treat skin ulcers(Biland et al., 1985). Recently, it has also 
been used as intra-arterial infusion to treat long bone fractures(Khomutov et 
al., 1999) and radiation damage(Beetz et al., 1996). 
Actovegin® is a deproteinised haemodialisate of ultra filtered calf serum of 
animals under 8 months of age, produced by Nycomed Austria GmbH. It is 
licensed for the treatment of disturbances in the cerebral circulation, 
peripheral blood disturbances (arterial angiopathy, ulcers), skin grafting and 
burns, wound-healing, and mucous membrane lesions. It is not in the British 
National Formulary (BNF), but has been used by clinicians across Europe, 
China and Russia for over 60 years. It contains physiological electrolytes, 
essential trace elements, amino acids, oligopeptides, inositolphospho-
oligosaccharides (IPOs), carbohydrate and nucleosides with a molecular 
weight of no more than 6000 Daltons. Although, there have not been any 
randomised control trials in relation to its efficacy in the treatment of muscle 
injuries, it has been used by many high profile sports doctors across the UK 
and Europe in treating muscle tears. In 2006, an article from the Times 
newspaper reported the comment from Dr. Hans-Wilhelm MOller-Wohlfahrt, 
team doctor for the German national football team and Bayern Munich 
Football Club regarding the use of Actovegin®. In this report Dr. MOller-
Wohlfahrt discussed his experience with Actovegin® and the success of its 
treatment with high profile sports people such as Maurice Green, Asafa 
Powell, Diego Maradona, Darren Gough and Paula Radcliffe(Crompton, 
2006). "I am an empirical doctor and, over 30 years, I have treated so many 
that nobody can tell me it doesn't work. Nobody I have seen has had an 
adverse effect, or an allergic or other reaction." 
Doping Control 
Intramuscular Actovegin® is not prohibited for either in or out of competition 
use according to UK sport and WADA(WADA, accessed 03/08/09) . We have 
also received written confirmation from the FA which states that Intramuscular 
injection of Actovegin® are not prohibited for either in or out of competition 
use. According to the lastest information by UK Sport, Actovegin® is listed as 
a legitimate drug that can be used both in, as well as out-of-competition. 
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Safety 
There are many clinical studies which have demonstrated its safety and 
efficacy (Oerev'yannykh et al., 2008, Boyarinov et al., 1998, Appiah, 2002, 
Biland et al., 1985, Khomutov et al., 1999, Beetz et al., 1996). A recent 
randomized double-blind multicentre study with 562 patients further reinforced 
the safety profile with Actovegin®(Ziegler et al., 2009). 
The manufacturer Nycomed Austria GmbH confirms that all measures are in 
place to guarantee the Transmissible Spongiform Encephalopathies (TSE) 
safety of Actovegin®(Nycomed). According to the latest guidelines from the 
European Medicines Agency (EMEAl410101 final issued in February 2001) 
and the Final Opinion of the Scientific Steering Committee on the 
geographical Bovine Spongiform Encephalopathy (BSE) risk (issued in July 
2002) the safety of a medicinal product is determined by 4 important factors: 
1. Animals as source of material: the most satisfactory source of materials is 
from countries which are free of BSE and have appropriate surveillance 
systems. Materials may be used from countries with a low BSE incidence. 
2. Parts of animal bodies and body fluids used as starting materials: tissues 
and body fluids are categorised in four categories (from category I = high 
infectivity like brain to category IV= safest category, no detectable infectivity 
like blood and milk). 
3. Age of animals: the sourcing from young animals is seen as very important 
safety factor. 
4. A production process should be designed which is thought to remove or 
inactivate TSE agents. 
Austria is officially categorised as a BSE and Scrapie free country by the 
World Organization for Animal Health and the Scientific Steering Committee 
of the European Union. The calf blood used as raw material for Actovegin® 
derives from calves born, raised and slaughtered in Austria. Blood is in the 
safest tissue category (IV). The calves were never fed animal carcass fodder 
and are declared fit for human consumption, which has been proven by 
veterinary certificates(Nycomed). Moreover the traceability of every 
Actovegin® batch back to the individual calves as blood donors is ensured. 
The mother cows of the calves can also be traced. The manufacturing 
process of Actovegin® is BSE validated, thus proven to be capable of 
removing hypothetically present TSE agents(Nycomed). 
ActoFC Protocol 9 
3.0.0 ActoFC Obs 
Trial Objectives and Purpose 
In professional elite-level athletes, Orchard et al (2008) summarised that 
currently almost all our so-called knowledge in the treatment of muscle 
injuries was based on very poor scientific evidence (Orchard et al., 2008). Dr. 
Mueller-Wohlfahrt's Actovegin® injection treatment regime for treating muscle 
injuries was considered by the panel of experts to be the current best practice 
(Orchard et al., 2008). In the season of 2008-2009, we employed Dr. Mueller-
Wohlfahrt's treatment regime to treat grade 1 and 2 hamstring injuries in 
professional football players in Cardiff. All 8 players reported they "felt better" 
after the initial injection in terms of pain and mobility. According to the team 
physiotherapist, the injured players reached rehabilitation key stages earlier 
than expected and, in some cases, players returned to play 10 days earlier 
than expected with the same type of muscle injuries. 
In terms of the professional elite athlete, shortened recovery time could mean 
continuing training, increased game play and benefit to the team and club. As 
our preliminary experience suggests that Actovegin® is safe in patients and 
may even be associated with improved outcomes. This evidence requires 
validation through a prospective randomised trial. Therefore, a PhD study 
under the supervision of Professor Len Nokes, titled "A pilot study into 
intramuscular injection therapy of Actovegin® in elite football players with 
muscular injury" has been approved by Cardiff University and supported by 
Cardiff City Football Club. 
Aims 
Evidence obtained so far with regard to the efficacy of Actovegin® in muscle 
injuries remains largely anecdotal. Despite the lack of scientific understanding 
of the biological action of Actovegin®, it is predicted that the use of 
Actovegin® in athletes will become more widespread in the future. 
Pharmacodynamic studies suggested that Actovegin ® can increase the 
respiration capacity of cells, improve oxygen and glucose utilisation, 
optimisation of mitochondria and exhibit protective effect on hypoxic cells 
(Obermaier-Kusser et aI., 1989, Kuninaka et aI., 1991). 
The aims of this proposed is to extend the preliminary clinical study on the 
efficacy of Actovegin® treatment in muscle injuries 
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Trial Design 
Hypothesis for Clinical Trial 
Intra muscular Actovegin® injections can reduce number of days for the 
player to return to training with the first team following from grade I or " 
muscle injuries. 
Primary outcome 
Number of days from injury for the player to return to training with the first 
team 
Secondary outcome: 
Player's perception of pain and effectiveness of treatment 
Player's isokinetic and isometric data 
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Selection and withdrawal of Subjects 
Inclusion Criteria: 
Informed consent 
> 18 years 
Clinical and MRI diagnosis of muscle injuries 
Grade 1 or 2 muscle tear 
No previous allergic reaction to Actovegin® 
Exclusion Criteria: 
Grade 3 or more muscle injuries 
Fractures 
Other soft tissue injuries besides muscle tears 
Withdrawal Criteria: 
Acute or delayed hypersensitivity reaction 
Infection 
Request of the player 
Discretion of the investigator or club management 
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Study design: 
A team of elite football players (n=21) 
Pre-season physical and isokinetic testing 
The study will be explained to all players by the Cl and PI. 
All players will receive study information sheets 
Informed consent will be taken with the consent form 
Follow this group of player for the season as team physician 
Clinical examination and MRI to confirm diagnosis of grade 1 and 2 muscle 
tear. 
Players will be divided into 2 groups: 
1) Actovegin® 3ml 
2) Physio only 
Injection sites will be cleaned with alcohol wipes and 1 orange needles will be 
used for the injections. 2ml injected directly to the injury site, 
1 st injection takes place at diagnosis 
2nd injection 1 day after 1 st injection 
3rd injection 2 days after 1 st injection 
Both groups (control and treatment) will undergo same physiotherapy protocol 
provided by the club. 
The club will monitor players' recovery progress; complete recovery will be 
deemed as the player's return to training with the first team. 
Day 1 Day 2 Primary outcome 
1st Injection 2na 3ra lsokinetic testing Return to play 
Injection Injection 
Injury confirmed Deemed fit to return 
by MRI 
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Adverse events 
Any adverse event during the study, whether or not related to the test 
medication will be assessed by the principal investigator and documented with 
the adverse events report form. (Appendix C). They will be reviewed within 
24hours by the Chief and Principal investigators. 
GMC registered doctors who are trained in life support and are able to deal 
with anaphylactic reactions will perform the injection therapies. Oxygen and 
adrenaline will be available at all times. 
Serious adverse events 
1. Death 
2. Anaphylactic reactions 
Although it is very unlikely that serious adverse events will occur, these will be 
recorded on the adverse event forms (Appendix C) and will be reviewed within 
24hours by the Chief and Principal investigators. Notification will also be given 
to the MHRA, Cardiff University R&D office and NRES. 
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Statistics 
As this is a pilot study, approximately 18 players will be enrolled to the study 
over the study period. The study will have 80% power at a 5% significance 
level. Through the power calculation, this study can detect a standard 
difference of 1.5 standard deviations. 
Data collection: 
All data will be entered using a password protected excel spreadsheet (Data 
A). Personal information will be stored as a separately protected excel 
spreadsheet (Data B). A unique identification number will be used to link 
between the data bases. Only the Cl and PI will have the password to access 
these spreadsheets. 
All participants' personal data and results will be coded and anomimised, and 
stored in a password protected database. Any announcement or publication of 
results and publicity concerning the study will require approval of all 
investigators. Such publications will be in the names of all the investigators. 
All publications, posters, oral presentations at scientific meetings, seminars, 
and any other forum will only contain the group mean data, no identifiable 
data will be included. 
Quality assurance: 
PI or Cl will perform data entry. A hard copy will be printed (Data A only), 
countersigned and dated by PI and Cl each time data is entered into the 
database. This paper copy will be filed into a locked cabinet and reviewed by 
the monitoring committee at monthly meetings. 
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Regulatory Approval 
Ethics/regulatory approval 
Ethic approval was granted via Cardiff University, Cardiff School of 
Engineering Research Committee. 2nd July 2009. 
NHS ethic approval is currently in process 
MHRA regulatory approval is in progress 
ISRCTN registration number: 
EudraCT number: 2009-014603-31 
Indemnity 
Cardiff University holds 'Clinical Trial' insurance which applies to this trial. 
Note that insurance cover is not automatic and will need to be agreed on a 
trial-by-trial basis. The Clinical Trial insurance provides negligent harm cover 
for the design and management of the trial. Cover for clinical negligence will 
be provided by PI and Cl personal medical insurance indemnity. 
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Appendix G 
Consent forms for the clinical study 
Reference to page 148 
Paul Lee 
CONSENT FORM 
A pilot study of intramuscular injection therapy with 
Actovegin on elite football players with muscular injuries. 
PLEASE INITIAL NEXT TO EACH NUMBER 
1.1.2 
1. I confirm that I have read and understand the information sheet 
dated .................... for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care or 
legal rights being affected. 
3. I agree to take part in the above study. 
Name of Patient 
Name of Person 
taking consent 
Date 
Date 
Signature 
Signature 
1 copy for participant; 1 copy for researcher file 
Appendix H 
MRI reports 
Reference to page 167 
IMAGING REPORT 
KI /MS 
Dear Or N 
Re: 
Thank you for referring this patient. 
••••• MRI RIGHT HAMSTRING 
Examination No: 1 si ••• 
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IMAGING REPORT 
KLlKP 
DearDrN _ 
Re: 
Thank you for refe rnng this palient 
Examination No' 20_ 
CrOC5cadal r Road 
Pcntwyn 
Caldiff 
CF23 SXL 
Tel 029 2073 5515 
Fax 0292073 5821 
Page 1 of 1 
V·.'W\'J.Spifc"lealthcarc.(om/Glrciiff 
A skin marker was placed at the site of the patient's symptoms and th is was very close to the injection site. 
The scan confirms what is predommantly a Grade I tear of rectus and I find it difficult to completely exclude a 
small Grade 11 tear 
Yours sincerely 
f 
l1 
DRKL __ _ 
Consultant Radiologist 
CD with patient. report to L •••• 
IMAGING REPORT 
KL/KS 
DearDrN_ 
Re: 
Thank you for referring this patient. 
MRt SCAN RIGHT THIGH 
Examination No: 19 ••• 
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A sk in marker was placed over the area of concern to the patient. This lies at 
the distal edge of a grade I musculotendinous tear of the longhead of biceps 
femoris about 5cm distal to the ischial tuberosity. The examination is 
otherwise unremarkable. 
Yours sincerely 
Consultant Radiologist 
Disc with patient - report to Or N_ 
IMAGING REPORT 
KLlCM 
Dear Or N 
Re: Mr 
Cardiff City Fe Ninian Park Road Cardiff 00 000 
Thank you for refernng tI is patient 
MRI LEFT THIGH _ 
Examination No 19_ 
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CJrdiff 
CF238XL 
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Ww\v.spirehealt rcare .comlcardiff 
The scan confirms a grade 2 muscu lotend inous tear of the long head of biceps femOriS about gcms below 
the ischial tuberosity . The skin marker that he has put on IS quite accurate in demonstratmg the level of the 
injury 
Yours sincerely 
Consultant Radiologist 
DISC with patient. report to Or 
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Abstract 
T 
Muscle injuries are one of the most common 
sport related injuries. their incidence varying 
from 30-55 % in all sports injuries. They account 
for the loss of 90 training days and 15 matches 
per club per season in elite football (soccer). In 
recent years, the use of Actovegid!!> in sports 
medicine has caused a lot of controversy in 
many sports disciplines. Although it is unlikely 
for this deproteinised substance to have oxygen-
enhancing capacity, there is an anecdotal belief 
that Actovegin(!) can increase an athlete's perfor-
mance. Actovegin(!) is produced by Nycomed 
Clinical Relevance 
T 
There are numerous anecdotal beliefs and there 
is much media attention regarding Actovegin 
injection therapy, but the published scientific 
evidence and clinical trials are largely ignored. 
This short review will "reintroduce" the scientific 
evidence around this contentious topic and will 
aid sports clinicians to examine evidence with an 
open mind. From our experience with this pilot 
study, Actovegin injection therapy seems safe and 
well tolerated. Further objective evidence is needed 
before any meaningful conclusions can be drawn 
for this new treatment of muscle injuries. 
Introduction 
T 
Muscle injuries are one of the most common 
sports related injuries, their incidence varying 
from 30-55% [13,27]. An audit published by The 
Football Association (FA) in 2004 suggested that 
12% of all injuries were hamstring injuries. They 
are 2.5 times more common than quadriceps 
injuries [3,29]. In the 2 seasons from 1997 to 
1999. 749 hamstring injuries were reported 
across the 91 British football clubs [29]. They 
Austria GmbH and has been used by doctors 
across Europe, China and Russia for over 60 
years. Nevertheless, very little is known regard-
ing the effects of Actovegin on muscle injuries. 
This article reviews the current evidence on 
Actovegin®, its legal status with sports governing 
bodies and its potential role in sport injuries. We 
will also report our experience with this drug in 
treating muscle injuries. In this pilot study, play-
ers in the Actovegin treatment group were able 
to return to play 8 days earlier (95 % Cl -1.249 
to -14.7510) compared to physiotherapy alone 
(p=0.033). No adverse reactions were recorded 
in any of the participants. 
accounted for the loss of 90 training days and 15 
matches per club per season [29]. A recent pro-
spective cohort study published with the Union 
of European Football Associations (UEFA) con-
firmed that hamstring injuries were the single 
most common injuries in professional football 
players, representing 17% of overall injuries [11]. 
Similar observations regarding hamstring inju-
ries were reported by Bennell et al. [5] in Austral-
ian Rules footballers, with hamstring injuries 
accounting for 86.4 injuries per 10000 playing 
hours. 
Hamstring injuries are often diagnosed and man-
aged by the team clinician. Ultrasonography and 
Magnetic Resonance Imaging (MRI) can be useful 
in confirming the diagnosis and aiding the clini-
cian to make decisions with regards to treatment. 
Rest. immobilization [13]. physical therapy and 
sometimes non-steroidal anti-inflammatory 
drugs (NSAlDs) [23] have been the mainstay of 
therapy for grade 1 and 2 muscle injuries [14]. 
Immobilization can lead to improved granulation 
of the injured muscle and promote healing. but it 
will cause significant atrophy of healthy myofib-
ers and joint stiffness [13]. Although some stud-
ies have shown that the administration of NSAlDs 
promotes muscle healing by reducing degenera-
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tion and inflammation [1], other research has demonstrated that 
NSAlDs are detrimental to the entire healing process [19,25]. 
Recently, new treatment options such as growth factor injection 
therapy have shown good therapeutic results. However, due to 
their performance enhancing and anabolic properties, growth 
factors are prohibited by the World Anti-Doping Agency (WADA) 
under section Ml and S2 of the WADA prohibited list [28]. 
In 2008, a best practice statement summarised that currently 
almost all our knowledge in treating muscle injuries has a basis 
of level 4 or levelS [20]. This panel of experts also concluded that 
Actovegin injection therapy could be important in the treatment 
of muscle injuries [20]. Although its intramuscular use is not 
prohibited by the regulatory authority, World Anti-Doping 
Agency (WADA) [28], athletes and coaches have reservations 
about its use. In this paper, we have reviewed the evidence for 
Actovegin and report our experience with this drug in treating 
muscle injuries in our pilot study. 
Background 
... 
Actovegin<!l is a deproteinised haemodialysate produced by 
Nycomed Austria GmbH. Clinically, it is used as an intravenous 
infusion to treat acute stroke [7,10], postpartum haemorrhage 
[2] and as a topical form to treat skin ulcers [6]. Recently, it has 
also been reported to be used as an intra-arterial infusion to 
treat long bone fractures [15] and radiation damage [4]. Clini-
cians across Europe, China and Russia have used Actovegin for 
over 60 years [4,18,22,30]. It contains physiological compo-
nents, electrolytes and essential trace elements, 30% of organic 
components are amino acids, nucleosides, intermediary prod-
ucts of carbohydrates and fat metabolites [18]. It does not con-
tain growth factors or hormone like substances, as it is ultra 
filtered to 6000 Daltons. It can be administered as tablets, topi-
cal formulations, injections or infusions via intramuscular, intra-
venous or intra-arterial routes [18]. 
Many studies have tried to identify the active ingredients in this 
mixture, but have been unsuccessful. Schoenwald et al. [24] sug-
gested that the active fractions in Actovegin were strongly nega-
tively charged and were thought to be phosphorylated and/or 
sulfated oligosaccharides of approximately 3000 Daltons in 
molecular weight and different to the IPO fraction reported by 
other studies. This fraction is also resistant to proteinase K diges-
tion, which suggests that it is unlikely to contain peptides [24]. 
Actovegin also showed a synergistic effect on cell proliferation 
with growth factors such as Epidermal Growth Factor (EGF), 
Basic Fibroblast Growth Factor (bFGF), and Endothelial Cell 
Growth Factor (ECGF), causing an increase in cell numbers, 
increase activity of acid phosphatase and an improved level of 
thymidine incorporation compared to Actovegin alone [24]. 
Therefore. the active compounds in Actovegin are unlikely to be 
these growth factors or their derived fragments [24] . The trivial 
nutritive effects of Actovegin were excluded as a mixture of the 
same level of amino acids and substrates did not stimulate pro-
liferation or have insulin like activity in vivo [24]. 
Clinical Evidence 
... 
Although the active ingredients within Actovegin are yet to be 
identified, there are many clinical studies to confirm its safety 
and effectiveness. There has been one case report of a possible 
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anaphylactiC reaction related to the use of intravenous Actovegin 
injection by an amateur sportsman. In this report, the so-called 
"anaphylactic reaction" was not confirmed with any biochemis-
try and the patient improved with antibiotics. The author later 
stated in the communication letter that this patient had taken 
Actovegin once before with no adverse reaction. Therefore, the 
most likely cause for this acute shock was due to bacterial con-
tamination during injection not anaphylactic reaction to the 
drug [16]. A double-blind placebo controlled single centre study 
with recreational athletes demonstrated that ultrasound guided 
para-tendon injection of Actovegin was effective in the treat-
ment of Achilles tendinitis [22]. The tendon cross section mea-
surement was reduced significantly (p < 0.0001), patients' 
physical activity and perception to pain was also improved 
(p<0.002) in the treatment group [22]. The overall patient satis-
factory score was also significantly better in the Actovegin group 
(p<O.OOOl) and no adverse event was reported in this study 
[22]. Although it is a relatively small-scale study with limited 
power, it is a well-conducted study that was featured in a 
Cochrane review. Ziegler et al. [31] reported a double-blind mul-
ticentre randomized control study with 567 patients treated 
with daily high dose intravenous Actovegin infusion for sympto-
matic diabetic polyneuropathy. No anaphylactic reactions were 
reported in this study after 5620 infusions of the maximum 
dose of Actovegin. The adverse effect profile was no different 
compared to placebo [31]. 
Legal Status 
... 
Besides its clinical properties, there are anecdotal beliefs 
amongst athletes that Actovegin possesses an oxygen carrying 
capacity and has the potential to enhance oxygen uptake, which 
leads to better performance. Although these claims are not based 
on any objective scientific evidence, the IOC announced in 
December 2000 that Actovegin was banned under the classifica-
tion of blood-doping agents. 2 months later, however, the IOC 
lifted the ban as there was no evidence that Actovegin actually 
enhances performance [26]. In a recent study with 567 diabetic 
patients, no improvement of muscle strength or condition was 
found after treatment with the maximum recommended dose of 
Actovegin for 160 days [31]. Currently, intramuscular use of 
Actovegin is not prohibited in or out of competition according to 
the latest search of the Global Drug Reference Online (Global 
DRO), which is approved by UK Anti-Doping (UKAD), the Cana-
dian Centre for Ethics in Sport (CCES), the United States Anti-
Doping Agency (USADA) and WADA [9]. 
Evidence on Actovegin in Muscle Injuries 
... 
The treatment of muscle tears with intramuscular Actovegin 
was first published by pfister and Koller in 1990 [21]. Their par-
tially blinded case control study with 103 patients, showed a 
reduction in recovery time with the treatment group of 5.5 
weeks compared with 8.3 weeks for the control group [21]. 
However, in this study, the diagnosis of specific muscle injuries 
was only based on clinical finding and was not graded according 
to MRI. Patients were recruited from various sports and levels 
and the treatment regimen and rehabilitation protocol were not 
standardised. Actovegin was mixed with local anaesthetics 
before injection, therefore its pharmacodynamics and pharma-
cokinetics were altered. The final outcomes were based on 
patients and various clinicians' subjective observations and 
there was no pre injury data to compare outcomes. Despite these 
limitations, it is the first published study regarding the use of 
Actovegin as an intra-muscular injection and no adverse events 
were reported in this paper. Wright-Carpenter et al. [30] com-
pared Autologous Conditioned Serum (ACS) to Actovegin in a 
small non-randomised study. The Actovegin group was created 
by the retrospective analysis of the Pfister and Koller study, 
therefore should not been seen as new evidence. Ziegler et al. 
[31) reported a double-blind multicentre randomized control 
study with 567 patients treated with 20 daily infusions followed 
by 140 days of oral Actovegin. Although muscle assessment was 
not the primary objective in this study, it suggests that Actovegin 
does not have anabolic or ergogenic activity in terms of muscle 
development. It does not improve muscle strength (p=0.731) or 
muscle reflex (p=0.571) [31). Furthermore, there was no 
significant difference in the adverse event rate compared to 
placebo [31). 
In 2006, an article from the Times newspaper reported a com-
ment from Dr. Hans-Wilhelm Muller-Wohlfahrt, team doctor for 
the German national football team and Bayern Munich Football 
Club regarding the use of Actovegin(l). In this report Dr. MUller-
Wohlfahrt discussed his experience with Actovegin(l) and the 
success of its treatment with high profile sports people such as 
Maurice Green, Asafa Powell, Diego Maradona, Darren Gough 
and Paula Radcliffe [8] "I am an empirical doctor and, over 30 
years, I have treated so many that nobody can tell me it doesn't 
work. Nobody I have seen has had an adverse effect, or an aller-
giC or other reaction." [8). Although it is not a published clinical 
study, his 30 years specialist experience with muscle injuries in 
elite athlete should not be overlooked [20]. There is no study 
that reports the use of intramuscular injection of Actovegin as a 
single therapy to treat muscle injuries. Therefore, we will report 
our experience with this drug in this pilot study. 
Method 
'f' 
Prospective data was collected during the 2008-2009 season 
from a professional football team competing in the UK Champi-
onship League for players who sustained grade 1 or 2 hamstring 
injuries according to the grading system described by Jarvinen 
et al. [13]. 
After initial assessment and diagnosis by the team physician or 
physiotherapist, all injured players underwent MRI to confirm 
the diagnosis. Actovegin injection therapy was initiated imme-
diately once muscle fiber tears were defined as moderate strains, 
characterized by a stretch injury with detection of bleeding on 
MRI scanning (grade I or 11 tears) [13]. Players with normal MRI 
findings or grade III tears were excluded in this report. Players 
who refused Actovegin treatment were allocated to the control 
group. All players in the Actovegin treatment group followed the 
same injection protocol (0 Fig. 1) of 3 intramuscular injection 
therapies and the same hamstring specific rehabilitation proto-
col. There was no blinding or randomization in this study. 2 ml of 
Actovegin were injected into the injury site under direct palpa-
tion. The injection process was repeated after 24 h (0 Fig. 1). 
Players who opted-out of the injection therapy followed the 
same rehabilitation protocol. All players were discouraged from 
taking any anti-inflammatory (NSAlDs) or oral supplements 
during the rehab period. Players were able to return to training 
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Fig. 1 Injection and rehabilitation regimen. 
Rehabilitation regimen: 
Assessment for lumbar/sacral and pelvic dysfunction carried out on daily 
basis during rehabilitation. Any dysfunction is treated accordingly. 
Stage A: RICE. gentle movement (3 days) 
Low-to moderate-intensity sidestepping. grapevine stepping. single~eg 
stand progreSSing from eyes open to eyes closed. prone abdominal body 
bridge 
Stage B: Mobilize hamstring to full range. core stability exercise (2-7 days) 
Moderate- to high-intensity sidestepping. grapevine stepping. single-leg 
stand windmill touches. push-up stabilization with trunk rotation. fast feet 
in place. proprioceptive neuromuscularfacilitation trunk pull-downs with 
Thera-Band. symptom-free practice without high-speed maneuvers 
Stage C: Strengthening exercise. core stability exercise. proprioceptive. 
CV (3-14 days) 
High-intensity sidestepping. grapevine stepping. single~eg stand windmill 
touches. swiss ball stabilization with trunk rotation. proprioceptive 
neuromuscular facilitation trunk pull-downs with Thera-Band. running 
with ball 
Stage D: Sudden movement. stop start. cutting (1 - 4 days) 
Swiss ball stabilization with trunk rotation. nordic hamstring curl. cutting 
exercise with ball. sudden stop and start running with ball. 
with the first team once they had completed the rehabilitation 
program and passed the assessment by the team physiotherapist 
as per stage D in the rehabilitation program (0 Fig. 1). 
Statistical analyses were performed using SPSS version 17.0 
(SPSS, Chicago). Actovegin treatment group was compared to 
Control group using Student's 2 two-tail unpaired Hest. 
p-value < 0.05 was considered to be significant. Our study has 
been performed in accordance with the ethical standards of the 
IjSM [12]. It has been ethically reviewed and approved by the 
Cardiff University. 
Results 
'f' 
There were 11 MRI confirmed hamstring injuries in the club 
during the 2008 and 2009 seasons. The mean age of injured 
players was 23 and all injuries occurred at the musculotendi-
nous junction of biceps femoris. There were 3 grade 11 injuries 
and 8 grade I injuries. 4 players had previous hamstring inju-
ries but had been symptom free for at least 6 months. All play-
ers were able to progress through the rehabilitation program 
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Table 1 Results for Actovegin and control group. 
Season Age Treatment MRI findings Day 1055 Means 
200B 26 Actovegin grade 11 tear 22 1B.7 
2009 24 Actovegin grade 11 tear 21 S.D.4.93 
2009 1B Actovegin grade 11 tear 13 S.E.M.2.B5 
200B 22 Actovegin grade I tear 10 12· 
2009 25 Actovegin grade I tear 9 S.D. 2.94 
2009 19 Actovegin grade I tear 14 S.E.M . 1.47 
2009 26 Actovegin grade I tear 15 
200B 19 control grade I tear 26 20· 
200B 28 control grade I tear 16 S.D.4.54 
2008 22 control grade I tear 21 S.E.M 2.27 
2008 24 control grade I tear 17 
• p<O.OS between groups. S.D. · Standard Deviation. S.E.M. ~ Standard [lTor Mean 
pain free. No recurrent muscle strains or injuries were recorded 
during rehabilitation. No adverse reactions were reported 
with Actovegin injections and all players in the Actovegin 
group received 3 doses of Actovegin as stated in the treatment 
protocol. 
7 players had Actovegin treatment and 4 players opted-out of 
the injection therapy. In the Actovegin group 3 players had grade 
11 injuries and 4 players had grade I injuries. All 4 players in the 
control group had grade I injuries. The mean number of days lost 
in the control group was 20 with a range from 16 to 26 days; in 
the Actovegin group the mean number of days lost with grade I 
injuries was 12 with a range from 9 to 15 days (0 Table 1 ). There 
was a significant statistical difference when the Actovegin group 
was compared to the control group (p = 0.033). In grade I ham-
string injuries, players in the Actovegin treatment group were 
able to return to play 8 days earlier (95% Cl -1.249 to -14.7510) 
compared to physiotherapy alone. For Grade 11 injuries, the mean 
number of days lost in the Actovegin group was 18.67 with a 
range from 13 to 26 days. Statistical analysis cannot be per-
formed as there were no subjects with grade 11 injuries in the 
control group. 
Discussion 
• 
It is evident that hamstring injuries are very common in sports 
with high demands on speed and power such as football (soc-
cer). The incidence during our study was comparable to recent 
literature [11,29). The Actovegin injection therapy regimen 
described in this paper for grade I hamstring injuries appears to 
significantly reduce the number of days for return to play, with a 
mean of 8 days reduction compared with rehabilitation therapy 
alone (p<O.05).1t is difficult to perform full economic costing for 
elite football players, as it is impossible to attach a value for a 
player to be able to play the next game. 
In vivo and in vitro studies suggest that Actovegin contains some 
active components, although they are yet to be identified. It has 
been used by clinicians across Europe, China and Russia for over 
60 years to treat stroke and diabetic neuropathies [6, IS, 18, 
22,30). There is limited evidence on its role in the treatment of 
muscle injuries and no evidence regarding any performance 
enhancing properties. There has only been one published clini-
cal study to investigate its role in muscle injuries when mixed 
with local anaesthetics (21). Although an unpublished case 
series with Dr. Hans-Wilhelm Mtiller-Wohlfahrt's injection regi-
men seems to have good results, it has also been mixed with 
Traumeel and local anaesthetics (8). There have been no clinical 
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studies investigating the effect of stand-alone Actovegin therapy 
in muscle injuries. From our review, Actovegin is a drug that has 
60 years of track record in clinical use and it has a well-estab-
lished safety profile. The only anaphylactic case report published 
could be discounted, as the cause is most likely to be bacterial 
contamination of injection site. There is no evidence of an ergo-
genic effect with Actovegin. Many official governing bodies 
including WADA, UKAD, CCES and USADA do not prohibit its use 
intramuscularly. On the other hand, it is not on the British 
National Formulary (BNF) and Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) in the UK and Food and Drug 
Administration (FDA) in the USA have not approved its use. 
In professional elite-level athletes, Orchard et al. [201 summa-
rised that currently almost all our so-called knowledge in the 
treatment of muscle injuries was based on very poor scientific 
evidence. The career Iifespan for the professional elite athlete is 
often short lived, shortened recovery time could mean continu-
ing with training, increased game play and benefit to the team 
and club. 
Due to the unique relationship between sports physicians and 
athletes, they are often under pressure to seek the latest "active" 
or "cutting edge" treatments [17J. Athletes are often not inter-
ested in being part of a Clinical Trial. Therefore, it is not always 
possible to get a large number of participants who are profes-
sional athletes. There is also much publicity about the use of this 
drug based on anecdotal assumptions on its questionable poten-
tial ergogenic properties [17]. Actovegin is not licensed to treat 
muscle or soft tissue injuries and its evidence is limited. Never-
theless, there is published evidence demonstrating its efficacy 
and safety [2,6,7,15,22 ,31]. 
limitations 
• 
This is a non-blinded and non-randomised observational pilot 
study with subjective assessments for return to play. The poten-
tial psychological effect of injection therapy and placebo effect 
cannot be ruled out in this study; ideally a placebo injection 
should be used alongside Actovegin. Due to the competitions of 
the sport, it is not possible to standardise the rehabilitation regi-
men between clubs, therefore only a single football club was 
used, hence the patient numbers in each group were small. The 
power of this study is 84 %. 
In our study, all the injections were performed by one of the 
authors (LN). Injection sites were marked with permanent 
marker on the first injection, under direct palpation of the max-
imum tenderness point of the muscle. Ultrasound guidance was 
not used as our clinical marking corresponded to the location of 
injury on the MRI. 
Conclusion 
• 
This article summarises the current evidence on Actovegin, 
there is no evidence that Actovegin can enhance athletes' per-
formance. Although our report is based on a non-randomised 
observational pilot study with subjective assessments for return 
to play, the impact of Actovegin injection therapy must not be 
overlooked. Compared with conventional conservative RICE and 
NSAID therapy, Actovegin proposes an exciting and legal alter-
native for high performance athletes. From our experience, 
Actovegin injection therapy seems safe and well tolerated. More 
objective evidence is needed before any meaningful conclusions 
can be drawn for this new treatment of muscle injuries. Despite 
our positive experience with Actovegin, we do not advocate its 
use until further high quality evidence can be obtained. Medi-
cine is a form of science as well as an art. Physicians should proc-
ess the evidence (in whichever form that it may come) with an 
open mind. Premature conclusions should not be drawn based 
on limited evidence. Further research must be encouraged to 
investigate the effects of Actovegin on muscle injuries. Injection 
therapy could potentially revolutionise the treatment of muscle 
injuries, it should not be regarded as "Snake oil". 
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NUTRITION AND ERGOGENIC AIDS 
Actovegin® - Cutting-edge Sports Medicine or 
"Voodoo" Remedy? 
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Abstract 
Actoveginc> is a deproteinized serum extract of bovine ongln, and in 
recent years it has been used widely in treating sport injuries with many 
anecdotal reports of success. However, the use of Actovegine in sport 
medicine has caused a substantial amount of controversy, especially 
concerning its supposed oxygen-enhancing capacity and an anecdotal 
belief that its use can increase an athlete's performance. In 2009, a 
sports physician was arrested with this "performance-enhancing drug," 
while an editorial in a sports medicine journal strongly questioned the 
evidence base for using this drug for acute muscle injury. There is also a 
report that suggested that Actovegine might have induced anaphylactic 
shock in a cyclist. In this review, we have systematically examined the 
current evidence on Actovegin". Its mechanism of action, clinical evi-
dence, legal status with sports governing bodies, and its potential role in 
sport injuries will be discussed. 
and doctors still have reservations 
about its use in sports medicine. In this 
article we review the evidence of the 
efficacy of Actovegin" as a drug and dis-
cuss its potential role in sports medicine. 
Methods 
A comprehensive literature search 
was performed on MEDUNE (1950 to 
2010), PubMcd, Embase (1980 to 
2010), the Allied and Complementary 
Medicine Database (1985 to 2010), 
ScienceDirect, Scopus, BIOSIS, the 
Cochrane Library, and Google. The 
title, abstract, and key words were 
Introduction 
Acrovegin" has received a great deal of media attention in 
the recent years, especially surrounding its use in sports 
medicine. In 2009, a sports physician was arrested with this 
performance-enhancing drug, whereas an editorial in a 
sports medicine journal strongly questioned the evidence 
base for using this drug for acute muscle injury (12). There 
is also a report that suggested that Actovegin" might have 
induced anaphylactic shock in a cyclist (20). However, there 
also are good safery results from a large, multicemer, ran-
domized, control trial (36). Nevertheless, Actovegin" has 
received much publicity, and there also arc many anecdotal 
beliefs surrounding this drug (12). Currently, Actovegin" 
is not on the World Anti-Doping Agency's (WADA) pro-
hibited substance list (34). However, many athletes, coaches, 
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searched using the terms "Actovegine," 
"injection therapy," and "muscle inju-
ries." No language restrictions were 
imposed; original articles were obtained if possible and 
translated to English. Only relevant articles were included in 
this review after discussion between the authors. 
Background 
Actovegin" is a deproteinized hemodialysate of ultra-
filtered calf serum from animals under 8 months of age, 
produced by Nycomed GmbH, Linz, Austria. Austria is offi-
cially categorized as a bovine spongiform encephalopathy-, 
transmissible spongiform encephalopathy-, and scrapie-free 
country by the World Organization for Animal Health and 
the Scientific Steering Committee of the European Union. 
The manufacturing process of Actovegin" is bovine spongi-
form encephalopathy validated, thus proven to be capable 
of removing hypothetically present transmissible spongi-
form encephalopathy agents (23). It is ultrafiltered to 6,000 
Da; therefore, it does not contain protein, growth factors, 
or hormonelike substances. Actovegin" contains physiolog-
ical components, electrolytes, and essential trace elements. 
Amino acids, nuclcosides, and intermediary products of car-
bohydrate and fat metabolites constitute approximately 30% 
of organic components in Acrovegill" (23). The active ingre-
dients in this mixture have yet to be identified. Actovegin'" can 
be administered as tablets, topical formulations, injections, 
Actovegin 
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Of infusion via :ntramuscular, intravenous, or intra-arterial 
routes (23). 
Actovegin~ is a licensed drug in Europe, China, and Russia 
and has been used by clinicians for more than 60 yr 
(3,23,28,35). Clinically, it has been used as an intravenous 
infusion to treat acute stroke (5,11) and as a topical form to 
treat skin and mouth ulcers (4). It also has been reported to 
be used as an intra-arterial infusion to treat long-bonc 
fractures (17) and postpartum hemorrhage (2) . Solcoseryl 
(Valeant Pharmaceuticals International, Moscow) is another 
widely used drug in the same calf serum hemodialysate 
group, but there has been no published report comparing 
the ingredients or biological actions between Actovegin~ and 
Solcoseryl. In this review, we will only focus on the evidence 
around Actovegin". 
Mechanisms 
During the past 60 yr, researchers have endeavored to 
identify the active ingredients in Actovegin~ but have been 
unsuccessful. Studies ill vitro have suggested that it pro-
motes oxidative metabolism and shifts the redox balance of 
cells into the direction of oxidized substrates. Actovegin*, 
therefore, initially was thought to have protective effects 
against hypoxic cell injury (30). Hoyer and Betz (14) dem-
onstrated that Actovegine does not directly influence cells 
during the ischemic period because tlte intracellular levels of 
glucose and lactate are similar to untreated animal cells 
during this period. Therefore, its mechanism of anion is 
thought to improve the efficacy of a cell's energy balance in 
the postischemic metabolic events and interrupt the process 
of cell damage to avoid further cell death (14). 
Inositol phosphate oligosaccharides (IPO) are one of the 
putative ingredients in Actovegin" (24). The IPO have been 
shown to have a partial insulin-like effect on the glucose 
transport activity of adipocytes but do nor induce carrier 
translocation or stimulate insulin reccptor kinase ill vitro 
or il1 vivo (24). It has bccn reported that IPO activate glu-
cose transporters, hence promoting glucose uptake by cells 
(10), IPO can contribute up to 50% of the maximum insu-
lin effect on glucose transport and also can stimulate the 
activity of certain enzymes including pyruvate dehydro-
genase, the key enzyme of the citric acid cycle (24). It has a 
synergistic effect with insulin and promotes glucose activ-
ity when insulin levels are suboptimal but does not alter 
the peak effect (24). A strongly negatively charged sul-
fated oligosaccharide of approximately 3,000-Da molecular 
weight also has been isolated from Actovegin", which is 
different from the IPO fraction reported by the other studies 
(30). This fraction has a similar effect to IPO but with less 
effectiveness. 
Actovegin" has a synergistic effect on cell proliferation 
ill vivo with epidermal growth factor, basic fibroblast 
growth factor, and endothelial cell growth factor, causing 
an increase in cell numbers, an increased activity of acid 
phosphatase, and an improved level of thymidine incorpo-
ration compared with controls (30). These effects are re-
sistant to proteinase K digestion; therefore, the active 
compounds of Actovcgin~ arc unlikely to be growth factors 
or their derived fragments (30). The trivial nutritive effects 
of Actovegin* were excluded beca use a mixture of the same 
WWW.acsm-csmr.org 
level of amino acids and substrates did not stimulate pro-
liferation or have insulin-like activity ill vivo (30). 
Actovegin~ is likely to have membrane-stabilizing ef-
fects in ischemic cells. This may be due to the presence of 
negatively charged oligosaccharides, shifting the cells to 
the direction of oxidized substr~tes. At the immediate pos-
tischemic period, these factors may help cellular recovery. 
Its insulin and growth factor synergistic properties also 
could be beneficial and make the initial recovery period 
more efficient. Therefore, Actovegin" is assumed to be use-
ful in circulatory disturbances and postischemic events. 
A recent study ill vivo indicated that Actovegin" could 
regulate the expression of cell surface receptors on macro-
phages, which indicates their phenotypic subgroups in the 
inflammatory sequence leading to muscle repair (18)_ Fur-
thermore, Actovegin!> can upregulate some of the inflam-
matory mediators that may have an important role in 
regulating the inflammatory process in muscle healing (18). 
Clinical Reports Not Related to Muscle Injuries 
Although the active ingredients in Actovegins are yet to 
be idcntified, many clinical studies have indicated its safety 
and effectiveness. There has been one case report of a pos-
sible anaphylactic reaction related to the use of intravenous 
Actovcgin" injections by an amateur cyclist. rn this report, 
the diagnosis of "anaphylactic reaction" was not confirmed 
with any biochemical testing, and the patient improved with 
broad-spectrum antibiotics, The author later stated in the 
communication letter that this patient had used intravenous 
Actovegin" once before with no adverse reaction; thus, an 
anaphylactic response is unlikely. However, it is possible 
that the first lIse of Actovcgin* has primed [he immune cells 
to react severely after the second or subsequent admin-
istrations. Because the patient improved on broad-spectrum 
antibiotics, the most likely cause for this acute shock was 
due to bacterial contamination during injection, not ana-
phylactic reaction to the drug (20). 
Pforringer et al. (28), in a double-blind, placebo-con-
trolled, single-center study with 60 recreational athletes, 
demonstrated that ultrasound-guided paratenon injection 
of Actovegin" was effective in the treatment of Achilles 
tendinitis. The tendon cross-sectional measurement was 
reduced significantly (P < 0.0001); patients' physical activ-
ity and perception to pain also were improved (P < 0.002) in 
the treatment group (28). The overall clinical outcome, 
which is measured by patients' satisfactory score, was sig-
nificantly better in the Actovegin~ group (P < 0.0001), and 
no adverse event was reponed in this study (28). Although it 
is a relatively small-scale study with limited power, it is a 
well-conducted study that was featured in a Cochrane 
Review. Ziegler et al. (36) reported a double-blind, multi-
center, randomized, control study with 567 patients with 
type 2 diabetes, in which 281 patients were treated with 20 
daily high-dose intravenous Acrovegin" infusions followed 
by 1,800 mg of Actovegin" daily for 120 d in the treatment 
of symptomatic diabetic polyneuropathy compared with 
placebo. Total symptom score of the lower limbs, vibration 
perception threshold, Neuropathy Impairment Score of the 
Lower Limbs, and quality of life (SF-36) were used as 
patient-reported outcome measures, which all showed a 
statistically significant difference compared with placebo 
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and baselme scores (1' < 0.05). Furthermore, no anaphy-
lactic reactions were reported with this study after 5,620 
infusions, and the adverse effect profile was no different 
compared with placebo (36). 
legal Status 
Besides its clinical properties, there are anecdotal beliefs 
among athletes that Actovegin" possesses an oxygen-carrying 
capacity and has the potential to enhance oxygen uptake, 
which leads to better performance. Although these claims 
arc not based on any objective scientific evidence or pub-
lished clinical reports, the International Olympic Commit-
tee announced in December 2000 that Actovegin" was 
banned under the classification of blood-doping agents. 
Two months later, however, the International Olympic 
Committee lifted the ban because there was no evidence 
that Actovcgin" actually enhances performance (32). So far, 
there have not been any sports-related studies or perform-
ance testing with this drug on healthy individuals. Cur-
rently, intramuscular use of Actovegin" is not prohibited in 
or out of competition for any given sport according ro the 
latest search (2010) in the Global Drug Reference Online, 
which is approved by U.K. Anti-Doping, the Canadian 
Centre for Ethics in Sport, the U.S. Anti-Doping Agency, 
and WADA (13). According to the latest 2011 WADA pro-
hibited list, Actovegine is not prohibited in any sports. How-
ever, WADA has issued a specific guidance on Actovegin" 
on its Web site. According to section M2 of the WADA code, 
the volume of intravenous injection of any Ilonprohibited 
substance must not exceed 50 mL with a simple syringe, 
and further serial injections must be at least 6 h apart (34). 
Therefore, it should be stated clearly here that Actovegin" 
cannot be administered by intravenous infusion or single 
intravenous injection with a volume exceeding 50 mL (34). 
Muscle Injuries 
Muscle injuries are onc of the most common sports-
related injuries; their incidence varies from 30% to 55% 
(15,22,33). Rest, immobilization (15), physical therapy (7), 
and nonsteroidal antiinflammatory drugs (NSAID) (29) 
have been the mainstay of therapy for muscle injuries (16). 
Immobilization may lead to improved granulation of the 
injured muscle and promote healing, but it will cause sig-
nificant atrophy of healthy myofibers and joint stiffness 
(15). Although some studies have shown that the admin-
istration of N5AID promotes muscle healing by reducing 
degeneration and inflammation, other studies have demon-
strated that N5AID are detrimental to the entire healing pro-
cess (1,21,25,31). Recently, new treatment options such as 
growth factor injection therapy have shown good therapeu-
tic results. However, because of their performance-enhancing 
properties, growth factor hormones are prohibited by WADA 
under sections Ml and 52 from the WADA prohibited list 
(34). In 2008, Orchard et al. (26), in a best practice state-
ment, suggested that the evidencc on current treatments in 
muscle injuries is low; further research in new treatment such 
as Dr. Mtiller-Wohlfahrt's Actovegin" and Traumeel (Heel, 
Inc., New Mexico) injection therapy should be explored. 
A recent comprehensivc review of the cellular and mo-
lecular mechanisms of muscle regeneration suggested that 
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muscle repair after muscle strains is initiated by necrosis. 
Posttraumatic necrosis of the myofibers stimulates an in-
flammatory response mediated by macrophages (8). This, 
followed by differentiation of satellite cells then maturation, 
leads to new myofiber formation (8). This process is differ-
ent from thc sequence of events observed during embryonic 
myogenesis. 
Macrophagcs traditionally have becn viewed as scav-
engers only involved in the removal of necrotic debris; 
however, recent studics have suggested that they also may 
have an active role in promoting muscle regeneration 
(8,18). Muscle fiber necrosis leads to dissolution of the 
plasma membrane causing rapid disintegration of myofi-
beils (8). This activates thc complement cascade causing 
chemotaxis of leukocytes and monocytes from blood. 
Recent studies suggest that there are two distinct sub-
populations of macrophages sequentially involved in this 
process (8). The early invading "phagocytic" macrophages 
(CD68+), characterized by the expression of the CD68 cell 
surface marker and lacking the CD163 marker, reach the 
highest concentration in damaged muscle at about 24 h 
after the onset of injury and then rapidly decline. These 
CD6S" macrophages arc proinflammatory phagocytes that 
secrete inflammatory cytokines such as the turnor necrosis 
factor and interleukin-l and are responsible for the removal 
of necrotic debris. After 48h, a second subpopulation of 
"nonphagocytic" macrophages (CD163+), characterized by 
the expression of the CD163 surface marker and lacking the 
CD68 marker, was then found and reaches a peak at day 
4 after the initial injury. This CD163+ subgroup displays 
an antiinflarnmatory property and secretes cytokines, such 
as interleukin-10, which contributes to the termination of 
inflammation (6,8). 
Therefore, macrophages have a central regulatory role in 
the muscle response to injury (6,8). A recent report sug-
gested that Actovegin" may cause up-regulation of the 
CD68+ subgroup of macrophages and the precursor of the 
CD163+ subgroup ill vitro (6,8,18). However, it is only a 
preliminary laboratory-based gene expression report; it may 
or may not translate to clinical practice. Therefore, pre-
mature conclusions must not he drawn until more research 
is published in this area. 
Evidence on Actovegin" in Muscfe Injuries 
The treatment of muscle tears with intramuscular 
Actovegin" was first published by Pfister and Koller (27) in 
1990. Their partially blinded case control study with 103 
patients showed a reduction of recovery time with the treat-
ment group of 5.5 wk compared with 8.3 wk for the control 
group (27). However, in this study, patients were recruited 
from various sports and levels, and the treatment regimen 
and the rehabilitation protocol were not standardized. The 
diagnosis of muscle injuries was based only on clinical find-
ings and was not graded according to magnetic resonance 
imaging. Actovegin" was mixed with local anesthetics be-
fore injection; therefore, its pharmacodynamics and phar-
macokinetics were altered. The treatment regimen in this 
study was not standardized, the number of injections ranged 
from three to eight, and the final outcomes were based on 
patients' and various clinicians' subjective observations, and 
there were no prcinjury data to compare outcomes. Despite 
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the limitations vf the study, it is the first published study 
regarding Actovegin's use as an intramuscular injection in 
the treatment of muscle injuries, and no adverse events were 
reponed in this article. Since Pfister and Koller (27), there 
had not been any published report in the medical litera-
ture regarding the use of Actovegin" in muscle injuries until 
Wright-Carpenter et al. (35) in 2004. In this small non-
randomized study, autologous conditioned serum was com-
pared with Actovegin". The Actovegin" group in this study 
was created by the retrospective analysis of the study of 
pfister and Koller; therefore, it should not be seen as new 
evidence. 
Ziegler et al. (36) reported a double-blind, multicenter, 
randomized, control study with 567 diabetic patients trea-
tcd with Actovegin" for diabetic neuropathies, which was 
discussed above. Although muscle assessments were not the 
primary objective for this study, it was measured as a scc-
ondary objective to monitor the progression of treatment. 
There was no significant difference in the adverse event rate 
compared with placebo; Actovegin" did not improve muscle 
strength (P = 0.731) or muscle reflex (P ::: 0.571) (36). 
Therefore, it is reasonable to conclude that Acrovegin" is 
a safe drug and does not have anabolic or ergogenic effects 
on muscles. 
Lee et al. (19) repoered the first single Actovegine intra-
muscular injection therapy on high-level professional foot-
ballers. The therapy regimen described by Lee et al. for 
magnetic resonance imaging-proven grade I hamstring 
injuries seems to significantly reduce the number of days 
for return to play. with a mean of 8 d of reduction com-
pared with rehabilitation therapy alone (P < 0.05). Al-
though this is an observational study with only 11 subjects 
and without a placebo injection group, potential psycho-
logical effects of injection cannot be ruled out. Nevertheless, 
this study provided important pilot data regarding the use 
of single Actovegine intramuscular injection therapy for 
muscle injuries. 
Discussion 
III vivo and ill vitro studies suggest that Actovegin" con-
tains some active components, although they arc yet to be 
identified. It is a licensed drug that has been used by clini-
cians across Europe, China, and Russia to treat stroke and 
diabetic neuropathies (4,17,23,28,35). There is limited evi-
dence on its role regarding the treatment of muscle injuries 
and no evidence regarding any performance-enhancing 
properties (27). Recently, there have been ill vitro research 
data suggesting that Acrovegin* may have a role in the 
modulation of the inflammatory process in muscle repair 
after traumatic injuries (6,8,18). 
An unpublished case series with high-profile sports peo-
ple such as Maurice Green, Asafa Powell, Diego Maradona, 
Darren Gough, and Paula Radc!iffe suggested that Dr. 
Hans-Wilhelm Muller-Wohlfahrt's injection regimen with 
a mixture of Actovegina, Traumeel, and local anesthetics 
seems to have good anecdotal results (9,26). There has been 
only one small clinical study investigating the effect of stand-
alone Actovegin" therapy in muscle injuries. Our review 
describes the clinical use and evaluation of Actovegine for 
more than 60 yr with an apparently good safety profile. The 
only anaphylactic case report published could be discounted 
www.acsm·csmr.org 
because the cause is most likely to be bacterial contamination 
of the injection site. Actovegin" does not improve muscle 
strength or muscle reflex, and there is no evidence of an 
ergogenic effect reported. 
The mechanism of action with Actoyegin" Can potentially 
protect ischemic cells, modulate the inflammatory process, 
and help the initial phase of recovery from acute muscle 
injuries become more efficient. Skeletal muscle is a very 
vascular structure and is highly energy dependent. Once 
injured, blood flow often is disturbed, which leads to cell 
ischemia and energy imbalance. Therefore, Actovegin" 
injection therapy to the injury site might aid recovery and 
limit further ischemic effects and control cellular damage 
from the initial injuries. 
Official governing bodies including WADA, U.K. Anti-
Doping, the Canadian Centre for Ethics in Sport, and the 
U.S. Anti-Doping Agency do not prohibit its usc intra-
muscularly. On the other hand, it is not on the British 
National Formulary, and the Medicines and Healthcare 
products Regulatory Agency in the United Kingdom and the 
Food and Drug Administration in the United States have not 
approved its use. Although it is not uncommon in modern 
medical therapy, the intramuscular use of Actovegina to 
treat muscle injuries is off-license. 
In professional elite-level athletes, Orchard et al. (26) 
summarized that currently, almost all our so-called knowl-
edge in the treatment of muscle injuries was based on very 
poor scientific evidence. The career Iifespan for the pro-
fessional elite athlete often is short-lived; shortened recov-
ery time could mean continuing with training, increased 
game play, and benefit to the team and club. 
Because of the unique relationship between sports 
physicians and athletes. they often arc under pressure to 
seek the latest "active" or "cutting-edge" treatments (12). 
Athletes often are not interested in being part of a clinical 
trial. Therefore, it is not always possible to get n large 
number of participants who are professional athletes. There 
is also much publicity about the use of this drug on the basis 
of anecdotal assumptions on its questionable theoretical 
ergogenic properties and placebo effects (12). To obtain the 
highest level of evidence and rule out placebo effects with 
intramuscular Actovegin" therapy, a control must be estab-
lished first. Because the traditional treatment of muscle 
injuries is based on low-level evidence, there has not been 
any report or evidence on intramuscular isotonic saline 
injection therapy. Therefore, it is unethical to assume that 
intramuscular isotonic saline is a placebo and can be used as 
control group. Nevertheless, Actovegin" is not licensed to 
treat muscle or soft tissue injuries, and its evidence is limi-
ted. There is published evidence demonstrating its efficacy 
and safety for a variety of conditions not related to muscle 
injuries (2,4,5.17,28,36). 
As modern sports physicians, wc must apply the princi-
ples of evidence-based medicine when considering new 
therapies. Physicians should process these evidences carefully 
and pay attention to detail, especially when the published 
medical literatures arc limited. This article summarizes the 
current evidence on Actovcgina• Through our research, there 
is no evidence that Actovegin" can enhance an athlete's 
performance. Further research must be encouraged to in-
vestigate the effects of Actovegin" on muscle injuries before 
Current Sports Medicine Reports 189 
Supplied by The British Library - "The world's knowledge" 
it can be labeJed as an effective treatment. Injection therapy 
could potentially be useful in the treatment of muscle inju-
ries; therefore, it should not be regarded as 3 "witchcraft" 
remedy. Currently, Actovegin" falls somewhere in between 
cutting-edge and "voodoo." 
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